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SUMMARY
The kinetics of a Iternative-pathway mediated haemolysis
were studied in sera from a number of vertebrate
species. Rabbit erythrocytes in a veranol buffer
supplemented with magnesium chloride and ethylene glycol
bis tetraacetic acid (EGTA) were used as a target for
these assays. Human sera showed significant variations
in the kinetics of the lytic reaction at dilutions above
1:2. A number of factors appeared to contribute to
these variations and no single determinant of reaction
kinetics could be identified. Sera from domesticated
and feral animals showed little variation within any
species, but marked differences were seen between the
species studied. Badger, ferret and hedgehog exhibited
potent alternative pathway activity while mouse serum
showed very little. The results of kinetic assays of
alternative pathway haemolytic activity and total
haemolytic complement activty were compared with those
of conventional, endpoint, assays. No classical pathway
activity could be elicited from mouse serum. Inbred
strains of mice showed significant differences in the
kinetics of alternative pathway mediated haemolysis
between the males and females of each strain examined,
and between some of the strains examined. These 
' Y x o C
differences did^affect the spread of mycobacteria after 
subcutaneous and intravenous injection. Human sera with 
a defective ability to opsonise yeasts showed normal 
lytic activity in the kinetic assay. In contrast, sera 
from children and adults with obsructive jaundice which 
exhibit enhanced opsonic activity also showed 
accelerated reaction kinetics in the lytic assay.
To the Memory of Dorothy Peters, Louis Pillemer
and Rodney Porter.
 Technology limits Science........
John Landon, 1976
"...Very often a solution turns on devising some means 
of quantifying phenomena or states that have hitherto 
been assessed in terms of "rather more," rather less,"
or "a lot of," ........ To quantify is not to be a
scientist, but goodness, it does help.....
Sir Peter Medawar, 1979
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1.1 THE MAMMALIAN IMMUNE SYSTEM
The immune system is a diverse collection of cells and 
secreted (or humoral) products but so far studies of 
innate and acquired differences in immune responsiveness 
have tended to concentrate on particular aspects of the 
immune system, notably lymphocyte responses (Dausset and 
Contu, 1980). The work to be described here seeks to 
broaden these studies by examining the complement 
system, particularly the alternative pathway of 
complement activation, using a novel application of an 
assay of complement activity.
Attempts to study individual components of the immune 
system, such as the alternative pathway, must take 
account of the possible influence of other mechanisms at 
all stages because the immune system contains such a 
diversity of processes. The host defences of each 
individual are a complex mosaic resulting from the 
interplay of genetic and environmental influences as 
well as the intricate interactions of the components 
themselves (Table 1-1).
Although tissue-based reactions are probably of greatest 
importance in immune responses, the ready availibility 
of blood samples has made this the medium of choice for 
the study of the cellular and humoral components of the 
immune system, particularly in man, where ethical 
considerations severely limit the scope for the study of 
tissue samples. While the results of investigations 
performed on blood samples have proved invaluable, there 
are certain disadvantages to their use which will emerge
The cells of the immune system come originally from the 
haemopoietic (blood-forming) tissues of the body , and 
arise from a population of relatively undifferentiated 
cells known as stem cells. The stem cell pool is 
maintained by regular cell division. Hormones produced 
by other cells in the haemopoietic tissues act on the 
stem cells causing them to differentiate along a variety 
of developmental pathways (Nicola and Vadas, 1984;
Figure 1-1).
In most cases, the cells released from the haemopoietic 
tissues are functionally mature, or nearly so. 
Thymus-derived or T lymphocytes however, complete their 
maturation in the thymus gland (Haynes, 1984), under the 
influence of hormones secreted by the epithelial cells 
of the thymus (Stites, Caldwell and Pavia, 1980). 
Thymus-derived lymphocytes are close to functional 
maturity when released into the bloodstream.
Each of the cell types depicted in Figure 1-1 is 
recognised by means of certain distinctive features. 
Originally the classification was made on the basis of 
their morphology and staining reactions (Bessis, 1973). 
These are now supplemented by biochemical, serological 
and functional criteria (Cawley and Burns, 1980;
Klinman, 1981; Reinhertz and Schlossman, 1981; Taussig, 
1984a) .
Erythrocytes , platelets, and neutrophil polymorphs 
remain in the blood stream in normal circumstances and 
approximately 50% of the neutrophil polymorphs in the 
bloodstream circulate freely. The remainder are 
intimately associated with the endothelial cells which
(Wilkinson and Lackie, 1979). It is thought that these 
are the cells which move into the tissues when 
inflammatory reactions cause changes in capillary 
permeability.
In transit to the tissues are the eosinophil polymorphs, 
basophil polymorphs and monocytes. Tissue basophils 
were named mast cells by early histologists. Monocytes 
which have entered the tissue spaces are called 
macrophages or histiocytes. Tissue eosinophils have not 
been given a distinctive title, possibly because they 
were rarely observed by histologists.
It is generally accepted that macrophages differ in some 
respects from blood monocytes. Important distinctions 
have been described in their surface chemistry and in 
their functional capabilities (Simon, 1979; van Furth 
and Willemze, 1979). Macrophages appear to display 
further changes if they take up long-term residence in 
certain tissues and organs.
Lymphocytes display patterns of migration which are 
quite different from those described above. They leave 
the bloodstream in specialised blood vessels known as 
post - capillary venules or high endothelial venules 
(Weissman et.al., 1978) found in lymph nodes and other 
lymphoid tissues. The capillaries in other tissues and 
organs adopt this morphology during chronic infections 
(Ford, 1983). Such changes are said to be associated 
with the movement of lymphocytes into inflamed regions. 
Lymphoid tissues are those in which large populations of 
lymphocytes are found, and they often display a high
Primary lymphoid tissues are the sites of lymphocyte 
development (Taussig, 1984a), in adult humans the bone 
marrow and thymus gland. Secondary lymphoid tissues are 
the areas in which the mature lymphocytes reside during 
intervals in their travels around the body. With the 
exception of the spleen they consist of little more than 
lymphocytes, macrophages, and antigen processing cells 
in a connective tissue framework. A variety of 
secondary lymphoid tissues have been recognised. They 
show various degrees of complexity in their 
organisation, ranging from the sub - mucosal aggregates 
of lymphocytes described above, to large regional lymph 
nodes. Many of the cellular responses associated with 
lymphocyte-mediated immunity occur in secondary lymphoid 
tissue.
Bone marrow derived (B) lymphocytes tend to remain in 
the secondary lymphoid tissues for long periods, while 
thymus derived (T) lymphocytes recirculate more 
regularly. This recirculation takes them from the lymph 
nodes to the lymphatic vessels, which lead back to the 
bloodstream. Thus even the furthest reaches of the 
lymphatic system are subjected to regular visitation by 
T lymphocytes, and the greater part (ca 70%) of the 
blood lymphocytes are found to be T lymphocytes 
(Taussig, 1984a).
The blood plasma is an aqueous solution of electrolytes, 
small organic molecules and proteins. Many of these 
proteins have transport functions, while others are 
involved in other aspects of homeostasis (Allison,
are produced by the liver. Two groups of proteins which 
do not fall completely within this classification are of 
particular interest, antibodies (immunoglobulins; 
Steward, 1984) and complement. Antibodies are secreted 
as a result of B lymphocyte activation during an immune 
response. The specificities of the antibodies found in 
the blood plasma generally reflect the body's recent 
antigenic experience. The complement proteins stand out 
as a powerful adjunct to antibody activity, and as a 
valuable defence system in their own right.
When an inflammatory episode causes changes in capillary 
permeability, neutrophil polymorphs move into the 
tissues. Plasma proteins move with them, forming an 
inflammatory exudate (Simon, 1979). Until recently it 
was generally accepted that small amounts of these 
proteins cross the walls of capillaries under normal 
circumstances (the process of transudation), providing a 
supply of important proteins in the extravascular 
spaces. The concentrations achieved in the tissue 
fluids by means of transudation have not been widely 
studied, but are said to be significantly less than 
those seen in blood plasma (Hay, 1979). The ratio of 
small to large proteins in lymph, is said to be higher 
than that found in the plasma, suggesting some form of 
filtration.
Local antibody production in the tissues is well 
documented however (Bienenstock and Befus, 1980), and 
all the antibody classes may be found in the tissues, 
regardless of their molecular weight. In addition ,
macrophages secrete the complement components needed to 
enhance their functions, creating regions of alternative 
pathway activity around themselves. In this model, the 
complement proteins found in the blood plasma are 
secreted by the hepatocytes, and only enter the tissues 
when inflammatory reactions alter the capillary 
permeability. Such events would accentuate the 
irregular distribution of the complement components in 
the tissue spaces. The secretion of complement proteins 
by macrophages has been demonstrated in a series of 
carefully designed experiments, but the model developed 
from these results has not received universal acceptance 
(Ezekowitz, 1983) .
1.2 PHAGOCYTOSIS AND THE IMMUNE SYSTEM
Neutrophil polymorphs and macrophages possess highly 
developed capacities for phagocytosis. They are able to 
ingest "foreign" materials as well as denatured "self" 
components. The ingested materials are subjected to the 
actions of microbicidal substances and digestive enzymes 
(Stossel, 1974; Bellanti, 1971). In most instances 
these will degrade them to soluble fragments which can 
be excreted or reutilised, as appropriate. These 
systems are not totally effective and a number of 
microorganisms can survive within the phagocytic cells 
(Edelson, 1982; Iglesias, 1984). They provide 
significant challenges to the success of the immune 
system, since phagocytic cells are the focus of most of 
the diverse mechanisms found in the immune system.
which are subsequently ingested will be considered in 
due course, when the mechanisms by which the complement 
system interacts with its activators are discussed. 
Neutrophil polymorphs are short lived cells (Wilkinson, 
1983). When confronted with "foreign" material, they 
are as likely to discharge the contents of their 
cytoplasmic granules into their environment as to 
indulge in phagocytosis (Figure 1-2).
There has been an extended debate on the extent to which 
cells of the monocyte-macrophage lineage maintain their 
numbers by cell division in the periphery (van der Meer, 
1980). The difficulties of experimentation in this 
field have hampered the resolution of this problem. The 
microbicidal and digestive systems found in these cells 
have not been studied to the same extent as those of the 
neutrophil polymorphs in man, but work done in other 
species indicates that they possess a similar range of 
activities to the neutrophil polymorph, but that the 
individual systems are generally less potent in the 
monocyte-macrophage line (Stossel, 1974).
Phagocytic cells are a feature of the host defences of 
most animals and their functions are undoubtedly crucial 
to the control of infectious disease (van Furth and 
Willemze, 1979). In man, numerous diseases have been 
associated with failure of neutrophil polymorph 
production (Horwitz, 1982). In every case the 
deficiency has been associated with a marked 
susceptibility to infection. Inborn errors of 
metabolism which are manifested in neutrophil polymorphs
example a deficiency of the enzyme NADPH oxidase 
prevents the production of adequate amounts of hydrogen 
peroxide which is necessary for the oxidative killing of 
bacteria (Figure 1-2). Few innate deficiencies of the 
monocyte-macrophage system have been reported, but the 
vital role of these cells in host responses to 
infectious diseases is well documented (Rosenthal,
1980).
Innate deficiencies of lymphocytes ,such as the Di 
George syndrome and the Severe Combined Immuno­
deficiencies (Hayward, 1977) are associated with 
recurrent, life-threatening infections which begin soon 
after birth. These observations suggest that phagocytes 
alone cannot provide adequate protection against 
infection in warm-blooded animals. The evolution of 
lymphocytes has contributed a variety of mechanisms 
which help to contain the threat from pathogens and 
their toxic products, as well as others which attract 
phagocytes to the areas of lymphocyte activation, and 
also enhance the metabolic activity of the recruited 
cells (Table 1-1).
The activation of B and T lymphocyte clones requires the 
concomitant activation of helper (or inducer) T 
lymphocyte populations. An additional requirement is 
that antigenic determinants must be presented to the 
lymphocytes in an organised array, associated with 
certain of the cell surface proteins coded by genes in 
the major histocompatibility complex (Owen and Crumpton,
1980), on the surface of so-called accessory cells.
Macrophages can perform this function in-vitro, and were 
once thought to do so i n-vivo (Rosenthal, 1980). Recent 
work has attributed in-vivo accessory cell function to a 
number of specialised cells known as antigen processing 
cells (Chestnut and Grey, 1984).
The cellular and humoral defence mechanisms described so 
far, are those which have clearly defined roles in 
immunological reactions in-vit ro and in-vivo. Current 
research literature contains numerous reports of other 
mechanisms as well as novel interactions of the systems 
already described. All have been demonstrated with 
relative ease in-vitro. For some their relevance to 
host defences is emerging as suitable technology becomes 
available, for others this exercise has proved more 
difficult and it is not realistic to make assumptions 
about their physiological significance at present.
Table 1-1 includes two important examples of such 
mechanisms, the K cell phenomenon (Adams, Lewis and 
Johnson, 1983) and the natural killer cell (Koren and 
Herberman, 1983; Klein, 1983).
The serious consequences of lymphocyte deficiencies 
described earlier confirm that these benefits are 
regularly employed in normal indivduals. Nevertheless, 
they cannot be used effectively in the absence of 
phagocytes, which remove much of the debris produced 
during lymphocyte responses. Furthermore, the products 
of these responses cannot be disseminated through the 
body fluids and tissues in effective amounts in the 
first few days of an infection which has not been 
previously encountered. It is therefore important to
available to deal with an infection before the products 
of lymphocyte activation are deployed effectively. The 
alternative pathway of complement activation is one such 
mechanism, arguably one of the most important (Fearon 
and Austen, 1980 ) .
The overt consequences of complement activation by 
either pathway include the recruitment of neutrophil 
polymorphs (and possibly macrophages) to the site of 
activation (vascular permeability and chemotaxis) and 
enhanced interaction between the complement-coated t 
activator and these phagocytes (opsonisation). Finally 
the disruption of the plasma membrane of some cellular 
targets (lysis, one form of cytotoxicity, Table 1-1) is 
also seen.
Activation of the alternative pathway can therefore 
provide a readily available substitute for some of the 
effector mechanisms of lymphocyte-mediated immunity 
(Table 1-1). The prominent feature of this 
substitution is the recruitment of phagocytic cells, and 
enhancement of their activity through opsonisation of 
the material which caused activation. Furthermore, the 
alternative pathway is inevitably activated in the wake 
of classical pathway activation, so that it is also 
involved in the expression of antibody-mediated immunity 
when lymphocyte activation has occurred. The complement 
system will now be considered in greater detail.
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The term complement was coined by Ehrlich at the turn of 
the century to describe a heat labile component of 
animal sera which was needed to complement the activity 
of antibodies in order to produce cell lysis. As with 
immunoglobulins, the detailed structure of the 
complement system was not open to investigation until 
the technology of protein chemistry developed in the 
1950's.
The complement system is a collection of proteins 
(Lachmann, 1975; Brown and Frank, 1981; Reid and Porter,
1981) found in the blood plasma and other body fluids 
(Table 1-2). A variety of inflammatory stimuli can 
activate the system, causing the proteins to interact in 
certain defined sequences. The products of these 
reactions are responsible for a number of effects on the 
surrounding tissues which can make a significant 
contribution to the body's attempts to eliminate the 
agent causing the inflammation.
The observation of serum-mediated cell lysis led to the 
discovery of the complement system, and today it is 
one of the well-known consequence of complement 
activation. It occurs because a protein complex formed 
by the association of several complement components is 
inserted into the plasma membrane or cell wall of the 
target. When eukaryotic cells such as the mammalian 
erythrocyte are used as targets, the effects of lysis 
are dramatically obvious. The significance of lysis in 
the control of microbial infections is less certain 
(Muller-Eberhard and Schreiber, 1980). Other, less well
important part of host defences against microbial 
infection. When activation occurs the capillaries in 
the vicinity become dilated as certain fragments of 
complement components cause the release of vasoactive 
substances from mast cells. These substances, which 
include histamine, also cause the contraction of smooth 
muscle. The change in capillary permeabilty allows the 
movement of neutrophil polymorphs and some plasma 
proteins from the bloodstream into the tissue spaces. 
Some of these fragments can also provide chemotactic 
stimuli which attract the neutrophil polymorphs to the 
focus of complement activation. Other protein fragments 
produced during the activation process coat the cell or 
molecule which caused the reaction. The phagocytic 
cells bear surface receptors (Dierich and Schulz, 1983; 
Wilkinson, 1983; Fearon, 1984) which bind strongly to 
these adsorbed fragments, increasing the efficiency of 
phagocytosis (opsonisation). It has been claimed that 
the presence of the complement fragments on the surface 
of ingested microorganisms is important in triggering 
the microbicidal mechanisms of neutrophil polymorphs 
(Yamamura and Valdimarsson, 1977; Leigh et. a l ., 1979). 
Whatever the significance of complement-mediated lysis 
in the control of infectious diseases, it is clear that 
complement activation provides a useful means by which 
phagocytosis can be enhanced during an inflammatory 
response.
Two major mechanisms of complement activation are 
recognised (Figure 1-3). Others have been reported
The so-called classical pathway was the first to be 
described. It requires the interaction of certain 
classes and sub-classes of immunoglobulin with their 
antigenic determinants in a suitable configuration. In 
contrast, the alternative pathway is activated by the 
binding of its early components to a variety of 
microorganisms, animal cells and molecules (Table 1-3). 
The early events in both pathways are depicted in 
Figures 1-4 and 1-5. They differ in a number of 
respects, but both deposit protein complexes which 
possess proteolytic activity on the activating surface. 
These complexes act only on the complement component C3, 
initiating the terminal reactions of the complement 
system which are common to both pathways. They are 
usually referred to as the classical pathway C3 
convertase and the alternative pathway C3 convertase. 
This binding of either convertase to the 
antigen-antibody complex or microorganism which caused 
them to be produced, focusses the effects of complement 
activation on the undesirable intruders.
The general structure of C3, and the effects of the 
convertase enzymes on it are shown in Figure 1-6. The 
fragment C3b contains a short-lived binding site 
(Muller-Eberhard and Schreiber 1980) which is able to 
form a thioester bond with the foreign surface which 
caused its production. The small fragment, C3a, 
diffuses into the body fluids. The biological effects of 
this and other complement fragments are summarised in 
Table 1-4. Since both C3 convertase complexes act as
to C3a and C3b before activity is lost. Many of the C3b
fragments will be scattered over the surface of the
antigen-antibody complex or cell which activated the
pathway. These C3b molecules bind strongly to the
receptors on the surface of phagocytic cells, and are
responsible for complement-mediated opsonisation. Other
fragments such as C4b may make some contribution to this
process (Holborow and Papamichael 1983).
If a single C3b fragment becomes associated with a C3
convertase complex, the enzymic specificity of the
complex is modified. It now binds and cleaves the
complement component C5 into two fragments C5a and C5b.
The C5a peptide diffuses into the surrounding body
fluids where its effects contribute to the inflammatory
response (Table 1-4). C5b binds firmly to the surface
which caused complement activation, at sites distinct
from those occupied by C3 convertase complexes and the
C3b opsonins (Muller-Eberhard, 1975). The components
C6, Cl, C8 and C9 associate with bound C5b to form the
complex that is responsible for cell lysis. At first,
it was thought that the composition of this complex was
C5b6789 (Mayer, 1973) and subsequently a dimer of
C5b6789 was proposed (Muller-Eberhard, 1980). The most
recent work sugggests a more complicated progression of
the assembly of these terminal components (Lachmann, 
v
1983; Mayer, Imagawa, Ramm and Whitlow, 1983), with a 
number of functional intermediates. As noted earlier, 
these events occur whenever complement is activated, 
regardless of the initiating pathway. They are often
not listed in bibliography;
Biology of the Complement System:
A Summary;Progressin Immunology, v,
445, Yamamura, Y. & Tada, T., Editors,
Academic Press, Publishers.
referred to as the common attack pathway (Figures 1-7 
and 1-8) .
Now that the general principles of complement activation 
have been described, the detailed structure of the C3 
convertase complexes can be examined. When IgM, IgGl, 
IgG2, or IgG3 antibodies react with their antigenic 
determinants in a suitable configuration, they are able 
to bind the classical pathway component Cl (Porter and 
Reid, 1978; Burton e t . al., 1980). In essence, this 
requires two 7S immunoglobulin molecules to be 
juxtaposed. A single molecule of IgM can meet this 
requirement since it is composed of five 7S units. The 
IgG molecule consists of a single 7S unit, so that two 
molecules are required to bind close together for the 
association with Cl to occur (Figure 1-4). This 
juxtaposition is more probable when high concentrations 
of the required IgG antibody are present in the body 
fluids.
Cl is in fact composed of three different kinds of 
polypeptide subunits: Clq, Clr and Cls (Table 1-2). The
complete Cl complex is thought to contain a single
molecule of Clq, two molecules of Clr, and two molecules
of Cls. It is the clq subunit that binds to the
antigen-antibody complex. This event induces 
proteolytic activity in the Cls polypeptides by a 
mechanism which is still the subject of some debate.
The central question in this debate is whether the clr 
subunits acquire proteolytic activity in the course of 
Cls activation. The work of Porter's group (o p . cit. ) 
suggests that this is the case. Activated Cls has the
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cleave the classical pathway proteins C4 and C2.
C4 — > C4a + C4b 
c2 — > C2a + C2b 
The characteristics of each fragment are given in Table 
1-4. As these are enzymic reactions, several molecules 
of each protein will be cleaved before the activated Cl 
esterase molecules lose their activity. The fragments 
C2b and C4a diffuse into the body fluids, where they may 
be able to express their biological activities before 
they too are inactivated. The other fragments, C4b and 
C2a, associate on the surface of the immune complex 
which caused complement activation to produce the 
classical pathway C3 convertase C4b2a. This also has a 
short half-life, but should cleave several molecules of 
C3 before its activity is lost.
Activation of the alternative pathway contrasts sharply 
with that of the classical pathway. In fact, the 
components of the alternative pathway C3 convertase are 
constantly associating in normal blood plasma (Figure 
1-5). The complex C3bB is acted on by the circulating 
enzyme, factor D. C3bBb is produced as factor D cleaves 
factor B into a large fragment Bb and a small fragment 
Ba (Table 1-4). This complex reacts with the component, 
known as properdin to give c3bBbP. Each of these three 
complexes (C3bB, C3bBb and C3bBbp), have some C3 
convertase activity, but c3bBbP is the most active. In 
the absence of any cell or molecule capable of 
activating the alternative pathway (Table 1-3) it will 
lose its activity spontaneously (Figure 1-5). Before
and factor H (Table 1-2) rapidly destroy its biological 
activity.
Alternative pathway activation, or more precisely 
amplification of alternative pathway activity, occurs 
when a cell or molecule capable of binding to the C3bBbP 
complex enters the body fluids. Once bound, the 
convertase is protected from the actions of factor I and 
factor H and is able to effect the conversion of C3 to 
C3a and C3b (Fearon and Austen, 1977; Schreiber et. a l . ,
1978). The C3b fragments will then cause the expression 
of C5 convertase activity, opsonise the activator, and 
feed into the reactions which produce the C3bBbP complex 
generating further alternative pathway activity, the 
so-called feedback amplification loop, (Lachmann, 1975). 
The appearance of C5 convertase activity will trigger 
the common attack pathway. While the alternative 
pathway can be activated in isolation, the classical 
pathway cannot. When C3 is cleaved during classical 
pathway activation, some of the C3b fragments produced 
combine with factor B and properdin to form alternative 
pathway C3 convertase complexes in the body fluids.
This so-called fluid phase activation of the alternative 
pathway will inevitably augment the expression of 
classical pathway activity because of the alternative 
pathway feedback amplification loop (Figures 1-4 and 
1-5) . Thus activation of the classical pathway will 
always lead to activation of the alternative pathway.
Even a cursory glance at the consequences of complement
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response to infectious disease. Unchecked complement 
activity could damage host cells as well as those of the 
pathogen responsible for the infection. This is 
particularly true of the alternative pathway as it is 
always running, albeit at a very low level.
A number of proteins control the expression of 
complement activity (Table 1-2). Two of these have been 
described already (factor I and factor H ). The 
alternative pathway is held in check by these proteins, 
and it is probable that variations in the concentrations 
of factors I and H could allow inappropriate expression 
of alternative pathway activity (Lachmann and Halbwachs, 
1975; ) .
The presence of a circulating (auto)antibody (C3 
nephritic factor, C3NeF) to the alternative pathway C3 
convertase is sometimes associated with 
complement-mediated renal damage (Habib and Levy, 1979; 
Sissons and peters, 1979; Schreiber and Muller-Eberhard, 
1979). The association is not complete however, and the 
exact causes of the renal lesions are unclear.
The classical pathway generally requires immunoglobulin 
for its expression, although, as noted earlier Cl may be 
activated in the absence of antigen-antibody complexes 
(Loos, 1982). On the other hand, the alternative 
pathway requires only the pathogen or its secretions to 
provide a surface which can stabilise the alternative 
pathway C3 convertase, although not all microorganisms 
can provide such a surface.
The chemical nature of activating surfaces has been the
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that activators (or perhaps more appropriately, 
protectors) of the alternative pathway are relatively 
hydrophobic. Mammalian cells depleted of surface sialic 
acid by neuraminidase treatment become activators of the 
alternative pathway (Kazatchkine, Fearon and Austen,
1979), while the erythrocytes of inbred mouse strains, 
which bear differing amounts of sialic acid, activate 
the human alternative pathway with a relative efficiency 
determined by their sialic acid content (Nydegger,
Fearon and Austen, 1978). Sialic acid is a major 
determinant of the hydrophilic nature of animal cells. 
Support for this concept comes from the observation that 
those bacteria which secrete a sialic acid-bearing 
capsule do not bind the alternative pathway C3 
convertase, and seemed to have gained a marked 
evolutionary advantage. They are usually important 
animal pathogens (Jacks-Weis, Kim and Cleary, 1982), 
such as Streptococcus pneumonia. There have however 
been reports which suggest that sialic acid content is 
not the sole determinant of the ability to cause 
alternative pathway activation (Reid and Porter, 1981). 
Sulphated mucopolysaccharides may also be involved.
It is interesting that the recognition criteria of 
neutrophil polymorphs and macrophages appear to be 
similar to those of the alternative pathway (Wilkinson, 
1976; Weir and Ogmundsdottir, 1977). Thus, in the 
absence of antibody, the main cellular defences and the 
humoral mechanisms which will recruit these cells to 
areas of need, have similar, relatively non-specific
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some organisms. It had been tentatively suggested that 
phagocytes rarely ingest unopsonised particles, making 
the alternative pathway the key recognition mechanism 
(Mowbray, 1976). This suggestion may assume greater 
significance in the light of the work of Ezekowitz which 
was discussed earlier.
The advantages of specific, lymphocyte-mediated 
immunity are readily apparent. As noted earlier 
however, it can take several days for the effectors of 
lymphocyte- mediated immunity to reach adequate levels 
throughout the body fluids. The alternative pathway 
could provide valuable interim defences against many 
microorganisms (Fearon and Austen, 1980).
Recently, other functions have been attributed to the 
complement system. These are the ability to inhibit the 
formation of immune complexes, and to facilitate the 
solubilisation of preformed complexes (Takahashi, 
Takahashi and Hirose, 1980; Naama et. al., 1983; Skogh 
and Stendahl, 1983), and the ability to suppress certain 
lymphocyte responses (Weiler et. al., 1982; Morgan et. 
al., 1983).
These properties may be distinguished from those 
discussed earlier since they do not exert a direct 
effect on the course of a microbial infection. Instead 
they influence the milieu in which immune responses 
occur. It remains to be seen whether they make a 
significant contribution to the control of these 
responses.
1.4 THE ROLE OF THE COMPLEMENT SYSTEM IN DISEASE.
Despite the diversity of cells and molecules in the 
immune system, the' manifestations of its activity which 
contain, and evetually eliminate "foreign" materials are 
relatively few (Table 1-1). This table does however 
show that each manifestation, such as lysis or 
neutralisation, can be effected in a number of ways.
The complement system is able to provide most of them.
As noted earlier, the alternative pathway augments the 
expression of classical pathway activity, and in the 
absence of antibodies and activated T lymphocytes, it 
may provide the major vehicle of host defence. The real 
value of the alternative pathway can only be assessed by 
careful experimentation. The available evidence will 
now be examined
a. In-Vitro Studies 
Such studies have considered the effects of the 
in-vitro activation of serum complement on 
microorganisms and on the phagocytic cells of the immune 
system, as well as the lysis of suitable red cell 
targets. When an organism elicits antibody of the 
necessary class or subclasses, activation of the 
classical pathway is virtually inevitable, and the 
interaction of fresh immune sera with a given organism 
provides useful information on its susceptibilty to 
complement-mediated lysis. Fine (1981) has summarised 
the findings of a great deal of experimental work, which 
used a variety of techniques. He suggests that most 
eukaryotic cells are readily lysed by the classical 
pathway, as are many microorganisms, although a number
2i
of Gram-positive organisms, and some strains of 
Gram-negative organisms are exceptions. The role of the 
classical pathway-mediated lysis of viruses is unclear 
particularly because it can be difficult to distinguish 
between neutralisation of infectivity and physical 
disruption of the virion by the lytic activity of 
complement. The work of Apostolov and Sawa (1976) 
indicates that complement activation is not always 
beneficial. For instance, pretreatment of the Newcastle 
disease virus with antibody and complement caused 
disruption of the virion which facilitated subsequent 
fusion with erythrocyte membranes, and hence lysis of 
the erythrocytes.
The need to investigate the functional efficiency of the 
whole complement system has been underlined by Porter's 
speculations on the association of the genetic 
polymorphism within the complement system with certain 
diseases ( Porter, 1983; Davis, 1983;). Although each 
of the major activities of the complement system can be 
measured in-vitro, none of the assays currently 
available is sufficiently sensitive to test Porter's 
hypothesis (Welch, 1983). Erythrocyte lysis is commonly 
used in diagnostic and research laboratories to measure 
the overall potency of the complement system. Serial 
dilutions of each sample are tested for their ability to 
lyse a suitable red cell target (Lachmann, Hobart and 
Aston, 1973). The titre of lysis is taken to reflect 
the complement activity of the sample. Deficiencies of 
individual components may reduce this titre, but the 
assay lacks sensitivity, and in any case a low value
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Ideally, since the complement system is composed of a 
number of proteins each of which exhibit a particular 
biological activity, a complete analysis of the s y s t e m  
requires the measurement of both the concentration of 
each protein, and its biological activity (functional 
level). As has been shown for several enzymes, one does 
not necessarily reflect the other (Landon, Carney and 
Langley, 1978).
The measurement of individual complement components 
requires specific antisera and in a single species, the 
production of such reagents is a major task. When 
several species are to be studied this type of work 
would assume herculean proportions. Fortunately, the 
structure of individual components may be sufficiently 
conserved between the species in question to allow the 
use of antisera to the components of one species to 
study those from other animals (Nilsson and 
Muller-Eberhard, 1967). If neither option is available, 
the investigator can only measure activity, and is 
unable to investigate the molecular basis of his 
observations.
Investigation of alternative pathway-mediated effects, 
requires measures to prevent classical pathway activity. 
These include: the use of non-immune serum as a source 
of complement activity, adsorption of any antibodies 
from the test serum, the use of sera deficient in a 
classical pathway component, the use of EGTA to block 
classical pathway activity and magnesium ions to achieve 
optimum alternative pathway activity (Appendix 1) and
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purified components. Each approach has its merits and 
its drawbacks.
The work of Roberts and Phillips (1983) using a number 
of serum diluted in a magnesium-EGTA buffer against a 
number of serotypes of E. coli suggests that the 
kinetics of alternative pathway killing are slower than 
those of the classical and alternative pathways 
combined.
Muller-Eberhard and Schreiber (1980) employed the last
one to study the effects of alternative pathway activity
on a number of bacteria. Using scanning electron
microscopy they could distinguish between microbial
death and lysis of the cell. The latter required the
presence of lysozyme and it was complete within 60
minutes using dilutions up to 1:16. Beyond this
dilution the activity was lost. When virus-infected or
malignant eukaryotic cells were treated in the same way
8 6lysis (measured by the release of Rb label) showed 
similar kinetics. If cell metabolism was intact, the 
cells seemed more resistant to lysis.
The properties of the peptides produced during 
complement activation can be demonstrated in-vitro. For 
example, histamine released from basophil polymorphs or 
mast cells can be measured using fluorimetric assays 
(Siraganian, 1976), while the chemotactic peptides will 
cause neutrophil polymorphs to move through support 
media such as agarose gels (Nelson et. al., 1981) or 
nitrocellulose filters (Cates, 1981).
Pretreatment of microorganisms with immune sera
an organism is capable of activating the alternative 
pathway, similar opsonisation is seen in the presence of 
non-immune serum. Care must be taken to exclude the 
effect of opsonising antibody when alternative 
pathway-mediated opsonisation is studied in sera whose 
immune status is not known. Inactivation or inhibition 
of the classical pathway does not prevent 
antibody-mediated opsonisation. If opsonisation resists 
heating (56°, 30 minutes) or trypan blue treatment 
(Guckian, Christiensen and Fine, 1978), it is probably 
due to antibody.
In-vitro studies appear to support the view that the 
complement system in general and the alternative pathway 
in particular are potent components of the immune 
system, although the evidence is not complete,
b. The Role of Complement in Diseases Associated with 
Inappropriate Expressions of Immunity 
In 1975, Gell and Coombes proposed a classification 
which they hoped would facilitate the discussion and 
investigation of such immunological diseases. A 
modified version of their classification is presented in 
Table 1-5 as a background to this introduction. While 
the aetiology of many of these diseases is uncertain 
(Johnson, 1981), it has become clear that complement 
activation is a important effector mechanism in some of 
them. Classical pathway activation is responsible for 
the recruitment of neutrophil polymorphs following the 
binding of organ-specific autoantibodies to the 
components of their target organs in conditions such as
accumulation of neutrophils in tissues in which soluble 
immune complexes have been deposited during immune 
complex diseases (Table 1-5), and such deposits of 
immunoglobulin and complement components can be detected 
by immunofluoresence techniques (Jordan, 1976; Wilson, 
1976).
Diseases involving the alternative pathway alone are 
less common, but membranoproliferative glomerulo­
nephritis and paroxysmal nocturnal haemoglobinuria are 
thought to reflect inappropriate alternative pathway 
activation. As noted above, the first is a renal disease 
with characteristic clinical and laboratory findings 
(Habib and Levy, 1979; Sissons and Peters, 1979;
Schreiber and Muller-Ebernara, 1979). In a proportion 
of the subjects antibody to antigenic determinants on 
the C3bB complex has been demonstrated, and this 
antibody (known as nephritic factor) protects the 
alternative pathway C3 convertase complex from 
inactivation by factor H and factor I. It has been 
suggested that this protection is responsible for the 
renal lesions but, as noted earlier, the lack of a 
consistent association between the renal damage and the 
presence of nephritic factor does not lend support to 
this view.
As the name implies, paroxysmal nocturnal 
haemoglobinuria is associated with the occasional 
presence of haemoglobin in early morning urine samples 
(Gotze and Muller-Eberhard, 1972). It is thought that 
changes in the body fluids which sometimes occur during
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sleep favour the binding of the patients' alternative 
pathway C3 convertase to their own erythrocytes causing 
lysis. The condition appears to stem from a innate 
structural abnormality of the erythrocyte surface 
membrane in these people (Parker, Baker and Rosse,
1982).
These observations confirm the potency of the combined 
effects of the classical and alternative pathways, and 
suggest that the alternative pathway is a potent 
mediator of inflammation in its own right,
c. The Conseqences of Innate Complement Deficiencies 
Just as information on the importance of phagocytes and 
lymphocytes may be gained from the study of inborn and 
acquired deficiencies of these cells, so the 
investigation of subjects with complement deficiencies 
confirms the importance of both pathways in host 
defences (Agnello, 1978; Ruddy 1980). A cautionary note 
must be added to these observations: many of the defects 
are very rare, and the clinical histories recorded on 
these patients are sometimes incomplete. In such cases 
it is best to regard the clinical stigmata of a 
particular deficiency as uncertain, at least for the 
present. Some use has also been made of animal strains 
with innate deficiencies of complement components 
(Nilsson and Muller-Eberhard, 1967). The findings in 
humans and other species may be summarised as follows:
(i) Deficiency in C3, either a primary deficiency, or 
one due to a deficiency of C3b inactivator is associated 
with a life-threatening susceptibility to infection.
(ii) Lack of the classical pathway components, cl, C4,
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antigen- antibody complexes from the body fluids. A 
clinical syndrome resembling the immune complex disease, 
systemic lupus erythematosus (Hayward, 1977), is often 
present.
(iii) Deficiency of the components common to both 
pathways (C5 to C9) seems to cause a predisposition to 
infection. Infections with Neisseria are common in 
those cases so far reported, but the rarity of these 
conditions makes confident statements difficult at 
present.
(iv) Demonstrable defects of the alternative pathway 
components are exceedingly rare, and their clinical 
consequences are uncertain, but their rarity has been 
taken as evidence that they are incompatible with 
survival (Fearon and Austen, 1980). A number of reports 
have associated a defect in the ability of serum to 
opsonise yeasts with impaired alternative pathway 
activity (Miller, et. al., 1968; Soothill and Harvey, 
1976; Turner, et. al., 1978; Candy, et. al., 1980;
Turner, Mowbray and Robertson, 1981; Larcher, e t . al. , 
1982; Wyke, Rajkovic and Williams, 1983). A precise 
cause has yet to be demonstrated and in contrast to the 
other deficiencies described above, this is an 
unexplained clinical syndrome. The others are clearly 
defined complement defects in which the.clinical 
consequences are known to varying extents.
d. Attempts to Modify Complement Activity in-vivo.
The main research effort in this area has involved the 
use of cobra venom factor (Kawamoto et al., 1979; Vogel,
factor B in a number of species, forming a complex with 
C3 convertase activity which is not inhibited by factor 
H and factor I. Intraperitoneal injection of cobra 
venom factor consumes C3 and the late complement 
components producing transient complement deficiency.
If experiments last more than a few days further 
injections of cobra venom factor are required to sustain 
the depletion of complement. Hirsch (1982) has reviewed 
the use of this model, and concludes that the 
alternative pathway is able to control the blood-borne 
spread of a number of pathogens. He notes however that 
in the case of Sindbis virus infection in mice that 
while alternative pathway in serum reduces the number of 
lesions which appear in the brain following intravenous 
injection of the virus, it also appears to potentiate 
the subsequent brain damage. Animals treated with cobra 
venom factor had more infectious foci in the brain, but 
the development of brain damage around these foci was 
significantly delayed. It is important to note that the 
usual outcome of the infection, death, was not changed 
by cobra venom factor treatment.
There are some problems related to the use of cobra 
venom factor. For example, it produces a marked 
depletion of complement activity, and intermediate 
levels of depletion cannot be obtained. Repeated doses 
needed to maintain prolonged reduction in complement 
activity often results in the production of antibodies 
to cobra venom factor (Egwang and Befus, 1984). These 
reduce its efficacy, and introduce additional variables.
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alternative pathway activation. Hence, alternative 
pathway components are no longer available to react with 
any pathogens subsequently given to these animals, but 
the peptide fragments are responsible for the biological 
activities of the complement may be present in the 
animals' body fluids throughout any experiments. These 
preformed peptides might cause "bystander" damage to 
injected pathogens, and their presence would modify the 
environment in which the animals' host defences deal 
with experimental infections. It may be misguided to 
assume that cobra venom factor treatment provides a 
straightforward model of complement depletion (Weiler 
et. al., 1982).
The potency of the alternative pathway is clearly 
established by this work, but the extent to which
ft
differences in the rate of expression of alternative 
pathway activity might contribute to differences in the 
natural history and severity of infectious diseases 
remains unexplored. A more sensitive in-vitro assay of 
alternative pathway haemolytic activity would make it 
possible to answer this and other questions.
The limitations of the conventional in-vitro techniques 
for the measurement of haemolytic complement activity 
noted earlier were encountered during attempts to study 
the functional efficiency of the alternative pathway in 
serum samples which failed to opsonise baker's and brew­
er's yeast in-vit ro (Langley and Harvey, 1980). There 
was considerable evidence that the underlying defect was 
in the alternative pathway (Turner, Mowbray and
failed to reveal consistent evidence of complement 
dysfunction. It has been shown that other opsonins 
which are found in blood plasma may mimic the 
alternative pathway in some of the opsonisation assays 
currently used (Kerr et. al. , 1983). This could mean 
that the yeast opsonisation defect does not reside in 
the alternative pathway, making further investigation of 
the complement system irrelevant. There was however 
sufficient evidence at that time to suggest the need for 
a modified, more informative assay of alternative 
pathway lytic activity. It was therefore decided to 
investigate the kinetics of red cell lysis by monitoring 
the reaction continuously at a variety of serum 
dilutions. When a small panel of normal human sera were 
tested in this way there was considerable individual 
variation in the kinetics of alternative 
pathway-mediated lysis of erythrocytes (Langley, 
Griffiths and Laurence, 1982; Laurence, 1982).
If these observations were confirmed, the kinetic assay 
of alternative pathway activity could provide a simple 
but powerful technique to compare the overall efficiency 
of this pathway. In seeking such confirmation, it would 
be important to characterise the phenomenon carefully, 
and eliminate the influence of other plasma constituents 
such as antibody, on the kinetics of complement 
activity. Finally, the molecular basis of these 
variations in reaction kinetics and their relevance to 
the efficacy of host defences should be investigated.
The work to be described was designed to address each of
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Early Events in Classical Pathway Activation
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Table 1- 1
Effector Mechanisms of the Immune System
NEUTRALISATION AND CONTAINMENT 
Neutralisation: antibody alone
antibody and complement 
Entrapment antibody alone
antibody and complement 
complement alone 
Cytotoxicity: antibody and complement
complement alone 
cytotoxic T cells 
K cell phenomenon 
natural killer cells 
macrophages
RECRUITMENT OF PHAGOCYTES (AND OTHER EFFECTOR CELLS)
antibody and complement 
complement alone
lymphokine-producing T lymphocytes
OPSONISATION
antibody alone 
antibody and complement 
complement alone 
other opsonins 
ACTIVATION OF PHAGOCYTES
direct effects of microorganisms 
complement alone (Ba)
lymphokine-producing T lymphocytes
(C4a)
(agglutination) 
(immune adherence) 
(immune adherence)
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Proteins of the Complement System
MOLECULAR PROTEIN J_
WEIGHT* CHAINS CARBOHYDRATE
SEDIMENTATION ELECTROPHORETIC
VALUE MOBILITY
ALTERNATIVE PATHWAY
APPROXIMATE SERUH LEVEL 
uq/ml
absolute 
( KI 0"6 >
relative to. xi
C3b
B
176,000 
f170,000! 
93,000 1
2.7
10.6
8.3
6.2
beta - 2 
beta 225 2.41 37
D
(100,0001 
25,000 1 _ 3.0 alpha 1-5 0.04-0.20 0.6-7
(25,000!
P (properdin) (200,000) 4 9.8 5.2 beta 25 0.13 2
CLASSICAL
Clq
PATHWAY
410,000 14.0 11.0 gamma - i 200 0.49 6
Clr
(390,000)
168,000 _ _ 7.0 beta
Cls
(188,000) 
108,000 _ 4.0 alpha - 2 22 0.20 3
C2
(110,000!
117,000 _ _ 5.2 beta - 2 20 0. 17 3
C4
(117,000!
200,000 . - 8.7 beta - 1 400 0.20 3
* : first value. Hay and Movat, 1979; bracketed value, Brown and Frank, (1981)
: data not available
SYNONYHS; B, glycine rich beta glycoprotein (GBG1, C3 proactivator (C3PA); D, GBGase, C3PA convertase
Revised recommendations on nomenclture of- complement components, J Immunol. 127 : 1261 (1981)
PROTEIN
MOLECULAR PROTEIN 
WEIGHT* CHAINS CARBOHYDRATE
SEDIMENTATION
COMMON ATTACK PATHWAY
C3 185,,000 2
I 180,,000]
CS 200,,000 2
(206,,000)
C6 125,,000 1
(95,,000]
C7 120,,000 1
(120,,000]
C8 150,,000 3
I 163,,000)
C9 79,,000 1
CONTROL‘PROTEINS 
With clearly-defined function in-vivo
C4 binding 
protein 
Cl Inhibitor
95,000
(100,0001
150.000
570.000
105.000
With uncertain role in-vivo
C4b inactivator 
C6 inactivator 
Anaphylotoxin 
inactivator 
C5a chemotactic 
factor inactivator
88,000
310,000
9.5
8.7
5.7 
5.2 
8.0
4.5
6.0
4.0
6.6
9.5
4.0
ELECTROPHORETIC
MOBILITY
APPROXIMATE SERUM LEVEL
alpha
uq/ml
absolute
(xlO-6)
relative
■tfl-Ca
beta - 1 1200 6.49 ;0('
beta - 1 70 0.35 5
beta - 2 60 0.48 -
beta - 2 55 0.46 -
gamma - 1 55 0.37 6
alpha 60 0.76 i 2
beta - 2 40 0.42 7
beta 600 4.00 62
alpha - 2 180 1 .70 26
beta - 1 
beta - 1
-
-
-
alpha - 1 40 0.13 40
SYNONYMS: I, C3b inactivator (C3bIh’A), conglutinogen activating factor (KAF); 
inhibitor
Cl inhibitor. Cl esterase
1 Q U 1 C  X —
Activators of the Alternative Pathway
PROKARYOTES
-whole Escherichia coli
-lipopolysaccharide (endotoxin) from Gram-negative 
bacteria
-techoic acid from Gram-positive bacteria 
EUKARYOTES
-Yeast cells and the polysaccharide zymosan 
-trypanosomes and other protozoa 
-rabbit red cells
-neuraminidase treated sheep erythroytes 
-lymphoblastoid cell lines, e.g. Raji.
-HeLa cells
-measles virus infected cells
POLYANIONS
-dextran sulphate
-polyvinyl sulphate
-dinitrophenol/albumin conjugates
Based on Reid and Porter (1981)
B i o l o g i c a l  A c t i v i t i e s  o f  C o m p l e m e n t  F r a g m e n t s
FRAGMENT
C3a
C4a
C5a
C3e
C3d-k
C3b
C3d
C4b
B!
B.
* *
MOLECULAR
WEIGHT
9000
ca 12,000
41,000
170,000
25,000
60,000
33,000
PROPERTIES
spasmogenic activity 
enhanced vascular permeability 
immunosuppression 
granulocyte activation
spasmogenic activity 
chemotactic activity 
enhanced vascular permeability 
immunoenhancement 
granulocyte activation
leucocytosis
enhanced vascular permeability
leucocytosis
immunosuppression
opsonic activity
monocyte activation 
chemotactic activity
* fragment of alpha chain of C3 corresponding to C3d/g; Hugli 
T.E., Progress in Immunology, V : 419 (1983)7
** Earlier reports : C4b able to neutralise virus infectivity, C2a 
possessed kinin-like activity.
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A classification of Inappropriate Immune Responses
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2.1 BLOOD SAMPLES 
Sheep Erythrocytes
Blood taken as required, from a single ewe was used 
throughout the investigation described in Chapter 3.
Each sample was collected by venepuncture from the 
jugular vein, into Alsever's solution (Appendix I). The 
erythrocytes were immediately washed three times in 
phosphate-buffered saline, pH 7.2 (Appendix I), then 
stored in Alsever's solution for no more than three 
days. When small quantities of sheep erythrocytes were 
required at other times, aliquots of a commercial 
preparation (Appendix I) used regularly for diagnostic 
serology at the Royal Surrey County Hospital were 
obtained.
Rabbit Erythrocytes
Rabbit blood was collected into Alsever's solution by 
venesection, using an ear vein. The subsequent 
treatment of the erythrocytes was identical to that used 
for sheep erythrocytes. Cells from a single collection 
were used for individual experiments, and single animals 
were used for as long as possible during the study. 
Erythrocytes from Other Species
Blood samples were collected from other species by 
venesection (rabbit), venepuncture (ox, badger, sheep) 
and cardiac puncture (all other animals). Ferrets, 
hedgehogs and mice were bled under anaesthesia induced 
by ether; guinea pigs, hamsters and rabbits under 
barbiturate anaesthesia ("Sagatal", May & Baker), whilst
("Vetalar", Parke-Davis). Fowl, cattle and sheep were 
bled without anaesthesia. Once again, the treatment of 
the cells after collection was identical to that 
described for sheep erythrocytes.
Neuraminidase-Treated Erythrocytes
These were prepared using the method described in Figure 
2- 1 .
Serum Samples
When serum was required blood was taken into a plain 
glass container. The samples were allowed to clot at
room temperature and then separated at 4° as quickly as
possible. Thereafter, they were generally stored at 
-70°, but liquid nitrogen was used for long-term
storage, and for the work on mammalian sera described in
Chapter 3.
Dialysis of Serum
10mm Visking tubing (Appendix 1) was used to dialyse 1ml 
aliquots of serum against an excess (>2 litres) of 
complement fixation test diluent (Appendix 1) overnight 
at 4°. After a batch of samples had been dialysed in 
this way, they were all made to the same volume with 
complement fixation test diluent. The volumes used for 
particular experiments will be recorded at the 
appropriate point.
Adsorption of Serum
Antibodies to rabbit erythrocytes were removed from 
serum samples using the adsorption technique described 
by van Djik et. al. (1980): 1 volume of packed
erythrocytes was incubated at 0° (iced water bath) with
j volumes ui s o l u i i i  i u i  ou minutes or z < i  nours, witn 
occasional agitation. After incubation, the cells were 
sedimented by centrifugation (3000rpm, 4°, MSE 
"Chilspin"). The supernatant was removed carefully and 
generally used immediately. If storage was necessary, 
the conditions described above were used. Controls 
consisting of serum without added erythrocytes were 
subjected to the same treatment.
Normal Human Sera
Two members of staff (DL and PG) regularly provided 
serum samples and in addition, aliquots of samples taken 
from undergraduates for virology practicals were also 
used.
2.2 HAEMOLYSIN PRODUCTION 
Immunisation
For the work described in Chapter 3, sheep cells 
collected in the way described above were taken from 
storage in Alsever's solution and washed once in 
phosphate buffered saline. A 10% (v/v) suspension of 
the packed erythrocytes in phosphate buffered saline was 
then prepared. Table 2-1 lists the animals selected for 
immunisation, and the protocol used. Blood samples 
taken from the immunised animals were separated in the 
usual way, and the sera stored at -70°. Antibody titres 
(Table 2-1) were determined using a conventional 
haemagglutination assay (Hudson and Hay, 1980). When 
rabbit antiserum to sheep erythrocytes was needed for 
total haemolytic complement activity assays on other 
occasions, a commercial preparation was used (Appendix 
I) .
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Haemagglutination Assays
The haemagglutination method cited above was used to 
measure the titre of rabbit erythrocyte agglutinins. 
Initially a 2 hour incubation period was used, but this 
was subsequently increased to 24 hours to increase 
sensitivity.
An independent measure of rabbit erythrocyte agglutinins 
was made using an immunofluoresence technique. Serial 
dilutions of each sample were made in complement 
fixation test diluent using 200pl volumes in LP3 tubes 
(Appendix 1). Then 200pl of 1% (v/v) rabbit erythrocyte 
suspension in the same diluent was added to each 
dilution. After gentle mixing, the tubes wer^JjKurfraired 
at 37° for 30 minutes, or at 4° for 24 hours, when the 
incubation was completed, the cells were washed 3 times 
with complement fixation test diluent before 1 drop of 
polyvalent, fluorescein-labelled antiserum to human 
immunoglobulins (Appendix 1) was added to each tube. 
After 30 minutes at 37°, the cells in each tube were 
washed again, and examined using a fluoresence 
microscope system (Appendix 1) to determine the titre of 
cell-bound fluoresence. Appropriate controls were 
included in each batch.
2.3 COMPLEMENT COMPONENT LEVELS 
Immunochemical Assays
A single radial diffusion technique was used for this 
purpose (Dubock, 1982). Antisera to human complement 
components were purchased from Miles Laboratories 
(Appendix I). They were mixed with molten agarose at 56° 
in the proportions shown in Table 2-2. Individual gels 
were poured on alcohol-cleaned 3"xl" glass microscope
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slide. When these gels had set at room temperature, 
they were stored at 4° in a moist chamber until 
required. Storage never exceeded 48 hours. Wells (3mm
diameter) were cut in the agarose using a
commercially-available cutter (Appendix I). A standard
volume of serum (usually 4ul) was placed in each well.
Once loaded, the gels were returned to a moist box and 
incubated at room temperature for 24 hours. Thereafter 
they were kept at 4° and reexamined if necessary. To 
ensure reliable measurement of the precipitin rings, all 
the gels were dried and stained with Coomassie Blue 
reagent (Appendix I) before the diameter of each ring 
was measured. A ruler supplied by Behring Diagnostics 
(Appendix I) was used to make these measurements.
Assays were usually performed in duplicate. Each batch 
was standardised using serum obtained from apparently 
healthy subjects. These were used both singly, and as 
pools , according to the circumstances. The results 
were expressed as a percentage of the normal adult 
level.
Factor D Assays
These were performed using the modification of the 
method described by Martin et. al. (1976) shown in 
Figure 2-2.
2.4 COMPLEMENT ACTIVITY ASSAYS 
Alternative Pathway Haemolytic Activity
Alternative pathway diluent was used to prepare rabbit 
erythrocyte suspensions and to make any serum dilutions. 
This reagent consisted of complement fixation test
49
bis-tetraacetic acid, EGTA, sodium salt at 0.08 mol/1, 
and initially, magnesium chloride at 0.04 mol/1 
(Appendix 1) .
Activity was measured in three ways:
a. a conventional serial dilution assay identical to 
that used for total haemolytic complement activity 
except in the use of alternative pathway diluent and 
rabbit erythrocytes instead of complement fixation test 
diluent and sheep erythrocytes.
b. an independent assessment of alternative pathway 
haemolytic activity was made using a modified radial 
diffusion technique (Lachmann, Hobart and Aston, 1973) 
in which target erythrocytes were incorporated in 
agarose gels.
c. a timed-lysis assay of alternative pathway haemolytic 
activity based on the method described by Jones (1979) 
was also used. The important modifications were the 
omission of gelatine from the diluent, and the use of an 
optimum (4 mmol/1) magnesium concentration. Rabbit 
erythrocytes were suspended in alternative pathway 
diluent to give an absorbance at 700nm in the region of 
0.9, using 1 cm cuvettes. This corresponded to a red 
cell count circa 4 x 10^/ml. Most of the assays were 
performed in a Beckman Model 24 spectrophotometer. On 
some occasions it was necessary to analyse large batches 
of samples in a single day to ensure continuity of
Perkin-Elmer "Lambda" spectrophotometer was used as 
these instruments made it possible to analyse four or 
six samples simultaneously. According to circumstances, 
3000pl, lOOOpl or 500pl of cell suspension was used in 
the assay; serum volumes were chosen to give final 
dilutions between 1:2 and 1:75. The chosen volume serum 
was warmed to 37°. At zero time the appropriate volume 
of rabbit erythrocyte suspension was added from a 
pre-warmed stock. After gentle mixing, the reaction 
mixture was transferred to the a warmed cuvette within 
30 seconds. The progress of cell lysis was followed by 
measuring absorbance at 700nm, an index of light 
scattering, continuously using a chart recorder.
Total Haemolytic Complement Assays 
Sensitised Cells
These cells were produced by mixing antisera with a 3% 
suspension of sheep erythrocytes in complement fixation 
test diluent in proportions which corresponded to the 
next dilution above the haemagglutination titre of the 
antiserum in question (Higgins and Langley, 1985). The 
innate complement activity of each serum was destroyed, 
before use, by incubation at 56° for 30 minutes. Each 
mixture of sheep erythrocytes and sensitising antiserum 
was incubated at 37° for 15 minutes. The sensitised 
cells were then washed three times in complement 
fixation test diluent, stored at 4° in fresh diluent and 
used within 24 hours.
Activity Assays
a. a conventional, two-fold serial dilution test (Gewurz
In this assay, 20pl aliquots of a 3% (v/v) suspension of 
sensitised erythrocytes in complement fixation test 
diluent were added to an equal volume of serum or serum 
dilution. The controls consisted of an aliquot of cells 
mixed with an equal volume of diluent. Each microtitre 
plate was incubated in a moist atmosphere at 37° for 2 
hours. Lysis was assessed visually, as being complete 
or partial. The last dilution which caused significant 
lysis was recorded.
b. a timed-lysis or kinetic assay performed in a Beckman 
Model 24 spectrophotometer using 1cm glass cuvettes held 
at 37°. Sensitised sheep erythrocytes were suspended in 
ccomplement fixation test diluent to give an absorbance 
at 700nm (Aj q q ) circa 0.9. The sample dilution and the 
volume of this dilution needed to give suitable activity 
were determined for each experiment. A fixed volume 
(lOOOpl) of the sensitised cell suspension was used 
throughout this investigation. The chosen volume of 
diluted serum was mixed with the sensitised sheep 
erythrocytes using the procedure described for 
alternative pathway assays. The lytic reaction was 
followed by the measurement of 
2.5 STATISTICAL PROCEDURES
Basic analyses were performed using a Casio fx-180P 
calculator. More involved procedures were performed on 
the University of Surrey Prime computer system using 
routines from the Statistical Package for Social 
Sciences, SPSS, (Nie, et. al., 1975). Details of the 
individual routines will be given at the appropriate
52
2.6 OTHER METHODS
The methods described above are those which were used 
often in this investigation. Techniques used on an 
occasional basis will be described at the appropriate 
points in the text.
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Figure z- i
P r e p a r a t i o n  o f  N e u r a m i n i d a s e - T r e a t e d  E r y t h r o c y t e s
Neuraminidase Type V (Sigma)
(a) Dissolved in Distilled Water 
at 1 unit/ml
(b) Frozen in 150pl aliquots
Sheep Red Cells
Washed 3 times in 0.85% 
saline; supernatant and 
buffy layer removed.
Incubate in 37 water bath for 30 minutes with gentle mixing
NEURAMINIDASE (150pl) PACKED CELLS (3000pl)PHOSPHATE
BUFFERED
SALINE
(5000pl)
I
Wash cells twice in phosphate buffered salinet
Resuspend in appropriate buffer at required concentration
(Personal Communication, Taylor, C. (1981))
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Factor D Assays
FACTOR D DEPLETED SERUM (FDDS) AGAROSE GEL (washed in EGTA)
Sephadex G200 column in PBS 2.4% solution, melt in
Exclusion peak : FDDS boiling water bath, hold
50°
o
Warm to 50 and add to agarose:
EGTA to 10 mmol/1
MgCl2 to 4 mmol/1
rabbit erythrocytes to 1%
FDDS to 0.75%
Make agarose to 1% by dilution with warm CFTD 
Pour gels, leave to set overnight
Cut 3mm wells, fill with 4pl appropriate serum
Incubate at 4° overnight, then 2 hours at 37° after 
warming to room temperature
Read diameter of lysis
PBS : phosphate buffered saline
CFTD : complement fixation test diluent
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Production of Haemolysin Antisera: Protocol and Products
Production of antisera against sheep erythrocytes
Species No Breed/Strain
Inoculation Haemagglutination titres
Volume* Route^ Immunized
animals
Normal
sera
Ox 2 Jersey,
Hereford
3.0 IV 256,512 4
Rabbit 4 NZW x Lopear 1.0 IV 128,128,256,256 0
Mouse 15 CFLP 0.25 IP 128,256,5123 8
Hamster 10 Syrian 0.25 IP 128,128,256, 
256,2563
4
Guinea-pig 5 Hartley 0.5 IP 128,1283 4
Ferret 3 Polecat 1.0 IP 32,32,64 16
Badger 3 - 1.0 IV 64,64,128 8
Hedgehog 3 - 0.5 IP 8,64,64 8
Fowl 2 White Leghorn 0.5 IV 256,1024 32
^Volume (ml) of 10% SE suspension inoculated on each of days 1,2,3,5,7,9,11 
and 13. Animals were bled on day 15.
2
IV, intravenous; IP, intraperitoneal.
3
Pools of two or more individuals.
Table 2- 2
Proportion of Antiserum in Radial Diffusion Gels
COMPONENT % ANTISERUM %PEG
C3 1.0 -
factor B 1.0 -
properdin 1.0 1. 0
factor I 1.5 -
factor H 1.5 -
C 4 0. 5 -
Cl inhibitor 1.0 -
: Polyethylene Glycol
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3. ALTERNATIVE PATHWAY ACTIVITY ±n n u k w a l  >^n.tcA
3.1 INTRODUCTION
The demonstration of marked differences in the kinetics 
of alternative pathway activation in human sera 
(Langley, Griffiths and Laurence, 1982; Laurence, 1982) 
was an unexpected finding. When sera from certain 
mammalian species were also shown to have distinctive 
reaction kinetics a detailed investigation of these 
phenomena was carried out. This investigation, reported 
below, was designed to answer certain questions, for 
instance, (a) what is the activity of selected animal 
sera in the conventional assays of complement activity?
A number of publications (Rice and Crowson, 1950a,b and 
c; van Dijk et. al. (1983) had reported work of this 
kind, but the present study also examined serum from 
species not included in earlier work. (b) what is the 
pattern of results obtained when the kinetics of 
complement activation are studied in each animal serum? 
Although Polhill et. al. (1978b) had examined the 
kinetics of alternative pathway activation in mouse and 
chicken serum, there had been no systematic study of 
reaction kinetics using animal sera. It was also 
important to ask (c), whether the differences in 
reaction kinetics seen when certain human sera were used 
could also be found in a larger group of human sera and 
if so, are they reflected in the results of conventional 
assays of alternative pathway activity? Finally, (d) 
since a very simple dilution method had been used in the 
preliminary studies of the kinetics of alternative
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more time-consuming, conventional dilution protocol was 
investigated.
Total haemolytic complement activity and alternative 
pathway activity were measured by conventional and 
kinetic assays. It should be remembered that the former 
is not a measure of classical pathway activity. Since 
alternative pathway activity is inevitably recruited 
when the classical pathway is activated, total 
haemolytic complement activity represents the combined 
activity of both pathways. Its measurement does have 
value nevertheless, in that a comparison of total 
haemolytic complement activity and alternative pathway 
activity gives indirect information on classical pathway 
activity, and on the contribution of the alternative 
pathway to total complement activity.
3.2 MATERIALS AND METHODS
Total Haemolytic Complement Activity
The sera were tested against sheep erythrocytes
sensitised with haemolysins produced in each species.
In addition, the total lytic activity was also measured 
using sheep cells agglutinated with a low (1:10) 
dilution of each antiserum. After 25pl of diluted 
haemolysin and sheep cell suspension had been incubated 
together for 60 minutes to produce agglutination, 50pl 
of fresh serum was added. The subsequent incubation and 
examination were done in the usual way.
General Screen of Alternative Pathway Activity.
1% suspensions of erythrocytes from each of the species 
to be studied were prepared in alternative pathway
diluent. Equal (25pl) volumes of each suspension and 
each test serum were mixed in a 96 well microtitre plate 
so that each erythrocyte suspension was tested against 
each serum. The plate was then incubated in the usual 
way. In order to eliminate the possibility that the 1:2 
dilution used might reduce inhibition of the classical 
pathway by the alternative pathway diluent, the 
experiment was also done using double strength 
alternative pathway diluent (Appendix 1).
Interpretation of Microtitre Plate Assays 
A simple criterion of variation used in clinical assays 
was adopted: differences in titre which exceeded one 
dilution step were regarded as significant.
3.3 RESULTS
3.3.1 ANIMAL SERA
Total Haemolytic Complement Activity Against Sensitised 
Cells
The control titre in each experiment (Figure 3.1 to 
3.10, left-hand plot) represents the alternative pathway 
activation by the sheep erythrocytes, while the 
difference between the titre of total haemolytic 
complement activity and the control titre indicates the 
amounts of classical and alternative pathway activity 
which are expressed after activation of the classical 
pathway by the sensitised sheep erythrocytes. Chicken 
serum did not cause a significant increase in lysis, 
while hedgehog serum gave a 2-3 well increase in the 
titre of lysis with most cells and hamster serum did so 
with some: those sensitised with rabbit, guinea pig and 
bovine haemolysins. Guinea pig complement also caused
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antibodies (rabbit, hamster, guinea pig and bovine). 
Despite the marked l.ysis of the control cells by badger 
serum, the combination of badger antibody and badger 
serum produced the strongest reaction seen in the 
homologous reactions.
Total Haemolytic Complement Activity Against 
Agglutinated Cells
Interaction of agglutinated erythrocytes with complement 
from the same species as the antibody causing 
agglutination produced a spectrum of results (Figures 
3.1 to 3.10, right-hand plot). There was little 
difference in the extent of lysis of sensitised and 
agglutinated erythrocytes in the hedgehog, guinea pig 
and rabbit systems, although complete lysis was seen in 
each well with the sensitised cells, the equivalent 
wells tended to show only partial lysis in the test 
using agglutinated cells. A marked increase in total 
haemolytic complement activity against agglutinated 
cells was seen with the hamster and bovine systems. The 
effect was most marked in the case of bovine antibody 
and complement. In contrast, the use of agglutinating 
concentrations of antibody abolished total lytic 
activity in the badger and ferret systems.
In the heterologous reactions most antibodies appeared 
capable of reacting with most complement systems to the 
extent shown by the autologous mixtures of antibody and 
complement. Notable exceptions were the enhanced 
reactivity of hamster complement with sheep erythrocytes 
sensitised with rabbit, guinea-pig and bovine
with hamster antibodies, while hamster complement failed 
to react with hedgehog antibody. Human serum reacted 
well with most of the sensitised cells, whereas badger 
and ferret serum reacted poorly.
In some wells showing partial lysis of agglutinated 
cells there was dissociation of the unlysed 
agglutinates.
Kinetics of Total Haemolytic Complement Activity Against 
Sheep Cells Sensitised With Rabbit Haemolysin
At a serum dilution of 1:40, complete lysis of was 
achieved within 4 minutes using ferret, guinea pig 
badger and hedgehog serum (Table 3.1). It was completed 
within 7 minutes by human serum and 11 minutes by 
hamster serum. In all these examples, the lag time was 
less than 2 minutes, and in the case of the badger and 
the hedgehog, it was less than 1 minute. Chicken, 
bovine and murine sera did not show lytic activity at 
this dilution. Both chicken and bovine serum were able 
to lysis at a dilution of 1:2, but each showed 
distinctive kinetics. The reaction curve for chicken 
serum at this dilution resembled that obtained with the 
other sera at a 1:40 dilution. While the bovine serum 
showed a similar lag phase (2.2 minutes), the time to 
complete lysis was markedly extended (14 minutes).
Mouse serum failed to cause lysis of the sensitised 
cells at either dilution (Table 3.2) and also failed to 
produce lysis of sheep erythrocytes sensitised with 
murine antibodies, even at the lowest possible dilution, 
1:2. conversely, the mouse antibodies did fix guinea
cells. Since the main thrust of this work was concerned 
with the alternative pathway, this line of investigation 
was not pursued further.
Alternative Pathway Activity 
General Screen
Rabbit erythrocytes were lysed by all the sera tested 
(Table 3.3), so were guinea pig erythrocytes. Hamster 
cells reacted with all except human serum, while mouse 
serum was activated by all except hamster erythrocytes. 
In the assays of total haemolytic complement activity 
the control (sheep) cells were lysed to some extent by 
all except bovine serum, but this experiment, done in 
alternative pathway diluent, only ferret, chicken, and 
badger serum lysed the sheep erythrocytes. Apart from 
these exceptions, the general pattern was that 
erythrocytes from most species reacted with ferret, 
chicken, badger and bovine complement, although badger 
and ferret erythrocytes showed some additional 
reactions. The results obtained using double strength 
diluent were identical to those described above. 
Comparison of Alternative Pathway Activity 
Rabbit erythrocytes, sheep erythrocytes, and where 
possible, neuraminidase-treated sheep erythrocytes were 
used in a selection of conventional assays. All three 
were used in serial dilution assays, while only rabbit 
and sheep erythrocytes were used for radial diffusion 
assays. Figure 3.11 gives the results of the serial 
dilution tests and Table 3.4 the results of the radial 
diffusion assays.
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The relative activities in the sera tested were graded 
(Table 3.5), badger serum produced only partial lysis of 
rabbit erythrocyte's at the higher dilutions, while 
chicken serum did so at all dilutions. When sheep 
erythrocytes were used, chicken serum showed partial 
lysis at the higher dilutions. Rabbit serum was not 
active against sheep erythrocytes.
When neuraminidase-treated sheep erythrocytes were used, 
the relative activities were similar to those with 
rabbit cells , but the titres were slightly lower. 
Finally, each serum was mixed with suspensions of the 
three types of erythrocyte prepared in complement 
fixation test diluent rather than the alternative 
pathway diluent (Table 3.6). Certain anomalies can be 
seen when these results are compared with those from the 
initial screen and those of the radial diffusion assay. 
Human serum exhibited low activity in all analytical 
systems.
Kinetics of Alternative Pathway Activity
A range of serum dilutions was tested against rabbit 
erythrocytes (Table 3.7). It was necessary to perform 
the assays in two batches on successive days. Fresh 
reagents were used on each day and those made for the 
second day gave slightly lower figures for t50. The 
values of tL and t50 for the second batch have been 
weighted to compensate for this variation. When the 
results of the two batches are considered together, the 
activities obtained using the reaction mixture 600pl 
serum : 3000pl red cell suspension may be ranked (Table 
3.8) .
G3
both tL and t50 were greater than those seen at a 
dilution of 1:5 in other species.
The extent to which activity could be detected in 
dilutions greater than 1:5 correlated broadly with the 
conventional assays of alternative pathway activity, 
whose endpoints are the limiting dilutions for key 
components (Table 3.9)
3.3.2 HOMAN SERA 
Survey of Activity
Normal human sera were assayed for alternative pathway 
activity using the conventional titre and radial 
diffusion assays, and the kinetic method. The reaction 
mixture for the latter experiment was lOOpl serum and 
900ul rabbit erythrocyte suspension. The kinetics of 
alternative pathway lysis varied significantly between 
samples (Table 3.10) but there was little difference in 
the results of the conventional assays.
Comparison of Dilution Protocols
The protocols used to assay the human sera DL and PG are 
given in Table 3.11. The differences in the alternative 
pathway activity of the two sera (Figure 3.12) were less 
marked when the total volume of reactants was kept 
constant. Since the simple method of varying the volume 
of serum assayed (mixing fixed volume of red cell 
suspension with different volumes of serum) appeared to 
have no disadvantages, and was indeed more informative, 
it was used throughout the subsequent studies.
3.4 DISCUSSION
The wider implications of these results will be examined
I l l  L i l t ;  y c n e i a i  u x o ^ u o o x v ^ n  ,  u u u  u u u v - i .  _____
made at this point. Most sera gave a sigmoid curve when 
the lytic reaction in total haemolytic complement 
activity or alternative pathway haemolytic activity 
assays were monitored continuously. In practice the lag 
phase was not always distinctive, especially when 
activity was low at the chosen dilution. This is not 
unexpected since the dilutions in question often 
corresponded to those near the endpoint in serial 
dilution tests where the statistical probability of 
protein-protein interactions is minimal. It had been 
hoped that the rate of lysis (change in A^g/minute) 
could be calculated from all the reaction curves 
obtained in this investigation. In fact, the course of 
the lytic reaction was seldom linear and the calculation 
of reaction rates was difficult or impossible. To 
overcome this problem the derived value (t50-tL), the 
difference between the time to 50% lysis and lag time, 
was adopted as an index of the efficiency of the lytic 
reaction. Other workers who have used kinetic assays 
(Polhill et. al., 1978a,b) have restricted themselves to 
t50, but as this is a composite value (lag phase and 
early lytic reaction) its use can be misleading. In 
those reactions which gave a poorly defined lag phase 
and a slow lytic reaction however it was necessary to 
rely on t50 or even the rate of reaction. Fortunately 
such instances were rare. The time to 100% lysis (tlOO) 
was not regularly used because of the time involved in 
measuring it, especially in sera with low complement 
activities.
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case, sensitised and agglutinated erythrocytes, in which 
antibodies from one species with complement from a 
number of other species in assays of total haemolytic 
complement activity does confirm the feasibility of the 
traditional complement fixation test. In the second 
stage of complement fixation tests for the detection of 
antibodies, immune complexes formed from these
antibodies are usually reacted with guinea pig serum
complement. When the various immunoglobulins tested 
were used to sensitise sheep erythrocytes, the lysis 
which occurred was never very marked, even when guinea 
pig haemolysin was used to sensitise the sheep 
erythrocytes. When, however, agglutinated sheep 
erythrocytes were used instead of sensitised cells, more 
lysis was seen in each serum. These agglutinated cells 
were arguably more like the complexes produced in the 
first stage of a complement fixation test than 
sensitised cells, since the antigen : antibody ratio in
the latter is unusually high. None of the sera examined
exhibited more complement activity than guinea pig 
serum. In the final stage of a complement fixation 
test, the residual guinea pig complement is titrated 
using sheep erythrocytes sensitised with rabbit 
haemolysin. These reacted most effectively with guinea 
pig serum.
The dissociation of unlysed agglutinates in the presence 
of complement is reminiscent of the dissociaton of 
immune complexes decribed in earlier (Takahashi,
Takahashi and Hirose, 1980).
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Figures 3-1/10 
Animal Sera: Total Haemolytic.Complement Activity
= complete lysis in well
= partial lysis in well
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F i g u r e  3 - 1 1
Animal Sera: Alternative Pathway Activity
NORNAL SERUtt vs RABBIT REO CELLS 
12 10 8 G 1 2 2 4 6 8 10 12
i i i i i r
HUNAN
CHICKEN
RABBIT
BADGER
FERRET
GUINEA
PIG
HEDGEHOG
BOVINE
Jersey it:
1— i— i— i— i— i
12 10 8 G 1 2 Log Reciprocal Titre 2 4 G 8 10 12
2
t h c a  t a p a
NORNAL SERUfl vs SHEEP RED CELLS
12 10 8 G 1 2 2 4 G 8 10 12
HUNAN
CHICKEN
RABBIT
BADGER
FERRET
GUINEA
PIG
HEDGEHOG
BOVINE
Jersey
1-
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12 10 8 G 4 2 Log^ Reciprocal Titre 2 4 G 8 10 12
2
THCA TAPA
RE i. SEC N ) vs NORNAL SERA
12 10 8 G 4 2 2 4 G 8 10 12
:c
i— i— i— i— i— i—
12 10 8 6 4 2 Lo
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Comparison of Dilution Protocols for Human Sera DL
t ime 
(min)
10
J
H t 50 tL
0 2 4 6 8 10 12
10
A
0 2 4 6 8 10
varying total volume D ILUTIO NS fixed total volume
Animal Sera: Kinetics of Total Haemolytic Complement
Act ivity
Complement
Reaction volume (pi) Time (min) ot
source Se rum:SEA LP C 50 4 0 0
Human 2 5:1000 1.9 3.5 6.7
Ox 25:1000 — no activity—
Mouse
500:500
25:1000 
500:500
2.2 6.3
— no activity—
14.0
Hamster 25:1000 1.8 5.3 10.9
Guinea-pig 25:1000 1.1 1.7 3.1
250:250 1.7 5.4 10.5
Ferret 25:1000 1.0 1.5 2.3
Badger 25:1000 0.5 1.1 2.1
Hedgehog 25:1000 0.9 1.7 3.2
Fowl 25:1000 — no activity—
500:500 1.2 2.5 3.9
SEA: sensitized erythrocytes; LP: lag 
c100: t*me co 100^ lysis.
Table 3- 2
phase; t5o : time 
i
to 50% lysis;
Mouse Serum: Kinetics of Total Haemolytic Complement
Act ivity
Target Cells : Sheep Erythrocytes Sensitised with Mouse 
Haemolysin. Reaction Mixture : 250pl serum, 250pl cell 
suspension.
SERUM tL 150 tioo
Balb/c >20 >20 >20
C57Black >20 >20 >20
C3H >20 >20 >20
CBA >20 >20 >20
Guinea Pig 1.7 5.4 10.5
(control)
All mouse sera showed alternative pathway activity
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Animal Sera: Alternative pathway Activity in Radial
Diffusion Assays
Lysis of unsensitized erythrocytes in agarose gels
Serum Diameter of lysis (mm)
Species Volume (pi)
Sheep erythrocytes in 
CFTD APD
Rabbit erythrocytes in 
CFTD APD
2 7.8 6.4 6.9 6.2
Badger 5 8.3 6.9 8.8 7.9
10 10.0 7.6 9.2 8.5
2 7.4 7.5 7.2 7.4
Ferret 5 8.3 7.7 8.9 8.5
10 9.1
00 10.6 11.1
2 6.6 + 1 _ _
Rabbit 5 8.6 + - -
10 8.7 + - -
2 3.8 - 5.8 -
Guinea-pig 5 6.0 - 6.0 -
10 9.0 — 9.0
CFTD: complement fixation test diluent; APD: alternative pathway diluent.
^Weak positive results; also seen for human and hedgehog against SE in both 
diluents. Negative results against SE with ox, fowl, hamster and mouse. 
Against rabbit erythrocytes weak positive results were obtained with human 
serum (in both diluents) and hedgehog serum (in CFTD only). Negative 
results with ox, fowl, hamster and mouse.
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Animal Sera: Comparison of Activity in A l t e r n a t i v e #
Pathway Serial Dilution Assays
vs RABBIT .ERYTHROCYTES
hedgehog
Badger > ferret > chicken > guinea pig >
ox
vs SHEEP ERYTHROCYTES
Badger ox human
Ferret > chicken > hedgehog > guinea pig
human
78
Animal Sera: Haemolytic Activity in Complement Fixation 
Test & Alternative Pathway Diluents
vs RABBIT ERYTHROCYTES:
Increase in titre of lysis:
human
rabbit
ferret
hedgehog
bovine
No change in titre of lysis:
badger
chicken
Decrease in titre of lysis: 
guinea pig
vs SHEEP ERYTHROCYTES:
Increase in titre of lysis:
human
rabbit
badger
fer ret
guinea pig
No change in titre of lysis:
hedgehog
bovine
chicken (1 dilution)
vs NEURAMINIDASE-TREATED SHEEP ERYTHROCYTES:
Increase in titre of lysis:
human(*)
chicken
badger
ferret
guinea pig
hedgehog
bovine(*)
Decrease in titre of lysis:
mouse(**)
rabbit(**)
* no activity in alternative pathway diluent
** activity abolished in complement fixation test diluent
Animal Sera: Kinetics of Alternative Pathway Haemolytic
Act ivity
Timed-lysis assays of alternative pathway activation by rabbit 
erythrocytes
Serum
P v r* i m o r\ t-
Time (min) of
Species Volume (pl)^ LP n tn O c100
1 Human female 750 1.7 3.0 3.6
600 2.5 3.8 5.9
300 8.0 - -
Human male 750 2.7 7.0 9.2
600 3.5 9.2 12.4
Fowl 750 1.2 1.8 3.5
600 2.2 3.0 4.4
300 6.0 10.1 13.2
Ferret 1000 0 2.3 4.0
750 0 3.2 5.7
600 0.9 3.6 6.2
300 1.7 5.4 8.5
150 2.1 6.5 .0.0
75 3.2 15.0 -
Guinea-pig 1000 1.6 3.4 8.7
750 1.8 - -
600 2.3 - -
Mouse 5001 3.0 10.5 -
2 Human female 1000 1.0 2.7 4.0
750 2.7 4.9 6.7
600 3.7 6.0 8.0
Human male 1000 2.2 4.4 5.4
750 3.0 6.6 9.0
600 4.0 7.2 10.0
Badger 1000 1.0 3.0 4.0
750 1.2 3.2 5.0
600 1.4 3.8 5.5
300 1.6 6.4 -
Hedgehog 600 0.7 1.9 3.0
300 1.7 3.9 7.0
Hamster 1000 1.7 5.6 -
600 2.9 - -
Ox 600 2.1 3.1 5.0
300 4.7 10.3 13.0
LP: lag phase; t,^: time to 50% lysis; cioo: c*me to 100% lysis.
^Volume of serum added to 3 ml rabbit E suspension; except for mouse 
where 500 pi serum was mixed with 500 pi rabbit E suspension.
T a b l e  3 -  8
Animal Sera: Relative Alternative Activity in Kinetic 
Assay
BY 150-tL VALUE: 
chicken 
bovine 
ferret 
hedgehog 
badger 
human
HIGHEST:LOWEST HIGHEST:LOWEST
=3.8 = 4 . 8
BY tL VALUE: 
ferret . 
badger 
hedgehog 
bovine 
chicken 
guinea pig 
hamster 
human
SPAN BETWEEN 
THEM =2.5min.
SPAN BETWEEN 
THEM = 4.5min.
Table 3- 9
Animal Sera: Comparison of Activity in Alternative 
Pathway Serial Dilution & Radial Diffusion Assays
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Tapie j-iu
Human Sera: Comparison of Activity in Alternative
Pathway Serial Dilution, Radial Diffusion & Kinetic 
Assays
KINETIC: ASSAY
SAMPLE tL 150 TITRE RID
FEMALES
9.0PG 1.3 3.6 4
STl 2.1 4.2 4 7.9
ST 2 2.0 4.2 4 9.0
ST3 3.2 6.3 2 8.4
ST4 3.8 7.3 ' 4 8.8
ST5 3.2 7.7 4 8.9
ST6 3. 6 8.4 2 8.8
ST7 * 4.2 4 8.9
ST8 * 16.2 2 9.0
ST9 0.5 2.7 4 8.9
ST10 0.6 5.4 4 9.0
MALES
8.5DL 3.1 6.5 4
ST 11 1.1 3.2 4 9. 6
STl 2 3.8 6.2 4 9.3
STl 3 4.3 7.6 2 9.0
STl 4 * 6.7 4 8.7
MEAN (STANDARD DEVIATION)
8.9Whole Group 2.5 6.3 3.5
(1.3) (3.2) (0.9) (0.
Females 2.3 6.0 3.4 9.0
(1.3) (1.7) (1.0) (0.
Males 3.1 6.4 3.6
00 
00 
■
(1.4) (3.7) (0.9) (0.
Heated Serum Caused No Lysis.
Titre: titre in serial-dilution assay.
RID: radius of ring in radial diffusion assay
* : not discernable
TaDie j-ii
Human Sera DL & PG: Protocol for Comparison of Dilution 
Procedures
VARYING TOTAL VOLUME
(A) (B) .(C)
SERUM (pi) : 500 250 100
TARGET CELL SUSPENSION (pi) : 500 750 900
EFFECTIVE DILUTION 1:2 1:4 1:10
FIXED TOTAL VOLUME
(A) (B) (C) (D) (E) (F)
SERUM (ml) : 1.2 0.9 0.6 0.3 0.2 0.1
DILUENT (ml) : 0.3 0,6 0.9 1.0 1.1
DILUTION : 1:2.7 1:4 1:8 , 1:12 1:24
Each dilution mixed with 1.2 ml target cell suspension for
assay.
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4.1 INTRODUCTION
The work described in the previous chapter showed that 
serum samples from a number of vertebrate, species 
exhibited significant differences in the kinetics of 
alternative pathway-mediated red cell lysis. These 
differences could be demonstrated at dilutions which are 
in the range used for other functional tests of the 
complement system such as opsonisation assays (Levinsky, 
Harvey and Paleja, 1978) .Before attempting to 
demonstrate the clinical significance of these 
observations, an attempt was made to investigate their 
molecular basis. In the light of present knowledge, a 
number of possibilties exist:
a. that the phenomena are analytical artefacts or 
biological artefacts due to the biochemistry of the 
rabbit erythrocyte surface membrane.
b. that they represent real differences in the 
efficiency of complement activation which result from 
differences in the concentration of key complement 
components. The concentration of each component depends 
on the balance of synthesis, consumption in immune 
responses and catabolism by the reticuloendothelial 
system. Each could be varied by genetic influences, or 
by environmental factors such as diet. Straightforward 
techniques for the measurement of biosynthetic and 
catabolic rates are not available at present, and for 
this most investigators rely on the measurement of 
component levels as a general pointer. The relationship
levels of key components was explored with sera from two 
specific sources each known to be associated with 
changes in component levels and haemolytic activity. 
These were patients with rheumatoid arthritis and a 
group of premature and full-term neonates.
Rheumatoid arthritis is an immune complex disease 
associated with complement consumption and an acute 
phase reaction (that is, increased production of a 
number of proteins, including several complement 
components; Whicher and Chambers, 1984). Thus a variety 
of changes in the complement system should be found if 
sera from a group of patients with this disease are 
examined.
In the case of premature and full-term neonates, a 
number of reports (Sawyer et. al., 1971; Mills,
Bjorksten and Quie, 1979; Strunk, Fenton and Gaines,
1979) have indicated that complement activity at full 
term (i.e. those infants born at 38 weeks gestation) was 
between 60% and 90% of adult levels. Furthermore, it 
was found that premature infants showed a statistically 
significant correlation between birth weight or 
gestational age and total haemolytic complement 
activity. Therefore this study offered a unique 
opportunity to investigate the relationship between 
component levels and alternative pathway activity,
c. that the differences in reaction kinetics reflect the 
presence of differing amounts of "naturally-occurring" 
antibody to rabbit erythrocytes. While antibody is not 
an essential requirement for alternative pathway 
activation, it has been shown to play a part in the
and to modify the kinetics of red cell lysis. Oldstone 
and his colleagues (.Joseph, Cooper and Oldstone, 1975; 
Perrin et.al., 1976) demonstrated that the specific 
binding of large amounts of antibody to a selection of 
virus infected cells made possible alternative pathway 
activation not seen in the absence of antibody, while 
Tarr et. al. (1982) demonstrated a role for antibody in 
the alternative pathway-mediated killing of Haemophilus 
influenzae. Moore, Fearon and Austen (1981) came to 
similar conclusions Using mouse erythrocytes as a target 
of complement activity. In another study, Polhill et 
al. (1978b) used a kinetic assay of alternative pathway 
activity to study the effects of antibody on the rate of 
red cell lysis by the alternative pathway. They 
demonstrated that a gamma globulin component of serum 
was able to enhance alternative pathway haemolytic 
activity, and produced evidence that the component was 
immunoglobulin. In view of these observations a number 
of experiments were performed to test the hypothesis 
that such antibodies might be responsible for the 
distinctive reaction kinetics of the human sera DL and 
PG.
First these two sera, and a number of other sera were 
tested for the presence of antibody. Next, the sera 
were adsorbed with rabbit erythrocytes to determine the 
effect of removing any antibody present on alternative 
pathway activity. The effect of sensitising sheep 
erythrocyte with antibodies from each of the species 
studied in the previous chapter on the reaction of the
cells with the alternative pathway m  serum trom normal 
animals was also studied.
Generalised immunoglobulin deficiency (hypogamma- 
globulinaemia) in humans and chickens is said to be 
associated with a defect in alternative pathway activity 
which can be reversed by the addition of purified 
immunoglobulin to the serum in-vitro (Polhill et. al. , 
1978b; Johnston, Polhill and Pruitt, 1978). These 
authors claimed that their observations confirmed the 
role of antibody in governing the rate at which 
alternative pathway activity is expressed. The 
complement system in sera from a number of patients with 
various forms of hypogammaglobulinaemia was examined 
extensively to test this hypothesis. Finally an attempt 
to eliminate the effects of antibodies in human sera 
during haemolytic assays was made by modifying the 
surface of human erythrocytes so that they would 
activate the alternative pathway.
d. that the differences in activity result from 
differing levels of the low molecular weight inhibitor 
of complement activity reported by Baker, Parker and 
Osofsky (1984). This hypothesis was tested by examining 
the effect of dialysis on the complement activity of the 
human sera DL and PG. ^
e. that they result from the presence of allelic forms 
of key components which impart a distinctive level of 
activity to the individual's alternative pathway. The 
outbred nature and varied lifestyle of human populations 
made the definitive investigation of genetic variants
opportunities to study the products of defined gene 
pools. The serum alternative pathway activity of 
selected strains was investigated,
f. the possibility that other mechanisms governed 
alternative pathway activity remained. In a final 
attempt to define the basis of the variation in reaction 
kinetics more clearly, the response of alternative 
pathway activity in sera DL and PG to a number of 
dilution procedures was investigated.
4.2 MATERIALS AND METHODS 
Rheumatoid arthritis sera
These were provided by the Pathology Department at the 
Royal Surrey County Hospital, Guildford.
Neonatal Sera
Serum samples were collected from 38 premature and 
full-term neonates in the Special care Baby Unit at the 
Royal Free Hospital London when they were bled for other 
essential investigations. Gestational ages at birth 
ranged from 27 to 41 weeks. Where more than one sample 
was collected from an infant, the ages at which the 
second and subsequent samples were taken were expressed 
as a gestational age. Thus a sample taken two weeks 
after the birth of an infant judged to have been born at 
36 weeks gestation was refered to as the 38 week sample. 
Clinical Condition of Infant.
Because some diseases cause an acute phase response or 
complement consumption in-vivo the child's condition was 
assessed using the scale shown in Table 4.1 whenever a 
sample was taken.
Sixteen samples were obtained from the Immunodeficiency 
Referal Clinic at Northwick Park Hospital, London. 
Standard Sera
A panel of "normal" adult sera which included PG and DL 
were used as standards and controls for both the 
activity assays and the measurement of component levels. 
Standardisation of Activity Assays on Neonatal Sera 
Since the samples were collected over several months and 
analysed in two large batches, there was some 
"between-batch" variation in the reactivity of the 
rabbit erythrocytes used on each occasion with the 
standard sera. To overcome this the lag time (tL) and 
(t50-tL) were expressed as functions of those shown by 
the standard sera. The sensitivity of two functions was 
compared:
a. % normal adult = [lysis time of standard serum (min)
/ lysis time of test serum (min) x 100]
b. Difference in Activity = [lysis of test (min) - lysis 
time of standard (min)]
Tanned Red Cells
Human group 0 negative erythrocytes were treated with 
tannic using the method described by Hudson and Hay 
(1982).
Functional Test for Antibodies to Rabbit Erythrocytes
Sera were tested for haemolytic activity against rabbit 
erythrocytes, first in alternative pathway diluent, then 
in complement fixation test diluent.
Use of Haemolysins
The titre of alternative pathway-mediated haemolytic
a c t ivity dydlllbL anccp ci. jr U111.UV/J1 i-vu — --------
haemolysins produced in chickens, rabbits, ferrets, 
hedgehogs, guinea-pigs and cows using the microtitre 
plate assay. Each plate was read after incubation at 
37° for 2 hours.
4.3 RESULTS
Component Levels and Complement Activity in Rheumatoid 
Arthritis Sera
In these rheumatoid sera the properdin levels were 
generally reduced, while factor B levels were above the 
standard normal adult level (Table 4.2). Few samples 
however showed any associated changes in activity. One 
serum showed a marked decrease in alternative pathway 
activity, but the levels of each of the components 
measured fell into the general pattern seen in the rest 
of the group. A more detailed statistical evaluation of 
this limited study was not considered appropriate. 
Neonatal Sera
Preliminary tests indicated that lOOul of neonatal serum 
and 300ul of erythrocyte suspension gave suitable 
reaction curves. A summary of the results is presented 
in Table 4-3, with the appropriate statistical analyses. 
Lag time (tL) and (t50-tL) generally parallel each other 
between 27 and 41 weeks (Figure 4.1). The earliest 
results (27 weeks) for tL and (t50-tL) were both between 
20 and 40% of adult levels, but they reached the levels 
shown for most of pregnancy (tL ca. 60% ; (t50-tL) ca. 
50%) by 30 weeks. Generally speaking the + two standard 
deviation limit was still below 100% adult levels 
although sometimes close to it. One individual, PCI,
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and factor B levels.
The levels of properdin (Figure 4.3), factor I and 
factor H (Figure 4.4) and cl-esterase inhibitor (Figure 
4.5) changed relatively little, whatever the clinical 
condition of the infants. In contrast, the levels of C3 
(Figure 4.2), factor B (Figure 4.3) and C4 (Figure 4.5) 
showed considerable variations between samples and 
between indivduals. The changes in C3 and factor B 
levels did not appear to have a great deal of effect on 
total alternative pathway activity. It was apparent 
that the clinical classification used in this study did 
not correlate with the perturbations in C3, factor B and 
C4 levels, nor with the less dramatic changes in 
activity. There was no significant pattern in clinical 
grades of the infants recorded as each sample was taken 
(Table 4.3).
The Effects of Antibody
Examination of the human sera used for the survey of 
alternative pathway activity described in section 3.3 
failed to reveal significant amounts of haemagglutinin 
in any of the samples. When however, the indirect 
immunofluoresence technique was used, it became apparent 
that some immunoglobulin had bound to the cells at low 
dilutions (1:2 to 1:16).
In the functional test for antibody the human sera DL 
and PG showed enhanced activity against rabbit 
erythrocytes in complement fixation test diluent (Table 
4.4). After adsorption with rabbit erythrocytes at 4°, 
both exhibited reduced alternative pathway activity
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The titres to which alternative pathway activity was 
expressed against sheep erythrocytes sensitised with 
each of the haemolysin antisera are shown in Figures 4.8 
to 4-16 . They may be summarised as follows:
a. HUMAN SERUM (Figure 4.6): this only showed activity 
against sheep erythrocytes at a dilution of 1:2. When 
the cells were sensitised with chicken antiserum this 
activity was unaltered. Sensitisation with all the 
other antisera abolished lysis.
b. CHICKEN SERUM (Figure 4.7): this lysed unsensitised 
sheep cells to a titre of 1:16. All the sensitised
cells gave the same result.
c. RABBIT SERUM (Figure 4.8): this did not lyse sheep
erythrocytes. Only cells sensitised with hamster
antibodies induced alternative pathway activity, to a 
titre of 1:2.
d.BADGER SERUM (Figure 4.9): unsensitised sheep cells 
were lysed to a titre of 1:64. Cells sensitised with 
badger antiserum increased this titre to 1:128, as did 
those sensitised with chicken, mouse, ferret and 
hedgehog antisera. Guinea pig antibodies did not affect 
the activity of badger serum, while the others used 
(rabbit, hamster and bovine antibodies), increased the 
titre of activity to 1:256.
e. FERRET SERUM (Figure 4.10): the control cells were 
lysed to a serum titre of 1:64. Badger and hamster 
antibodies did not alter this result, but those raised 
in guinea pig reduced it to 1:32. The remaining 
sensitised cells (including those produced using ferret
f. HAMSTER SERUM (Figure 4.11):the control cell titre 
was 1:64. chicken, guinea pig and hedgehog antibodies 
decreased it to 1:8, while those from mouse, ferret and 
hamsters themselves decreased it to 1:4. Badger 
antibodies only produced lysis at 1:2, while the rabbit 
antiserum abolished activity. Only the bovine antiserum 
failed to affect activity.
g. HEDGEHOG SERUM (Figure 4.12):in this instance sheep 
cell lysis occurred to a titre of 1:32. The only 
deviation from this value by the sensitised cells was in 
the the case of those prepared with the antiserum raised 
in a hedgehog, as well as those from ferret and guinea 
pig. Each reduced the titre of activity to 1:16.
h. GUINEA PIG SERUM (Figure 4.13): a variety of results 
was obtained. The unsensitised sheep cells were lysed 
to a serum dilution of 1:512. The presence of badger 
antibodies on the cells failed to alter this result, 
while those from the hamster and Jersey cow serum caused 
a marked reduction in activity (titre 1:2). Guinea pig 
antibodies were less inhibitory (titre 1:8). Cells 
sensitised with mouse, ferret and hedgehog antisera were 
lysed to a titre of 1:16, while those treated with the 
antisera from the rabbit and the Hereford cow lysed to 
1:64.
i. BOVINE SERUM (Figure 4.14): this was not active 
against unsensitised sheep cells, and none of the 
sensitised cells elicited alternative pathway activity. 
Hypogammaglobulinaemic Sera
No gross deficiencies of haemolytic activity were seen
individual components were rare, marked increases were 
common. Antibodies to rabbit erythrocytes were common; 
titres ranged between 0 and 1:256. There was no obvious 
relationship between these titres and total alternative 
pathway activity.
Use of Modified Human Erythrocytes
Neuraminidase treated human erythrocytes failed to 
activate the alternative pathway. Tanned red cells were 
lysed very slowly by serum at a 1:2 dilution and did not 
provide the basis of a an assay for alternative pathway 
activity.
Low Molecular Weight Inhibitor
Dialysis reduced total haemolytic complement activity 
and alternative pathway haemolytic activity (Table 4.8) 
Inbred Mouse Serum
Significant differences (Table 4.9) were demonstrated in 
the alternative pathway activity of Balb/c, C57 black, 
C3H and CBA mice of both sexes.
Other Factors
Dilution of the human sera DL and PG with each other, 
and with a variety of diluents used in complement 
studies (Table 4.10) produced a number of changes in 
alternative pathway haemolytic activity (Figures 4-15 
and 16). When either serum was diluted with 
complement fixation test diluent (Figure 4.16a) there 
was a steady decrease in the alternative pathway 
activity. The lag time (tL) shown by undiluted DL was 
greater than that of PG. Dilution increased tL in both 
sera, but the change was less marked in serum PG. In
measured by the difference between the time to 50% lysis 
and lag time (t50-tL), was more susceptible to dilution 
in serum PG. When each individual's serum was diluted 
with autologous serum which had been heat inactivated 
(Figure 4.15b), there was little effect on the response 
of tL to dilution. While lytic activity was still 
abolished at the same dilution (1:2), heated serum 
diluent caused smaller changes in (t50-tL) in lower 
dilutions of DL than the complement fixation test 
diluent. When serum PG was diluted with heated serum 
both tL and (t50-tL) were little changed at tne lower 
dilutions and some activity was detectable in all 
dilutions. When serum PG was used to dilute serum DL 
(Figure 4.15b), enhanced activity was seen in all 
mixtures.
The use of heat inactivated PG to dilute serum DL 
protected alternative pathway activity, and this 
phenomenon was also seen when heated DL was used to 
dilute serum PG (Figure 4.16a). Finally, diluents 
produced by warming the sera to 50° for 10 minutes 
(nominally factor B depleted sera), generally enhanced 
activity (Figure 4.16b) in the way that native serum had 
done (Figure 4.15b). The curves showing the effect of 
each dilution protocol on lag time (tL) 
are very similar, and only the dilution of native DL 
with factor B depleted DL gives a distinctive pattern 
for the variation of (t50-tL) with dilution.
4.4 DISCUSSION
The differences which had been observed between the
associated with different concentrations of certain 
components, but it is seldom possible to measure all the 
components in each sample because of limits to the 
availibilty of samples or reagents, especially if feral 
animal sera are studied. This investigation was not 
exempt from such restrictions, and some compromises had 
to be made. In the sera from patients with rheumatoid 
arthritis the number of components measured was 
deliberately limited. For the work on neonatal serum 
samples C3, factor B and properdin together with the 
control proteins factor I and factor H were chosen as 
determinants of alternative pathway activity; a reliable 
factor D assay was not available at this time. C4 and. 
Cl esterase inhibitor levels were used to give some 
indication of the state of the classical pathway in 
particular and of complement protein metabolism in 
general. The limited amount of serum obtained from many 
infants made further investigations impractical. In any 
event, measurement of the remaining components would 
have caused an unacceptable increase in the cost of the 
work .
As noted earlier the significance of titrations of total 
haemolytic complement activity and alternative pathway 
haemolytic activity as indices of complement activity 
can be questioned. These techniques determine the titre 
of the component or components whose individual 
functions can be diluted out first; the relative 
activity of each stage of complement activation cannot 
be determined. In addition, the commonly used two-fold
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for a relatively insensitive analytical technique. The 
kinetic assays do however offer greater sensitivity.
The efficiency with which the lytic reaction is 
initiated and completed can be compared at a single 
dilution, so that differences in activity which would 
not be detected by the serial dilution methods can be 
studied with ease. Furthermore, if activity is studied 
at two or more dilutions, the effect of this progressive 
dilution on activity can also be studied.
Rheumatoid arthritis subjects were chosen because this 
disease is associated with an acute phase reaction that 
is increased synthesis of some complement components, 
and the activation of complement in diseased tissues, 
but the results suggested that there was no consistent 
effect on alternative pathway activity.
In neonates it had been shown (Sawyer, et. al.; Mills, 
Bjorksten and Quie; Strunk, Fenton and Gaines; op. cit. ) 
that complement component levels and haemolytic activity 
were 60 to 100% of adult levels in infants born n at 
term", that is 40 weeks gestation, and somewhat less in 
premature infants. Such infants should therefore 
provide samples with an interesting range of activities 
which could be compared with the levels of key 
components and inhibitors. The results presented here 
confirmed the earlier observations, and indicated that 
the use of kinetic assays did provide a more sensitive 
index of alternative pathway haemolytic activity and 
made it possible to compare the maturity of the reaction 
to assemble C5 convertase (lag time, tL) and those which
The expression "% standard serum" proved more sensitive 
than "difference in activity" (Figure 4.1). Inevitably, 
there was a bias to the selection of unhealthy subjects 
in this group of infants, but the use of a clinical 
grading system went some way towards allowing for the 
effects of disease on the complement system. It can be 
seen however, that a healthy infant, as defined by this 
classification was not exempt from perturbations in the 
complement system, nor did all sick infants always have 
abnormal results.
A small but significant number of premature infants 
develop a life-threatening bowel disorder known as 
necrotising enterocolitis (British Association for 
Perinatal paediatrics and Public Health Laboratory 
Service, Communicable Disease Surveillance Centre,
1983). Since the aetiology of this syndrome remains 
unclear it was hoped that this prospective study of 
neonatal complement might throw some light on this 
important clinical problem. The acute phase responses 
noted earlier were not unique to those infants who 
developed necrotising enterocolitis, and the condition 
was not associated with a unique pattern of complement 
activity.
Finally, the experiment in which two human serum samples 
were subjected to a number of dilution procedures did 
yield some information on the determinants of 
alternative pathway activity. Points of particular 
interest were (i) the enhanced activity seen when the 
two sera were mixed, (ii) the way in which serum PG
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during the course of dilution with heat-inactivated PG, 
and (iii) the decrease in (t50-tL) seen when DL was 
diluted with heat-inactivated DL was not apparent when 
factor B depleted DL was used, suggesting the 
involvement of factor B in this phenomenon. The 
addition of purified components to serum samples might 
be a valuable development of this procedure.
Neonates: Results of Complement Assays
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Figures 4- 6/14
Animal Sera: Alternative Pathway Activity Against 
Sensitised Cells
THCA : Total Haemolytic Complement Activity 
APA : Alternative Pathway Haemolytic Activity
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Figures 4-15/16
Human Sera: Dilution with Selected Reagents
ill
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N e o n a t e s :  C r i t e r i a  f o r  E a c h  C l i n i c a l  G r a d e
GRADE 0
Infants were well/very well, had rickets or apnoea when less 
than 28 weeks gestation requiring no more than minimal 
intervent ion.
GRADE 1
Included infants with apnoea when less than 28 weeks 
gestation requiring mild intervention (i.e. stimulation)., or 
apnoea when more than 28 weeks gestation. Also uncomplicated 
bradycardias of any nature; respiratory distress grade 1; 
loose stools including those secondary to phototherapy, or 
mild tachyopnoea of the newborn.
GRADE 2
Included bradycardia secondary to apnoea; idiopathic apnoea 
requiring ventilation; uncomplicated consolidation of one 
lobe of lung and respiratory distress syndrome grade 2.
Also, loose stools for reasons other than phototherapy, other 
causes of transient tachyopnoea of the newborn and minor skin 
inflammations.
GRADE 3
Infants with secondary apnoea requiring ventilation, and 
those with more than one lung lobe consolidated. Respiratory 
distress syndrome greater than grade 2.
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R h e u m a t o i d  A r t h r i t i s  S e r a :  R e s u l t s  o f  C o m p l e m e n t  A s s a y s .
Activity* Component Levels
(min). (% Standard Adult)
SAMPLE tL 150 C 3 B P H C4
Al 1.7 2.4 115 148 60 117 98
A2 4.2 10. 2 116 128 71 112 60
A3 1.8 2.6 113 140 54 115 9 7
A4 1.0 1.3 125 145 54 129 103
A5 1.6 2.4 118 158 63 112 90
A6 0.9 1.3 108 147 54 93 123
hi <0.4 0.5 83 141 71 93 96
A8 1.6 2.8 136 125 74 134 113
A9 0.9 1.4 130 196 77 131 103
A10 1.8 3.2 78 101 83 100 22
All 1.0 2.4 106 98 91 107 60
A12 2.8 3.5 125 120 57 122 102
Al 3 2.2 4.0 125 120 57 129 61
Al 4 1.4 1.9 120 140 34 124 #
STANDARD SERA
DL 1.2 1. 6 100 100 100 100 100
PG <0.2 0.3
*Reaction Mixture: 150pl serum, 500pl cell suspension
# : result not available
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Human Sera DL & PG: Functional Tests for Antibody
ACTIVITY ACTIVITY
IN APD IN CFTD
SAMPLE tL t50 tL t50 (MIN)
SERUM DL 2.5 5.5 0.6 0.8
SERUM PG 1.4 3.2 0.2 0.4
Table 4- 5
Human Sera DL & PG: Effect of Adsorption on Complement
1.4 3.2 0.2 0.4
 
Activity
ACTIVITY
SAMPLE tL t50 tlOO (MIN)
SERUM DL - UNTREATED 0.7 2.1 4.5
ADSORBED 0.9 4.8 >10.0
SERUM PG - UNTREATED 0.3 1.4 2.3
ADSORBED 0.4 3.5 >10.0
Hypogammaglobulinaemic Sera: Results of Complement & 
Other Assays
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Table 4- 8
Human Sera DL & PG: Effect of Dialysis 
Act ivity
(A) ALTERNATIVE PATHWAY ACTIVITY.
SAMPLE tL 150
SERUM DL - UNTREATED 0.7 2.1
DIALYSED >10.0 >10.0
SERUM PG - UNTREATED 0.3 1.4
DIALYSED >10.0 >10.0
(B) TOTAL HAEMOLYTIC COMPLEMENT ACTIVITY 
SAMPLE tL 150
SERUM DL - UNTREATED 2.5 4.3
DIALYSED 6.3 >20.0
SERUM PG - UNTREATED 1.8 3.3
DIALYSED 5.0 9.1
on Complement
tlOO (MIN)
tlOO (MIN)
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Table 4- 9
Inbred Mouse Sera: Kinetics of Alternative Pathway
Haemolytic Activity
ACTIVITY
SAMPLE tL 150 150-1
Balb/c,male 2.7(0.28) 12.8(3.20) 10.1
Balb/c,female 6.5(0) 12.7(2.33) 6.2
C3H/He,male 4.0(0.07) 9.0(1.34) 5.0
C3H/He,female 7.0(0.71) 12.0(0.78) 5.0
C57B1.,male 2.8(0.28) 9.4(2.83) 6.6
C57bl.,female 6.8(1.06) 11.4(0.64) 4.6
CBA, male 3.2(0.50) 8.3(1.41) 5.1
CBA, female 7.7(0.28) 11.8(0.28) 4.1
6 mice of each sex & strain bled, 2 pools of sera,
3 animals, prepared. Each pool assayedin duplicate. Value in 
brackets is Standard Deviation.
Reaction Mixture: 500pl serum + 500pl rabbit erythrocyte 
suspension.
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T a D i e  4 - 1 u
Human Sera DL & PG: Protocol for Dilution with Selected 
Diluents
SAMP LE{\ll) 400 300 200 100
MIXTURE
(SAMPLE/DILUENT) DILUENT(pl) - 100 200 300
TUBE NUMBERS
DL/PG 1-1 1-2 1-3 1-4
DL/CFTD 2-1 2-2 2-3 2-4
DL/HDL 3-1 3-2 3-3 3-4
DL/WDL 4-1 4-2 4-3 4-4
PG/CFTD 5-1 5-2 5-3 5-4
PG/HPG 6-1 6-2 6-3 6.-4
PG/WPG 7-1 7-2 7-3 7-4
PG/HPG 8-1 8-2 8-3 8-4
DL/WPG 9-1 9-2 9-3 9-4
PG/HDL 10-1 10-2 10-3 10-4
PG/WDL 11-1 11-2 11-3 11-4
KEY TO DILUENTS:
CFTD : complement fixation test diluent
HDL or HPG : serum heated at 56 for 30 minutes 
WDL or WPG : serum heated at 50 for 10 minutes
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5.1 INTRODUCTION
Inbred mice are frequently used in attempts to elucidat 
the genetic basis of immune responsiveness to purified 
antigens and microorganisms (Gasser and Silvers, 1974; 
Krco and David, 1980; Rosentreich, Weinblatt and 
O'Brien, 1982). The majority of these studies examine 
the role of lymphocyte-mediated responses such as 
antibody production, or delayed hypersensitivity 
reactions. Skamene and his colleagues have made 
extensive use of inbred mice in their investigations of 
host responses to a variety of microorganisms (Forget, 
et. al., 1981; Gros, et. al., 1981; Stevenson, et. al. , 
1981; Pelletier, et. al., 1982; Skamene, et. al., 1982) 
Their work with the vaccine strain of Mycobacterium 
bovis (BCG), defined each strain of mice examined as 
resistant or susceptible to BCG on the basis of the 
number of organisms which could be recovered from the 
spleen of each animal after intravenous doses of BCG 
(Gros, Skamene and Forget, 1981). Their data suggested 
that a component of the immune system acting early in 
the infection determined the extent of spleen 
colonisation. The investigation of the kinetics of 
alternative pathway-mediated erythrocyte lysis by sera 
from a selection of inbred mouse strains described in 
the previous chapter revealed significant differences 
between some of the strains, and between the sexes of 
each strain . It can be argued that such variations in 
alternative pathway activity are responsible for the 
patterns of spleen colonisation reported by Skamene's
shown to activate the alternative pathway (Symons, McKay 
and Wilkinson, 1972; Ramanathan, Curtis and Turk, 1980; 
Mowbray and Brown, 1983). The work to be described here 
set out to test this hypothesis.
Studies of this kind are rarely possible in humans. 
Instead, much use is made of in-vitro correlates of 
immunological functions such as the opsonisation tests 
described earlier. Abnormal opsonisation associated 
with the immunodeficiency syndrome seen in some neonates 
is thought to be due to a defect in the alternative 
pathway yet the conventional tests of alternative 
pathway haemolytic activity are seldom abnormal. This 
may reflect the insensitivity of these tests, but the 
defect in opsonisation may not interfere with the 
assembly of lytic complexes. Serum samples from 
patients with one of a number of primary and secondary 
liver diseases also show a significant incidence of 
opsonistion defects (Larcher et. al., 1983). Table 5-1 
summarises these findings. A selection of sera taken 
from children with such defects were analysed for 
alternative pathway activity using the kinetic method to 
establish whether defective opsonisation was associated 
with a distinctive change in the kinetics of alternative 
pathway haemolytic activity.
5.2 THE ALTERNATIVE PATHWAY IN MYCOBACTERIAL INFECTIONS 
IN MICE.
5.2.1 MATERIALS AND METHODS 
Bacterial Suspensions
BCG suspensions were prepared from a commercially
contents of 10 ampoules were suspended in sterile 
saline, pooled, and made to 40ml with sterile saline. 
Mycobacterium fortuitum was obtained from a culture 
collection held at the Central Veterinary Laboratory.
It was grown in liquid culture (Chadwick 1982), and the 
harvested slurry of microorganisms washed and diluted in 
sterile saline to give the required suspensions. The 
actual number of organisms present in all the 
suspensions was determined by titration.
Mice
All mice were purchased from Olac Ltd (Bicester, 
Oxon,U.K.) when 8-9 weeks old. Males and females from 
each of the following strains were used: Balb/c, C3H/He, 
C57Black, and CBA.
In the first experiment (subcutaneous injection of BCG 
in each sex and strain), the members of each sex and 
strain were divided into 5 groups of 6 mice designated 
A, B, C, D and E. Group A, the control animals received 
0.1ml sterile saline in the left shoulder; all other 
groups were given 0.1ml BCG suspension in the same site. 
Control animals were then housed separately from the 
test animals. The experimental groups from each sex and 
strain were examined on the following days after 
injection: A (controls), day 4; B, day 1; C, day 3; D, 
day 7; and E, day 28 (Table 5.2).
In the second experiment (intravenous challenge with 
BCG or M. fortuitum), males and females from the 
C57Black and C3H strains were used. In this case the 
experimental groups were: F, (controls); G, (BCG,
(BCG examined at 36h); J, M . fortuitum examined at 
36h). The mice in each group were given 0.1ml of the 
appropriate suspension in a caudal vein (Table 5.3). 
Collection of blood and tissue samples.
On the day of sampling, each animal was anaesthetised
with ether and weighed. Blood was collected by cardiac
puncture. In the subcutaneous challenge experiment, the
lymph nodes which drained the injection site and the 
spleen were removed from each animal and weighed. The 
spleen alone was removed from the mice which received 
intravenous challenges. Within each group of animals, 
blood samples, lymph nodes and spleens were examined in 
pools of three for ease of handling, e.g. mice 1-3, 4-6, 
and so on.
Culture of lymphoid tissue pools.
Each group of organs was homogenised in sterile saline
using Griffiths tubes. Ten-fold serial dilutions of
each homogenate were made in sterile saline over the 
1 fi
range 1:10 to 1:10 . Duplicate 0.2ml aliquots of each 
dilution were then cultured on Lowenstein-Jensen slopes 
enriched with pyruvate (Chadwick, 1982). All cultures 
were set up on the day of sampling, incubated at 37° and 
examined at regular intervals for 6 weeks.
Serum samples
Blood samples were kept on iced water until the 
collection of specimens was completed. They were 
allowed to clot at room temperature. After 
centrifugation at 4°, the serum was separated and stored 
at -70°. Total alternative pathway activity was
500pl rabbit erythrocyte suspension). The readings were 
taken until the lytic reaction was complete , or 20 
minutes had elapsed without evidence of cell lysis.
5.2.2 RESULTS 
Subcutaneous Challenge
The results are given in Figures 5.1 to 5.4. Replicate 
cultures of lymphoid organs showed poor agreement. 
Nevertheless, certain clear differences were seen, and 
when these are examined in conjunction with the data on 
organ weights it is possible to compare the kinetics of 
the inflammatory response in each sex and strain. In 
most cases lymph node size increased steadily; the 
smallest change at 28 days were seen in C3H/He (male and 
female) and in CBA females. Intermediate weights were 
by Balb/c females and CBA males, while C57Black males 
and females responded most markedly. The Balb/c males 
showed a distinctive peak of lymph node enlargement at 3 
days and a steady decline thereafter.
In all cases there was significant lymph node 
colonisation in days 1-7, and a decline in the number of 
organisms by day 28. Early spleen colonisation, cleared 
by day 28, was seen in CBA males and females, while the 
spleens of C57Black females were colonised throughout 
the experiment. Late colonisation was seen in the 
Balb/c male.
There was no obvious correlation between total 
alternative pathway activity and the time-course of 
spleen and lymph node infection, although all female 
mice showed lag time (tL) values which were longer than
the time to 50% lysis (t50) was also larger (extended 
times indicate lower complement activity). Low 
alternative pathway activity was not necessarily 
associated with spleen colonisation. In the Balb/c 
male, significant spleen counts were seen when the serum 
alternative pathway activity was greatest. The most 
striking feature of these results is the marked 
reduction in t50 seen in the serum of Balb/c and CBA 
males. In both cases this change in t50 is due to a 
marked decrease in (t50-tL). The CBA male also showed a 
small reduction in tL, but this is not significant. The 
kinetic assay is a simple bioassay which indicates 
relative complement activity. Therefore complex 
statistical analyses of the data could be considered 
inappropriate. It is possible to regard the differences 
in alternative pathway activity as significant if they 
exceed the 95% confidence limits, that is + two standard 
deviations (Strike, 1981). The results were however 
also analysed using SPSS programmes (Table 5.4). 
Intravenous Challenge
Although the culture, method lacked some precision, the 
differences in alternative pathway activity seen in 
control animals did not affect the magnitude of spleen 
colonisation. In the C3H/He males, the presence of 
M . fortuitum and BCG in the spleen had little effect on 
alternative pathway activity (Figures 5.5 - 5.6). The 
C3H/Ke females however, showed transient changes in t50. 
Associated changes in tL were not considered 
significant. In the C57Black males, there was a
marginal decrease m  ttu values during M . rortuitum 
infection, while BCG appeared to cause complement 
consumption (increased t50). M . fortuitum also produced 
a transient change in t50 in C57Black females, but BCG 
produced a marked and continuing effect . Spleen 
weights showed little variation in any group. Detailed 
statistical analysis was not considered appropriate for 
these resuIts .
5.3 ALTERNATIVE PATHWAY LYTIC ACTIVITY IN SERA SHOWING
DEFECTIVE OPSONISATION
5.3.1 MATERIALS AND METHODS
Serum Samplesr
Childhood Liver Disease
Samples were obtained from the Liver Unit at King's 
College Hospital, London. They were grouped as 
follows:
a. children without demonstrable complement defects - 
(childhood controls, 5 subjects).
b. geriatric adults without demonstrable complement 
defects - (geriatric controls, 4 subjects).
c. children with sickle cell disease - (5 Subjects).
d. children with chronic active hepatitis - (3 
subjects).
e. children with an innate deficiency of 
alpha-l-antitrypsin deficiency - (5 subjects).
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subjects).
Neonatal Opsonisation Defect
One of the sera examined in the work described in the 
previous chapter showed abnormal opsonisation activity. 
It was included in this investigation as a positive 
control.
Adult Liver Disease
These were obtained from patients awaiting surgery for 
obstructive jaundice due to malignant disease or 
gallstones at the Royal Surrey County Hospital,
Guildford.
5.3.2 RESULTS
Alternative Pathway Activity:
Childhood Liver Disease
The reaction mixture used for neonatal sera (lOOpl serum 
+ 300pl cell suspension) proved unsuitable, higher 
dilutions were required because of the higher 
alternative pathway activity in children and adults. 
These were: A, 50pl serum + 500pl cell suspension 
(effective dilution 1:11); B, 50pl serum + lOOOpl cell 
suspension (effective dilution 1:21); C, 25pl serum + 
lOOOpl cell suspension (effective dilution 1:41).
Results obtained using mixture A are shown in Figure 5.7 
(time to 50% lysis, t50) and Figure 5.8 (lag time, tL, 
and (t50-tL)). The sera from children with biliary 
atresia caused instantaneous lysis, but the activity of 
the other sera could be measured at this dilution. 
Furthermore, when the sera from children with these
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and C, the alternative pathway activity was lost (Figure 
5.9). Only sera from patients with severe liver damage 
showed decreased lytic activity. Reaction mixture B 
proved suitable for the analysis of serum from children 
with extra-hepatic biliary atresia, and many still 
exhibited activity when reaction mixture c was used 
(Figure 5.10). The spectrum of activity seen using 
reaction mixture B is compared with the clinical 
condition of the children in Table 5.5.
Neonatal Opsonisation Defect
Alternative pathway activity was normal in this serum 
(Table 5.6)
Adult Liver Disease
Adults with obstructive jaundice also showed increased 
alternative pathway activity (Table 5.7)
5.4 DISCUSSION
In the mouse experiments, the poor reproducibility of 
bacterial counts was at first attributed to the tendency 
of BCG suspensions to aggregate (Brown and Brown, 1982). 
Hall's recent comments (1985) on the dangers of making 
assumptions about pathways of lymphoid drainage may also 
have some bearing on this matter.
Only in C57black mice was there a marked difference in 
the early uptake of organisms between males and females 
after subcutaneous injection of BCG. This difference 
was not seen when mice of this strain were given an 
intravenous dose of BCG. Although the complement 
activity of male and female mice in each strain is 
different, the natural affinity of mycobacteria for the
would seem to ensure that entry into these target cells 
preceeds effective complement activation. The report by 
Johnson et. al. (1980) is of interest in this respect.
In a study of 92 human subjects with active 
tuberculosis, they found that sera from 13 (14%) 
exhibited defective opsonic activity. Unlike those with 
normal activity, none of these patients developed 
extra-thoracic foci of infection. These results would 
suggest a role for complement-mediated opsonisation in 
the spread of mycobacteria. Discussion of the role of 
the alternative pathway in the development of the later 
stages of inflammatory responses ( that is, 7 days and
fSlwt
after) ,|since lymphocyte activation would then be 
established. More intricate experiments would be needed 
to discern the role of alternative pathway activity.
The results obtained from the analysis of sera from 
human neonates suggested that acute phase responses 
(which involve enhanced production of complement 
components) do not affect alternative pathway haemolytic 
activity. Nevertheless, it could be suggested that the 
differences in alternative pathway activity seen in mice 
given BCG reflect differences in the response of the 
macrophage-interleukin 1-hepatocyte axis to BCG 
infection. Measurement of the murine acute phase 
protein SAP (Pepys, 1982) could be used to test this 
hypothesis. It has, however, been suggested (Pepys,
1985) that a much larger experiment would be needed to 
ensure reliable results because of the variability of 
SAP results in mouse populations. Analysis of the serum
provide reliable data on SAP levels. Since the effects 
of BCG infection differ so markedly according to strain 
of BCG used (Orme and Collins, 1983a), it would also be 
interesting to repeat this work using other strains of 
this organism.
Impaired opsonisation was not associated with retarded 
red cell lysis. Where however, the sera possessed 
increased opsonic activity (Larcher, et. al., 1983) a 
marked acceleration of alternative pathway-mediated 
haemolysis was seen. All the subjects suffered from 
some form of biliary obstruction. The significance of 
these observations is underlined by the fact that these 
sera caused lysis at dilutions which abolished the lytic 
activity of normal sera. Morrison et al (1984) reported 
markedly increased concentrations of alternative pathway 
components in these circumstances. More recent work in 
this Department (Ahmed and Langley, 1985) suggests that
only modest increases in C3 and factor B occurs in the
serum of adults with obstructive jaundice. As this work 
also suggests that in-vivo activation of C3 occurs in
some of these patients, it can be argued that the
enhanced lysis was a bystander effect due to 
pre-existing alternative pathway activation. Increased 
levels of endotoxin from Gram-negative gut flora are 
often found in sera from these patients (Pain 1985). As 
noted earlier, endotoxins are potent activators of the 
alternative pathway.
A programme of further investigations is in progress. 
Three important questions are:
b. do bile, and its principal components such as 
bilirubin and the bile salts , affect macrophage 
function?
c. do C3d levels reflect an enhanced turnover of the 
alternative pathway in-vivo?
Other findings include the demonstration of normal 
alternative pathway activity in sickle cell disease, in 
contrast to earlier reports of deficiencies (Koethe, 
Casper and Rodey, 1976; Wilson, Thompson and Sissons, 
1979; Larcher e t . al.> 1982). In the other liver 
diseases studied alternative pathway activity was 
generally similar to that shown by the control sera, 
although severe loss of hepatocellular function caused 
reduced alternative pathway haemolytic activity.
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Inoculum : 10 organisms
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Childhood Liver Disease: Alternative P a t h w a y  Activity
(As L a g  Time (tL) & (t50-tL)). Mixtures B & C
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Figure 5 - i u
Biliary Atresia: A l t e r n a t i v e  pathway Activity^ Mixtures 
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Subcutaneous BCG in Inbred Mice; Experimental Protocol 
Mice of both sexes from each strain (Balb/c, C3H/He, 
C57black and CBA) divided into 5 groups of 6 mice:
Injection A B C  D
 CmT] ---------------------
Saline: 0.1 -
BCG
Suspension: - 0.1 0.1 0.1 0.1
Control animals housed separately after injection
Examined on
Day: 4 1 3 7 28
Blood taken by cardiac puncture under ether anaesthesia, 
Lymph nodes draining injection site (2), and spleen 
weighed & cultured
Table 5- 3
Intravenous BCG and M. fortuitum in Inbred Mice:
Mice of both sexes from two strains (C57black and 
C3H) divided into 5 groups of 12 mice
Injection F G H I J
(ml)
Saline: 0.1 -
BCG
Suspension: - 0.1 0.1
M. fortuitum 
Suspension: - 0.1 0.1
Control animals housed separately after injection
Examined at
(hours) 24 12 36 12 36
Blood taken by cardiac puncture under ether anaesthesia, 
Spleen weighed & cultured
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Table 5- 4
Statistical Analysis of Data from Inbred Mouse 
Exper iments
Subcutaneous Injection of BCG
The data were analysed using the SPSS analysis of variance programme 
on the University of Surrey computer (Significant results p < 0.001).
COMPLEMENT DATA tL t50
Degrees of F Signi ficance F Signi f icance
Freedom o"E F oT F
One-Way Interactions
breed ■ 3 42.5 0. 000 26.6 0. 000
sex 1 723.9 O.OOC 30.8 0. 000
day 3 14.4 0.000 3.5 0.026
Two-Way Interactions
breed-sex 3
breed-day 9
sex-day 3
Three-Way Interactions
breed-sex-dav 9
44
7
7
5.9
0 . 000 
0.000 
0.001
0 . 000
0.001
0.000
0.0C4
0.002
OTHER DATA (not given in detail; see page 131)
Organ Cultures:
Lymph Nodes:
significant F values in all 
except sex-day two-way 
interaction.
S p leen:
results not significant.
Spleen Weights
Only showed significant F value in 
one-way interaction with breed. 
Lymph Node Weights
Significant F value with breed and 
day in tests of one- and two-way 
interaction.
FOOTNOTE
The data from exploratory experiments such as these can be analysed 
very^effectively using the methods of Dunnett and Tukey (Denenberg, 
1976 ). This was not possible with these results because the way 
in which the experiment had been designed.
especially chapter 8.
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B i l i a r y  A t r e s i a :  C l i n i c a l  C o n d i t i o n  o f  E a c h  C h i l d
SUBJECT NUMBER 
1 
2
3
4
5
6
CORRECTIVE SURGERY 
ON BILIARY TRACT?
No Surgery
Yes, postoperative 
sample
Yes, postoperative
Yes, postoperative 
sample
Yes, sample taken 
immediately after 
operat ion
No surgey
Yes, preoperative 
sample
CLINICAL CONDITION. 
Very jaundiced, died 
No longer jaundiced
Poor, but not 
jaundiced
Good
Reassessed,not bilary 
atresia
Poor, but did well 
after surgey
No surgery Poor, died
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Neonatal Opsonisation Defect: Results
Method of Levinsky, Harvey and Paleja (1978)
Infant PC1 (Results of Complement Assays, Table 4.2)
(a) Screening Test
Opsonisation Indices (mean number of yeasts per neutrophil) 
At recommended dilution:
Normal Adult (DL) 2.4
Infant PC 1.4
No Serum 1.0
(b) Opsonisation Indices: Range of Serum Dilutions
LUTION SERUM DL INFANT PC ' CONTROL
nil 3.7 3.0 -
1:5 3.1 2.0 -
1:10 2.9 1.6 -
serum _ _ 1.03
‘X
O b s t r u c t i v e  J a u n d i c e  i n  A d u l t s :  A l t e r n a t i v e  P a t h w a y
A c t  i v i t y
tL t50 t50-tL
50fil serum/lOOOpl cell suspension (1:21)
Subject:
JE 2.0 2.7 0.7
TA 4.5 6.1 1. 6
BR 6.3 7.5 1.2
Normal Adult (DL) >15 . 0 >15.0 —
Normal Adult (PG) 9.0 11.7 2.7
lOOpl serum/lOOOpl cell suspension (1:11)
Normal Adult (PG) 1 . 5 7 . 0  5.5
tL t50 t50-tL
50pl serum/lOOOpl cell suspension (1:21)
Subject:
JE 2.0 2.7 0.7
TA 4.5 6.1 1.6
BR 6. 3 7.5 1.2
Normal Adult (DL) >15.0 >15.0 -
Normal Adult (PG) 9.0 11.7 2.7
lOOpl serum/lOOOpl cell suspension (1:11)
Normal Adult (PG) 1.5 7.0 5.5
6. GENERAL DISCUSSION
It is important to set the relevance of kinetic analyses 
in perspective. The haemolytic activity of complement 
is commonly measured by making serial dilutions of each 
sample and finding the highest dilution at which lysis 
occurs after a fixed incubation period. This is usually 
fifteen to sixty minutes. A general indication of the 
total haemolytic activity or alternative pathway 
haemolytic activity is obtained in this way, and gross 
deviations from normal are easily detected. Essentially 
however, the analyst only measures the titres of 
components whose biological activities are most 
susceptible to dilution. The concentrations and 
identities of these limiting components are not 
revealed.
This approach is adequate for the preliminary assessment 
of residual complement activity in diseases associated 
with complement consumption in-vivo. If however, the 
investigator wishes to explore the functional efficiency 
of the complement system in greater detail, then 
dilution techniques have little value.
The need to establish the nature of complement 
consumption in diseased subjects is important , but are 
comparisons of the efficiency of complement activation 
also worthwhile? The case for such investigations was 
presented in the introduction to this work, and the 
subsequent demonstration of a spectrum of activation 
within human populations and between a variety of animal 
populations confirms its relevance.
It must be stressed that complement generates
case of the alternative pathway can substitute for 
lymphocyte-mediated immunity in the early stages of 
infection. Both classical and alternative pathways work 
together to provide a powerful extension of antibody 
function once classical pathway activation has occurred. 
Even though deficiencies of many complement components 
are not life-threatening, they do have a significant 
effect on the quality of life. Yet is it reasonable to 
argue that delay in the expression of complement 
activity, particularly that of the alternative pathway, 
in individuals with "normal" titres of haemolytic 
activity would have an effect on the course of an 
inflammatory reaction? Situations in which alternative 
pathway activity would have a vital role have been 
described already, but why should a few minutes delay in 
its expression matter?
Firstly, the ability of the alternative pathway to 
contain the replication of a dividing inoculum of 
bacteria could be influenced by the rate at which 
activation occurred. Also, since the blood volume of 
most animals passes around the vascular system in a few 
minutes (Strand, 1983), failure to express adequate 
alternative pathway activity against a blood-borne 
pathogen within that time would allow secondary 
infection of vital organs to occur unchecked. This kind 
of spread is a common feature of virus infections 
(Taussig, 1984b). Conversely, the ease of expression of 
complement activity in response to the deposition of 
immune complexes in key organs may determine the extent
14
immune complex disease. Indeed, the recent reports that 
complement may inhibit (Naama, et. al., 1983) or reverse 
(Takahashi, Takahashi and Hirose, 1980) the formation of 
immune complexes may mean that the system plays a more 
fundamental role in the pathogenesis of immune complex 
disease - that is making it possible for the damaging 
complexes to form in significant amounts in susceptible 
individuals. Finally, convincing reports that some 
product of C3 activation can inhibit a number of 
lymphocyte responses have appeared in recent years 
(reviewed by Weiler, et. al., 1982), thus an individual 
whose complement system activated rapidly might generate 
localised levels of this product which would reduce the 
extent of lymphocyte proliferation. Furthermore, since 
the alternative pathway is now thought to turn over 
continuously in normal individuals, held in check by the 
inhibitory factors I and H, it can be argued that a 
particularly reactive pathway might produce a 
environment richer in the inhibitory fragment of C3, 
with generalised effects on the kinetics of lymphocyte 
responses. The fragment of C3 known as C3d provides a 
useful index of complement consumption in-vivo since it 
is catabolised slowly (Vergani, et. al., 1983). The 
spread of C3d levels in normal subjects reported by 
these workers lends support to the suggestion that the 
rate of alternative pathway turnover can vary.
Although it may be simplistic to consider the 
alternative pathway acting alone in the control of 
blood-borne infections, a strong case emerges for the 
investigation of the kinetics of complement activation.
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The growing awareness of a dynamic e q u n i D r i u m  u e c w e e n  
microorganisms and their vertebrate hosts has replaced 
the more rigid concept of pathogenic and non-pathogenic 
organisms. The clinical spectra of diseases such as 
tuberculosis and leprosy (Lenzini, Rottoli and Rottoli,
1977) suggest a spectrum of immune responsiveness within 
apparently normal populations, and close examination of 
many of the more common infectious diseases reveals a 
similar pattern. A careful characterisation of the 
general kinetics of immune responsiveness might enable 
us to speak with greater confidence on resistance and 
susceptibility to infectious diseases and diseases of 
the immune system. An examination of the kinetics of 
complement activation is an important part of this work. 
Which of the biochemical reactions or biological 
activities of the complement pathways should be studied 
in this way? At this stage a firm answer is not 
possible, but since the haemolytic assays are easy to 
perform, and lysis involves the whole pathway in both 
alternative and classical pathway activation they were 
thought to be a good starting point.
In the kinetic assays of haemolytic complement activity 
lag time was thought to reflect the efficiency of the 
reaction which assembles effective C5 convertase 
complexes on the cell surface, at the dilution in 
question. On the other hand, (t50-tL) was thought to be 
a measure of the ability to sustain this convertase 
activity and the efficiency with which the terminal 
components (C5b, C6, C7, C8 and C9) associate to form 
the lytic complex and damage the cell membrane.
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If the kinetics of haemolysis are studied at a number of 
dilutions the effects of dilution on lag time and 
(t50-tL) can be studied. These dose-response curves 
proved useful in general comparisons of alternative 
pathway kinetics, while assays at a single dilution were 
sometimes used to compare the effects of a particular 
treatment or disease on alternative pathway activity.
The traditional serial dilution assays look at 
complement activity in discontinuous steps. A study of 
the kinetics of alternative pathway-mediated haemolysis . 
at various dilutions provides a way of removing this 
discontinuity and increasing the sensitivity of 
haemolytic assays.
Reports of earlier work on the kinetics of alternative 
pathway activation (Gallin, Clark and Frank, 1975;
Polhill et. al., 1978a,b) were found during the course 
of this work, but they did not investigate the effects 
of dilution on reaction kinetics nor did they attempt a 
comprehensive investigation of the phenomena reported.
The data on the kinetics of alternative pathway activity 
against rabbit erythrocytes revealed the interesting 
fact that differences in (t50-tL) were most marked in 
human sera. The relevance of these observations might 
be questioned because they are only apparent when the 
sera were diluted 1:10 or more; at a 1:2 dilution most 
sera gave similar results. perhaps they were merely 
in-vitro artefacts, but such dilutions are used in tests 
of accepted clinical significance such as the 
opsonisation assays (Levinsky, Harvey and Paleja, 1978). 
The fact that conditions have to be manipulated to
invalidate the results of these tests and such 
differences may be of greater significance in the study 
of the alternative pathway in tissue fluids. Although 
the recent work of Ezekowitz and his colleagues (1984) 
offered the model for the distribution of complement 
activity in the tissues described in the first chapter, 
the traditional view is that the greater part of this 
activity arises by transudation of complement components 
from the blood plasma. Most of the components are 
thought to be at significantly lower levels in the 
tissues. It is known that the ratio of large to small 
proteins is lower in tissue fluids than in blood plasma- 
(Hay, 1979), so that there may be differential 
accumulation of complement components in the tissue 
fluids according to their molecular weight. This adds 
an interesting new dimension to the question of 
complement activity in the tissues. If molecules such 
as immunoglobulin or low molecular weight inhibitor do 
modify complement activity, their differential passage 
across capillary walls might accentuate any differences 
in complement activity in the blood plasma and the 
tissue fluids. The spread of molecular weights seen in 
the complement components may also affect this 
distribution.
Both Ezekowitz (Ezekowitz, e t . al., 1984) and Whaley 
(1980) have shown that cells of the monocyte-macrophage 
system are able to secrete the components of the 
alternative pathway. This led Ezekowitz to suggest that 
these cells use the alternative pathway proteins which 
they produce to generate opsonins , and possibly
-A
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surrounded by a halo of enhanced alternative pathway 
availibility. Activation of these components would 
produce local vascular changes and cause exudation of 
plasma proteins , including complement components and 
other immunological effectors. In this model, the 
tissue fluids may be seen as containing a background of 
relatively low complement activity with areas of higher 
activity around the macrophages, and in areas of 
complement activation. These proposals raise the 
interesting question of the origins of the alternative 
pathway components found in the blood plasma. Are they 
derived from tissue macrophages, hepatocytes (Ramaaori, 
et. al., 1984), other tissues (Thompson 1983) or a 
combination of sites? Since activated macrophages 
secrete interleukin 1 which enhances the secretion of 
acute-phase proteins by hepatocytes (Dinarello, 1984), 
macrophages may have a fundamental role in the control 
of serum complement levels.
In any event, the final test of the hypothesis that the 
differences in alternative pathway haemolytic activity 
detected in-vitro are expressed in the body fluids 
in-vivo would involve a comparison of the inflammatory 
responses to alternative pathway activators in-vivo. 
Ideally, family studies should be made to ascertain the 
genetic element in these observations but the ethical 
and logistical constraints on such exercises in human 
populations would make it impossible to include a 
systematic study of this kind in the work described
protective immunity and the result of skin tests in 
diseases such as tuberculosis (Orme and Collins, 1983b) 
point to the practical benefits of such an 
investigation. A significant part of the skin test 
reaction may have more to do with complement activation 
than with delayed hypersesnsitivity reactions to 
tuberculin (Black, Niven and Humphrey, 1963).
In the study of the kinetics of total haemolytic 
complement activity and haemolytic alternative pathway 
activity in animal sera (Higgins and Langley, 1985), the 
benefits of these simple in-vitro assays were readily 
appreciated. A substantial body of information was 
obtained on the relative activity of the complement 
system in each of the species examined. As noted 
earlier, a complete investigation of the complement 
system would require antisera to individual components 
to measure their concentrations and erythrocytes bearing 
partially assembled complement complexes to study the 
biological activity of each component. Although they 
did not provide the same degree of insight, these 
kinetic assays did give information on the assembly and 
activity of functional complement complexes.
Measurement of total haemolytic complement activity and 
alternative pathway haemolytic activity on the same 
sample also proved informative. Effective lysis in the 
former argued against any defects in the terminal 
complement components (C5 to C9) which are common to 
both pathways. This clarified the interpretation of 
alternative pathway kinetics.
possibility that some species are phylogenetically close 
to the rabbit, while others are more distant. In other 
words, the distinctive reaction profiles reflect 
evolutionary differences in the which the extent to 
which the rabbit erythrocyte can bind to the alternative 
pathway C3 convertase of each species rather than 
absolute differences in alternative pathway activity.
The expression of alternative pathway activity against 
the panel of cells used in the general screen, and the 
spread of results for the titre of total alternative 
pathway activity argue against this suggestion, 
particularly when the results obtained with 
neuraminidase-treated sheep erythrocytes are considered. 
Analysis of the the alternative pathway haemolytic 
activity in rat serum (Langley and Bach, 1985) has also 
helped to refute this suggestion. Despite the close 
phylogenetic relationship between the rabbit, the rat 
and the mouse, rat sera showed similar activity to human 
serum in the kinetic assay, whereas mouse serum 
displays poor activity.
The limited number of individual samples examined in the 
screen of alternative pathway activity in various animal 
sera was unavoidable, but when larger numbers of badger 
(Heath, 1984) and bovine sera (Langley and Ray, 1984) 
were examined a remarkable similarity was seen in the 
results within each group. This contrasts with the 
spectrum of activity found in human sera. This 
difference might reflect the geographical constraints on 
wild and domesticated animals which would make them
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a diet which along with many other environmental 
factors, varied little. External influences on 
complement metabolism would therefore be limited. In 
contrast, humans have greater mobility and ingenuity, 
and hence a much greater scope for outbreeding and for 
producing varied environments. Modern medicine has also 
reduced the constraints on genetic diversity which 
operate in feral populations.
A clear distinction between genetic and environmental 
influences could not be made although the data obtained 
from inbred mice of both sexes suggest a powerful 
genetic influence: lag time (tL) varied to some extent 
between the strains examined, while (t50-tL) showed 
marked differences. The differing activities shown by 
sera from male and female mice within each strain raise 
the interesting possibility of genetic differences which 
are not primarily concerned with the complement system. 
Hormonal differences have been shown to determine the 
levels of certain classical pathway components in mouse 
serum (Ferreira, Weisz-Carrington and Nussensweig,
1978), but their relevance to the control of alternative 
pathway activity remains to be established. It has been 
reported recently that the properdin gene is x-linked in 
humans (Lachmann, 1982). A number of authors have 
discussed the implications of genetic variants of 
complement components (Rittner and Bertrams, 1981; 
Hauptmann, 1982; Davis, 1983; Porter, 1983), and the 
recent advances in genetic manipulation offer an 
exciting new approach to research in this area (Carroll,
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post-translational processes can produce protein 
variants (Williamson, Salamari and Kreth, 1973). 
Speculations on the effects of environmental factors on 
complement activity could take many forms. One 
intruiging possibility is raised by the apparent 
association between a primarily carnivorous diet and a 
potent alternative pathway. Badgers, ferrets and 
hedgehogs showed this pattern of activity, although 
there were some differences between them. Could it be 
that some component of the carnivorous diet modifies the 
activity of the macrophage-interleukin 1-hepato- 
cyte-complement axis? For the present this must remain • 
mere conjecture.
Some incidental and relevant information was obtained 
from these experiments on badger serum. Epidemiological 
evidence has suggested suggested that badgers were 
responsible for outbreaks of bovine tuberculosis in 
certain parts of the United Kingdom (Wilesmith, et . al. , 
1982; Little, et. al., 1982a,b), and the idea had 
developed that the badger was in some way susceptible to 
Mycobacterium bovis and perhaps immunodeficient (Barrow, 
1982). Indeed, Higgins and Gatrill, (1984) showed that 
the badger responded poorly to a number of antigens 
which elicited high antibody titres in the rabbit, 
although there is at present, no firm evidence of 
defective T cell function (Higgins, 1984). During the 
preparation of the haemolysin reagents used in this 
work, both badgers and ferrets produced low titres of 
antibodies in response to immunisation with sheep 
erythrocytes. The similarity of these results and that
is intruiging. Perhaps the erythrocytes were rapidly 
destroyed by the combined actions of the alternative 
pathway and the reticuloendothelial system. On the 
other hand, this phenomenon may have been the result of 
complement-mediated suppression of B lymphocyte response 
in the badger and the ferret. The ferret might provide 
a valuable model of the badger's immune system.
Since the alternative pathway is so potent in an animal 
which, if not excessively susceptible to M. bovis, 
certainly contracts the infection, one might ask if the 
alternative pathway offers any protection against 
mycobacteria. As noted earlier, several members of this- 
bacterial genus activate the alternative pathway, but if 
they were susceptible to serum-mediated killing, the 
blood-borne spread of the organisms should be minimal. 
Conversely, complement-mediated opsonisation of 
mycobacteria could hasten their entry to their main 
"target tissue", the cells of the macrophage-monocyte 
system. Thorns et. al. (1982) have reported that when 
hedgehogs are infected with M. bovis, the organisms 
become disseminated through the body fluids without 
adverse effects on the animals. In the kinetic assay of 
alternative pathway haemolytic activity, hedgehog serum 
was as potent as that of badgers and ferrets.
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human infant is capable of mounting an acute phase 
reaction. In these reactions, C3, factor B, and C4 
levels can increase dramatically, whereas properdin, 
factor I and factor H levels remain unchanged. The 
increased availibility of C3 and factor B had little 
effect on alternative pathway activity. It may be 
inferred that these components are not key determinants 
of activity once adequate levels are achieved, since 
their levels increased when inhibitor levels were 
unchanged or decreased, without significant effects on 
haemolytic activity. This observation prompted 
consideration of the relative concentration of 
complement components. In biochemical studies this 
would involve calculation of molar concentrations. Such 
an analysis of the complement system is not apparent in 
the literature. In Table 1-6 published values for 
molecular weight and component concentrations in human 
serum were used to calculate molar concentrations. This 
approach shows the complement system in a new light. 
Potential rate-limiting steps can be recognised, while 
many components are present in substantial amounts. 
Interestingly, careful examination of the results 
obtained from the analysis of neonatal sera suggests 
that increases in C3 and factor B may reduce alternative 
pathway activity in the kinetic assay.
So, it was not possible to identify the effect of 
individual components had on alternative pathway 
activity, since in general the levels of individual 
components develop together. While the statistical
the concentrat ion of a number of components, they cannot 
pinpoint limiting components. It would seem that the 
analysis of any clinical samples is unlikely to define 
the determinants of differences in reaction kinetics - 
it may suggest contenders but the complexity of the 
samples analysed militates against more precise 
observations. In retrospect, the idea that it could do 
so seems naive. Perhaps the approach used by 
Muller-Eberhard and Schreiber (1980) offers the only 
effective course. Purification of the components and 
the analysis of the activity of the pathway 
reconstituted from these purified components in-vitro.
In this way permutations of component concentrations 
could be tested. Because of the possibility that 
allelic forms of each component exist within the 
population, it would be necessary to have a panel of 
donors to provide starting material for the 
purification. It is clear that this would be a major 
undertaking, and as described, would not take account of 
the effects of other serum components on complement 
activity. Lachmann, Hobart and Aston (1973) have 
described a variety of techniques to deplete the 
concentration of individual components from serum 
samples, and these are widely used in clinical 
investigations and basic research. Some of them were 
used in this project, but they were not totally 
effective. For example, the technique for factor B 
depletion (50° for 10 minutes), left residual 
alternative pathway activity, while longer periods at
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complement components. Complete removal or inactivation 
of a component by methods of this type is unlikely, and 
the extent to which the other components are affected is 
uncertain. In addition, some, such as the method for 
factor D depletion, involve dilution of the sample or 
modification of its general composition (ionic strength, 
pH). This must introduce uncontrollable, hence 
undesirable, changes which could easily affect activity 
assays.
The availibilty of monoclonal antibodies to complement 
proteins appears to offer a more reliable method of 
neutralising or removing selected components. To avoid 
the effects on the general composition of samples just 
described, the use of monoclonal antibodies bound to 
some solid-phase such as the side of a microtitre well 
or the surface of polystyrene beads is attractive. 
Addition of monoclonal antibodies to serum samples 
should also be avoided because although the selected 
component may be neutralised, the formation of immune 
complexes in-situ will affect the complement system via 
the classical or alternative pathways. Even the. use of 
solid-phase bound antibodies may cause problems since 
some antibody-coated surfaces activate the alternative 
pathway (Joseph, Cooper and Oldstone, 1975; Perrin e t . 
al. , 1976, Polhill et. al., 1978a,b; Moore, Fearon and 
Austen, 1981; Tarr et.al., 1982).
Oldstone's group clearly showed a role for antibodies in 
alternative pathway activation by virus-infected cells 
in-vitro. Similarly, Polhill et. al. (op. cit.)
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"naturally-occurring antibody" to rabbit red cells 
affected the kinetics of alternative pathway activity in 
an assay similar to the one described here. Antibodies 
to rabbit erythrocytes is certainly present in many 
human sera, although the titre can vary markedly. 
Adsorption of this antibody did reduce the efficiency of 
alternative pathway activation in the human sera DL and 
PG. This would point to some role for antibody, but it 
could be postulated that some alternative pathway C3 
convertase was also^during the adsorption process. 
Recently, analysis of C3, factor B and properdin levels 
in adsorbed sera has supported this view (Ahmed and 
Langley, 1985). In this context, the study on the 
effects of antibody from a number of species on the 
expression of alternative pathway activity against sheep 
erythrocytes was a most illuminating exercise. It 
showed that the effect of antibodies on the extent of 
lysis varied according to the species from which the 
antibodies came, and the serum from which the species 
providing the complement activity were taken. Given the 
diversity of immunoglobulin classes (isotypes) within 
and between the vertebrate species examined this seems a 
realistic finding.
None of the sera from hypogammaglobulinaemic subjects 
exhibited the degree of alternative pathway deficiency 
described by Polhill and his colleagues. In general, 
the levels of each complement component were high. 
Complement consumption may occur in the subjects 
receiving intravenous immunoglobulin therapy, as a
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1984). All the subjects in this study had received 
intramuscular injections of immunoglobulin.
The possibility of using modified human erythrocytes as 
a target for human alternative pathway activity seem to 
offer a valuable method of excluding the effects of 
antibodies on the expression of alternative pathway 
activity. It was particularly disappointing that the 
attempts to achieve it should prove unsuccessful. The 
use of alternative pathway activators such as inulin, 
zymosan or E. coli endotoxin (Table 1-3) to provide 
independent demonstrations of differences in the 
kinetics of alternative pathway reactivity was 
considered. Natural products such as inulin or 
endotoxins have no advantage over rabbit erythrocytes 
since the occurrence of antibodies against them in human 
sera is almost inevitable (Gallin, Clark and Frank, 
1975). The soluble activators, whatever their origins, 
present an additional problem. While the initial 
incubation of the chosen activator with serum is 
straight forward, the subsequent back-titration of 
residual complement, by whatever method, is done in the 
continued presence of the soluble activator (Riches and 
Stanworth, 1980). This must have an effect on the 
indicator reaction, and make the results of kinetic 
methods meaningless. Despite the technical difficulties 
in studying the effects of antibodies on the kinetics of 
alternative pathway haemolytic activity, it would seem 
that some isotypes have a significant effects, but they 
are not the only explanation of the differences in
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The examination of sera from inbred mouse strains did 
lend some evidence for their existence. Schreffler and 
his colleagues have described congenic mouse strains 
which exhibit functional variants of factor B (Atkinson 
et. al., 1982; Paolucci and Shreffler, 1983), but 
efforts to obtain serum samples derived from these 
animals proved unsuccessful. Since the genes for C3, 
factor B, and the classical pathway components C2 and C4 
lie within the major histocompatibility complex 
(Carroll, et. al., 1984), variants such as these would 
provide opportunities to test the hypothesis that innate 
differences in complement activity play a part in the 
aetiology of diseases such as rheumatoid arthritis and 
juvenile onset diabetes mellitus which are associated 
with the expression of certain products of the major 
histocompatibility complex in cell surfaces (Bodmer,
1980).
Complement-mediated killing of microorganisms relies on 
the same reaction sequence as complement-mediated 
haemolysis. If the differences observed in the 
alternative pathway activity of inbred mice have any 
significance, it had seemed most likely that it would be 
seen in an in-vivo test of microbial killing. In this 
respect, the lack of potency in the murine classical 
pathway added to the value of the inbred mouse as a 
model to test alternative pathway effects. The choice 
of mycobacteria in these experiments reflected local 
interests and the availability of resources - the cost 
of such experiments is high. In retrospect, the use of
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pharmacologically active components of these bacteria 
had a profound effect on the complement system in the 
mouse when injected by the subcutaneous route. While 
such effects are interesting, and may offer new models 
of altered alternative pathway activity, they did 
confuse the interpretation of the experiments with BCG. 
The alternative pathway does not appear to be 
responsible for the phenomena reported by Skamene's 
group (Gros, Skamene and Forget, 1981). Recently, their 
findings have been challenged by other workers (Orme, 
1984). Nevertheless, the observations on the 
alternative pathway haemolytic activity of inbred mice 
seem to support the concept of genetically determined 
differences in complement activity.
This investigation had arisen from observations made 
during attempts to elucidate the molecular basis of 
defects of opsonisation seen in some infants with 
recurrent infections. An important test of these 
differences in the kinetics of alternative 
pathway-mediated haemolysis was to establish whether 
they correlated with opsonic activity. Impaired 
opsonisation was not associated with retarded red cell 
lysis, but serum samples from children with biliary 
atresia showed enhanced opsonic and lytic activity.
Renal failure is a complication of obstructive jaundice 
in children and adults. The endotoxin which appears in 
the bloodstream as a result of biliary obstruction is 
said to damage the kidney directly (Pain, 1985), but 
these observations might indicate complement-mediated
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ability to clear radio-labelled albumin aggregates from 
the bloodstream (Pain, op. cit. ) , and while disordered 
Kuppfer cell function is thought to be responsible, the 
phenomenon might be caused by the abnormality of the 
complement system (Skogh and Stendahl, 1983).
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7. CONCLUDING REMARKS
The kinetic method offers a sensitive means of comparing 
complement activity in samples from a variety of 
species. Naturally-occurring differences demonstrated 
between certain species appear to offer a new range of 
experimental models in which the role of alternative 
pathway activity can be assessed. Jones (1979) 
originally proposed his method for use in diagnostic 
laboratories. The variations in alternative pathway 
haemolytic activity seen when human sera are diluted 
make the method unreliable for this purpose (Langley, 
Griffiths and Laurence, 1982), but they do open up new 
areas of research.
Apart from the low molecular weight inhibitors, most of 
the factors examined played a part in producing such 
variations. While these may be analysed in further 
studies, there is a case for examining the significance 
of the alternative pathway activity exhibited by given 
sera without attempting to determine its origins - it 
reflects the functional capabilitities of a part of host 
defences. In wider terms, investigations of the 
kinetics of the expression of opsonic, chemotactic, and 
complex solubilising activity are now indicated.
Existing complement technology is still relatively 
crude.
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APPENDICES
1. Buffers and Diluents 
Phosphate Buffered Saline
Phosphate Buffered Salts, Dulbecco Formula (modified);
Flow Laboratories, Irvine & Uxbridge;
Catalogue Number 28-103-05.
One tablet added to 100ml distilled water, autoclaved 10 
minutes at 115°.
Complement Fixation Test Diluent
Complement Fixation Diluent Tablets; Oxoid, Basingstoke; 
Product Code BR16;
One tablet added to 100ml warm distilled water, autoclaved 
before use, final pH 7.2.
Alternative Pathway Diluent 
Constituents:
(A) complement fixation test diluent (CFTD), as above.
(B) ethylene glycol bis(beta-amino ethyl ether) N, N', tetra 
acetic acid (EGTA), molecular weight 380.4;
Sigma Chemical Company, Poole; Product Number E4378.
0.08mol/L
(C) magnesium chloride hexahydrate, molecular weight 203.3 
Hopkins & Williams, Chadwell Heath;
Product Number 533000 2.0 mol/L
Standard Formulation ( "single- strength"):
9 volumes A + 1 volume B + 0.02 volumes C 
"Double - Strength" Reagent:
9 volumes "double-strength" CFTD (2 tablets/lOOml water) 
+ 2 volumes B + 0.02 volumes C.
Alsever's Solution
Flow Laboratories, Irvine & Uxbridge;
Catalogue Number 28-011-49.
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2. Other Chemicals 
Coomassie Blue
12.5g Brilliant Blue R (Sigma Chemical Company Poole, Product 
Number B0630) dissolved in a mixture of 50ml glacial acetic 
acid and 185ml distilled water. After staining, gels were 
washed glacial acetic acid/water mixture to remove excess 
dye.
Agarose
Sigma Chemical Company, Poole; Product Number A6013.
3* Antisera
Goat Antisera to Human Complement Components
Miles Laboratories, Stoke Poges:
C3 proactivator
(factor B) 68-020-1 C3b inactivator 68-020-1
properdin 68-030-1 beta-l-H 68-032-1
C3 68-004-1 C4 68-005-1
Rabbit Antiserum to Cl-inhibitor
Behring Diagnostics, Hounslow; Product Code OTNK 05 
Other Antisera
Sheep antiserum to human immunoglobulin, 
fluorescein-labelled; Code MF01.
Rabbit Haemolytic Serum Code VDl5.
Wellcome Reagents Limited, London.
4. Sheep Erythrocytes
Sheep blood in Alsever's solution;
Tissue Culture services, Slough.
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Gel Punch LKB, Sweden, Product code 94-92-6060 
Ruler for Measuring Precipitin Rings 
Behring Diagnostics, Hounslow; gratis.
6. Disposable Items 
Microtitre Plates
microwell plates, 96 U well, with lids;
Nunc, Kamstrupje, Denmark; Product Number 2-62170. 
Microtitre Plate Sealers 
Titertek plate sealers;
Flow laboratories, Irvine & Uxbridge;
Catalogue number 77-400-05.
Plastic Test Tubes
LP3 tubes; Luckham Ltd, Burgess Hill.
Dialysis Tubing
Dialysis tubing, Visking, 0.32mm thick, flat width 10mm; 
molecular weight cut-off 12,000-14,000 
Gallenkamp, London; Catalogue Number PJC-400-030R.
7. Fluoresence Microscope
Leitz Dialux 20 microscope, with incident light fluoresence 
and manufacturers" filter system for use with fluorescein.
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ABSTRACT
H i g g i n s ,  D.A.  a n d  L a n g l e y ,  D . J . ,  1 9 8 5 .  A c o m p a r a t i v e  s t u d y  o f  c o m p l e m e n t
a c t i v a t i o n .  V e t .  I m m u n o l .  I m m u n o p a t h o l . ,  9 :  3 7 - 5 1 .
A n t i s e r a  t o  s h e e p  e r y t h r o c y t e s  ( E )  w e r e  r a i s e d  i n  c a t t l e ,  r a b b i t s ,  m i c e ,
h a m s t e r s ,  g u i n e a - p i g s ,  f e r r e t s ,  b a d g e r s ,  h e d g e h o g s  a n d  f o w l s .  C r o s s  
a c t i v a t i o n  o f  t o t a l  h a e m o l y t i c  c o m p le m e n t  (THCA)  e xa m i n ed  a l l  c o m b i n a t i o n s  o f  
s e n s i t i z e d  sheep E and n o r m a l  s e r a  ( i n c l u d i n g  human);  k i n e t i c  a s s a y s  e xa m i n ed  
t h e  l y s i s  o f  E s e n s i t i z e d  w i t h  r a b b i t  a n t i b o d i e s .  From t h e  same s p e c i e s ,  a l l  
c o m b i n a t i o n s  o f  n o r m a l  s e r u m  a n d  x e n o g e n e i c  E w e r e  u s e d  t o  m e a s u r e  t o t a l  
a l t e r n a t i v e  p a t h w a y  a c t i v i t y  ( T A P A ) ;  TAPA was a l s o  a c t i v a t e d  b y  r a b b i t  a n d  
she e p  E i n  t i t r a t i o n s  and i n  a g a r o s e  g e l s ,  and e x a m i n e d  k i n e t i c a l l y  a g a i n s t  
r a b b i t  E.
O x ,  r a b b i t  a n d  f o w l  s e r a  w e r e  l o w  i n  THCA,  g u i n e a - p i g  c o m p l e m e n t  w a s  
u n i v e r s a l l y  a c t i v e ,  w h i l e  human c o m p l e m e n t  showed ma r ke d  s e l e c t i v i t y ;  f e r r e t ,  
b a d g e r  and hedgehog s e r a  w e re  a c t i v a t e d  t o h i g h  t i t r e s  b u t  p r o b a b l y  v i a  t h e  
a l t e r n a t i v e  p a t h w a y .  I n  s t u d i e s  o f  TAPA a n  i n v e r s e  r e l a t i o n s h i p  e x i s t e d  
be t w e e n  serum c o m pl e m e n t  a c t i v i t i e s  and t h e  a c t i v a t i n g  a b i l i t i e s  o f  E f r o m  t h e  
same s p e c i e s .  T h e  m o s t  e f f i c i e n t  a c t i v a t o r s  o f  a l t e r n a t i v e  p a t h w a y  w e r e  E 
f r o m  r a b b i t s  a n d  l a b o r a t o r y  r o d e n t s ,  w h i l e  t h e  s e r a  w i t h  b r o a d e s t  r e s p o n s e  
Were b a d g e r ,  f e r r e t  and f o w l .  K i n e t i c  s t u d i e s  o f  TAPA showed t h a t  i n i t i a t i o n
o f  l y s i s  a n d  s u b s e q u e n t  c o m p l e t i o n  o f  l y s i s  c o u l d  o c c u r  w i t h  d i f f e r e n t
e f f i c i e n c i e s ,  s u g g e s t i n g  t h e s e  e v e n t s  r e f l e c t e d  s e p a r a t e  e v e n t s  i n  c o m p l e m e n t  
a c t i v a t i o n .
INTRODUCTION
T h e  t e c h n o l o g y  o f  c o m p l e m e n t  f i x a t i o n  ( C F )  h a s  b e e n  i m p o r t a n t  i n  
d i a g n o s t i c  b a c t e r i o l o g y  and v i r o l o g y  f o r  many y e a r s .  The i n i t i a l  r e c o g n i t i o n  
o f  CF a s  a s e q u e l  t o  t h e  i n t e r a c t i o n  o f  a n t i b o d y  a n d  a n t i g e n  ( c l a s s i c a l  
p a t h w a y ,  CP)  has r e c e n t l y  been somewhat  o v e r s h a d o w e d  by  i n t e r e s t  i n  t h e  d i r e c t  
a c t i v a t i o n  o f  c o m p l e m e n t  by  a v a r i e t y  o f  s u b s t a n c e s  i n c l u d i n g  h e t e r o l o g o u s
0165-2427 /85 /$03 .30 © 1985 Elsevier Science Publishers B .V.
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c e l l s  nnd t h e  s u r f a c e  a n t i g e n s  o f  many pa t ho ge ns  ( a l t e r n a t i v e  p a t h w ay ,  AP) .  
Bot h p a t h w a y s  p l a y  i m p o r t a n t  r o l e s  in  t he  i n d u c t i o n  and s u p p r e s s i o n  o f  immune 
r e s p o n s e s ,  o p s o n i s a t i o n , i n a c t i v a t i o n  o f  v i r u s e s ,  l y s i s  o f  c e l l s  and b a c t e r i a ,  
i m m u n o p a t h o  1 o g y  an d  t h e  o u t c o m e  o f  h o s t - p a r a s i t e  r e l a t i o n s h i p s  ( M u l l e r -  
E b e r h a r t  and S c h r e i b e r ,  1980;  F i n e ,  1981;  W e i l e r  e_t a_l . ,  1982 ) .
I t  i s  w e l l  known t h a t  a n t i b o d i e s  f rom d i f f e r e n t  s p e c i e s  do not  a c t i v a t e  CP 
f r o m  a s i n g l e  s o u r c e  w i t h  e q u a l  e f f i c i e n c y  ( R i c e ,  1 9 8 0 ;  R i c e  an d  C r o u s o n ,  
1 9 8 0 ;  J a n k o v i c  an d  I s a k o v i c ,  1 9 6 0 ;  G i g l i  and  A u s t e n ,  1 9 7 1 ) ;  some a n t i s e r a  
a c t u a l l y  i n h i b i t  CP f i x a t i o n  ( a n  t i comp 1 emen t a  r  i  t y ) ( O r l a n s  e t  a l . ,  1 9 6 2 ) .  
W h e t h e r  t h i s  i s  an a b s o l u t e  d e f i c i e n c y  o f  t h e  a n t i b o d i e s  o r  a r e f l e c t i o n  o f  
s p e c i e s '  p r e f e r e n c e s  i s  l a r g e l y  unknown.  The s e r o l o g i c a l  s o l u t i o n  t o  t he s e  
p r o b l e m s  h a s  b e e n  t o  s u p p l e m e n t  t h e  x e n o g e n e i c  c o m p l e m e n t  w i t h  f r e s h  s e r u m  
a l l o g e n e i c  o r  s y n g e n e i c  t o  t he  a n t i b o d y  ( H o f f ma n  and M a y e r ,  1977;  M a r q u a r d t ,  
1 9 7 7 ) .  T h i s  l i as  a s s u m e d  t h a t  h o m o l o g y  b e t w e e n  a n t i b o d i e s  a n d  C l  c o u l d  
i n i t i a t e  t h e  c o m p l e m e n t  c a s c a d e ,  w h e r e a f t e r  i n t e r a c t i o n  w i t h  s u b s e q u e n t  
c o m p l e m e n t  c o m p o n e n t s  w o u l d  be u n h i n d e r e d  by s p e c i e s  r e s t r i c t i o n s .  S u c h  
m i x t u r e s  a r e  d i f f i c u l t  t o  s t a n d a r d i z e  and a r e  c o n c e p t u a l l y  and p r a c t i c a l l y  
u n d e s i r a b l e .  A b e t t e r  a p p r o a c h  w o u l d  be t o  d e f i n e  wh i c h  s p e c i e s '  c omp l e me nt  
i n t e r a c t  e f f i c i e n t l y  w i t h  w h i c h  s p e c i e s '  a n t i b o d i e s ,  an d  t o  u t i l i z e  t h e  
a p p r o p r i a t e  c o m b i n a t i o n s .  S i m i l a r l y ,  t h e  r e l a t i v e  e f f i c i e n c i e s  o f  AP 
a c t i v a t i o n  r e q u i r e  s t u d y .  A common method j o f  a c t i v a t i o n  i s  t o  use  x e n o g e n e i c  
E ( P l a t t s - M i l  I s  and I s h i z a k a ,  1 9 7 4 )  but  t he  s p e c i e s  s p e c t r u m  o f  i n t e r a c t i o n  
r e q u i r e s  e x a m i n a t i o n .  The w o rk  d e s c r i b e d  h e r e  i s  a p r e l i m i n a r y  s t u d y  o f  t he  
c r o s s  a c t i v a t i o n  o f  CP and AP by a n t i b o d y  and E b e t we en  n i n e  s p e c i e s .
MATERIALS AND METHODS
P r o d u c t i o n  o f  a n t i s e r a  t o  s he e p  e r y t h r o c y t e s  ( S E )
A s i n g l e  h e a l t h y  ewe was used as  a s o u r c e  o f  SE. B l o o d  was c o l l e c t e d  i n t o  
an e q u a l  v o l u m e  o f  s t e r i l e  A l s e v e r ' s  s o l u t i o n ,  pH 6 . 2 .  T h e  SE w e r e  w a s h e d  
t h r e e  t i m e s  i n  0 . 1 M  p h o s p h a t e  b u f f e r e d  s a l i n e ,  pH 7 . 2  ( P B S ) ,  t h e n  s t o r e d  i n  
A l s e v e r ' s  s o l u t i o n  a t  4°C f o r  up t o  3 d a y s .  J u s t  p r i o r  t o  i n o c u l a t i o n ,  t h e  
c e l l s  w e r e  washed a g a i n  in  PBS and a 107. ( v / v )  s u s p e n s i o n  was p r e p a r e d  i n  PBS.  
Th e  a n i m a l s  u s e d  an d  t h e  p r o t o c o l s  f o r  i m m u n i z a t i o n  ( C a m p b e l l  e t  a l . ,  1 9 7 0 )  
a r e  d e s c r i b e d  i n  T a b l e  I .  F e r r e t s ,  h e d g e h o g s  and  m i c e  w e r e  b l e d  u n d e r  
a n a e s t h e s i a  i n d u c e d  by  e t h e r ,  g u i n e a - p i g s ,  h a m s t e r s ,  m i c e  and  r a b b i t s  u n d e r  
a n a e s t h e s i a  i n d u c e d  by b a r b i t u r a t e s  ( " S a g a t a J " ,  May and B a k e r ) ,  w h i l s t  b a d g e r s
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were anaesthetized with ketamine hydrochloride ("Vetalar”, Parke Davis). Fowl
and cattle were bled without anaesthetic. Sera were separated, frozen at 
o
- 7 0  C,  a nd  l a t e r  t r a n s f e r r e d  t o  l i q u i d  n i t r o g e n .  A n t i b o d y  t i t r e s  ( T a b l e  I )  
we re  a ss a y e d  by d o u b l i n g - d i 1 u t i o n  d i r e c t  h a e m a g g l u t i n a t i o n  t e s t s  a g a i n s t  a 3% 
s u s p e n s i o n  o f  SE.
N or ma l  s e r a  ( c o m p l e m e n t )
B l o o d s  we r e  c o l l e c t e d  f ro m  u n i m m u ni z e d  a n i m a l s  and a l l o w e d  t o  c l o t  a t  0 °C  
f o r  up  t o  1 h r .  S e r a  w e r e  c l a r i f i e d  by  c e n t r i f u g a t i o n  a t  0 ° C  a n d  s t o r e d  i n  
t he  same way as t h e  a n t i s e r a .
T i t r a t i o n  o f  t o t a l  h a e m o l y t i c  c omp l e me nt  a c t i v i t y  (THCA)
A n t i s e r a  w e r e  i n a c t i v a t e d  a t  5 6 ° C  f o r  3 0  m i n  an d  m i x e d  w i t h  a 3%
s u s p e n s i o n  o f  SE i n  CF t e s t  d i l u e n t  ( C F T D )  ( O x o i d ) ,  t o  r e p r o d u c e  t h e  m i x t u r e
o
o n e  d i l u t i o n  a b o v e  t h e  HA t i t r e .  T h e  m i x t u r e s  w e r e  i n c u b a t e d  a t  37  C f o r  15
m i n  a n d  t h e  s e n s i t i z e d  c e l l s  ( S E A )  w a s h e d  3 t i m e s  i n  CFTD b e f o r e  b e i n g
r e s u s p e n d e d  a t  3% i n  CFTD.  E q u a l  v o l u m e s  ( 2 0  p i )  o f  SEA a n d  s e r u m  o r  s e r u m
o
d i l u t i o n  wer e  i n c u b a t e d  i n  m i c r o t i t r e  t r a y s  i n  a m o i s t  a t m o s p h e r e  a t  37 C f o r  
2 h r .  L y s i s  was a s s e s s e d  v i s u a l l y .
T i t r a t i o n s  o f  t o t a l  a l t e r n a t i v e  p a t hw ay  a c t i v i t y  (TAPA)
S e r i a l  t w o - f o l d  d i l u t i o n s  o f  e a c h  s e r u m  w e r e  made i n  m i c r o t i t r e  p l a t e s  
u s i n g  AP d i l u e n t  (APD) .  T h i s  c o n s i s t e d  o f  CFTD s u p p l e m e n t e d  w i t h  8mM e t h y l e n e  
g l y c o l  b i s - t e t r a a c e t i c  a c i d ,  s o d i u m  s a l t  ( S i g m a )  and  2 0  raM M g C l .  An e q u a l  
v o l u m e  ( 2 0  p i )  o f  r a b b i t  ( R)  E o r  SE s u s p e n s i o n  i n  APD was added t o  e a c h  w e l l .  
L y s i s  was a s s e s s e d  v i s u a l l y  a f t e r  2 h r  i n c u b a t i o n  a t  3 7 ° C  i n  a m o i s t  
a t m o s p h e r e .
R a d i a l  h a e m o l y s i s
TAPA was a l s o  a s s e s s e d  a g a i n s t  SE and RE by r a d i a l  h a e m o l y s i s  i n  a g a r o s e  
g e l  ( Lachmann e t  a l . ,  1 97 3 ) .
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TABLE I
Production of antisera against sheep erythrocytes
S p e c i e s No B r e e d / S t r a i n
I n o c u l a t i o n H a e m a g g l u t i n a t i o n  t i t r e s
Volume^ R o u t e ^ I mmuni zed
a n i m a l s
N or ma l
s e r a
Ox 2 J e r s e y ,
H e r e f o r d
3 . 0 I V 2 5 6 , 5 1 2 4
R a b b i t 4 NZW x L o p e ar 1 . 0 I V 1 2 8 , 1 2 8 , 2 5 6 , 2 5 6 0
Mouse 15 CFLP 0 . 2 5 I P 1 2 8 , 2 5 6 , 5 1 2 3 8
H am s te r 10 S y r i a n 0 . 2 5 I P 1 2 8 , 1 2 8 , 2 5 6 ,  
2 5 6 , 2 5 6 3
4
G u i n e a - p i g 5 H a r t l e y 0 . 5 I P 1 2 8 , 1 2 8 3 4
F e r r e t 3 P o l e c a t 1 . 0 I P 3 2 , 3 2 , 6 4 16
B a d ge r 3 - 1 . 0 I V 6 4 , 6 4 , 1 2 8 8
Hedgehog 3 - 0 . 5 IP 8 , 6 4 , 6 4 8
Fowl 2 W h i t e  L e g h o r n 0 . 5 I V 2 5 6 , 1 0 2 4 32
^■Volume ( m l )  o f  10% SE s u s p e n s i o n  i n o c u l a t e d  on e a c h  o f  d a y s  1 , 2 , 3 , 5 , 7 , 9 , 1 1  
and 1 3 .  A n i m a l s  w e re  b l e d  on d a y  15 .
n
I V ,  i n t r a v e n o u s ;  I P ,  i n t r a p e r i t o n e a l .
3
P o o l s  o f  two o r  more i n d i v i d u a l s .
T i m e d - l y s i s  a s s a ys
T h es e  w e r e  based on met h ods  d e s c r i b e d  p r e v i o u s l y  ( J o n e s ,  1 9 7 9 ) .  T h e y  w e r e
p e r f o r m e d  on a Beckman mo d e l  24 s p e c t r o p h o t o m e t e r  u s i n g  1 cm g l a s s  c u v e t t e s  
o
h e l d  a t  37C.  THCA was s t u d i e d  u s i n g  SEA sus pe n de d  i n  CFTD,  TAPA u s i n g  RE i n  
APD. C e l l  s u s p e n s i o n s  w e re  a d j u s t e d  t o g i v e  an a b s o r b a n c e  a t  700 nm (A700 )  ° f  
0 . 9 .  S e r a  a nd  E s u s p e n s i o n s  w e r e  w a r m e d s e p a r a t e l y  t o  3 7 ° C ,  m i x e d  i n  t h e  
c h o s e n  p r o p o r t i o n s  a n d  q u i c k l y  t r a n s f e r r e d  t o  t h e  s p e c t r o p h o t o m e t e r  w h e r e  
l y s i s  was f o l l o w e d  a t  700  nm.
Gr a phs  o f  A^qq v e r s u s  t i m e  wer e  s i g m o i d a l .  T h r e e  v a l u e s  f r o m  t h e s e  p l o t s  
c o u l d  be  u s e d  t o  d e s c r i b e  t h e  t i m e - c o u r s e  o f  l y s i s :  t h e  l a g  p h a s e  ( L P ;  t i m e  
f r o m  m i x i n g  t h e  r e a c t a n t s  t o  c o m m e n c e m e n t  o f  l y s i s ) ;  t h e  t i m e  t o  50% l y s i s  
( t ^ g ) ;  a nd  t h e  t i m e  t o  c o m p l e t e  l y s i s  ( t ^ g g ^ *  ^P was  c o n s i d e r e d  a n  i n d e x  o f
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t h e  t i m e  r e q u i r e d  t o  p r o d u c e  C3 c o n v e r t a s e ,  w h i l e  t ^ g - L P  o r  t ^ g g - L P  r e f l e c t e d  
t he  e f f i c i e n c y  o f  i n t e r a c t i o n  o f  t h e  membrane a t t a c k  c o m p l e x ,  C5 t o  C9.
RESULTS
THCA
C r o s s  a c t i v a t i o n  and t i t r a t i o n s  ( T a b l e  I I ) .  T h e r e  was c o n s i d e r a b l e  v a r i a t i o n  
b e t we en  s p e c i e s  i n  t h e  t i t r e s  o f  serum c o m p l e m e nt .  I n  g e n e r a l ,  v a r i a t i o n  was  
a p r o p e r t y  o f  t h e  c o m p l e m e n t ,  n o t  t h e  a n t i b o d y .  Thus o x ,  r a b b i t  and c h i c k e n  
c o m p l e m e n t  w e r e  l o w  i r r e s p e c t i v e  o f  t h e  a n t i b o d y  s o u r c e  a n d  e v e n  a g a i n s t  
h o m o l o g o u s  a n t i b o d y .  F e r r e t ,  b a d g e r  and  h e d g e h o g  s e r a  ha d  h i g h  t i t r e s  o f  
h a e m o l y t i c  a c t i v i t y ,  t h o ug h  t he  r e a c t i o n  a g a i n s t  u n s e n s i t i z e d  SE was a l s o  h i g h  
s u g g e s t i n g  t h e  a c t i v a t i o n  was  v i a  t h e  AP.  T h e  g r e a t e s t  v a r i a t i o n  o c c u r r e d  
w i t h  human c o m pl e m e n t  w h i c h  was a c t i v a t e d  e f f i c i e n t l y  by  ox ,  r a b b i t ,  h a m s t e r  
and b a d g e r ,  m o d e r a t e l y  by mouse,  g u i n e a - p i g  and f e r r e t ,  and p o o r l y  b y  hedgehog  
and f o w l  a n t i b o d i e s .  G u i n e a - p i g  was u n i v e r s a l l y  a c t i v e  t o  h i g h  t i t r e s ,  w i t h  
l i t t l e  a c t i v a t i o n  o f  AP by  u n s e n s i t i z e d  SE.
T i m e d - l y s i s  a s s a y s  ( T a b l e  I I I ) .  When 25 p i  s e r u m  was a d d e d  t o  1 m l  SEA 
s u s p e n s i o n ,  c om p l e m e n t  f r o m  g u i n e a - p i g ,  he dgeh og,  f e r r e t  and b a d g e r  i n i t i a t e d  
l y s i s  w i t h i n  1 m i n ,  a n d  t h e  p r o c e s s  was  c o m p l e t e  w i t h i n  3 m i n .  H a m s t e r  a nd  
human c o m pl e m en t  r e q u i r e d  2 - 3  min t o  p r o d u c e  d e t e c t a b l e  l y s i s ,  and 7 - 1 2  min  t o  
c o m p l e t e  i t .  Ox a n d  f o w l  s e r a  d i d  n o t  show a n y  l y t i c  a c t i v i t y  a t  t h i s  
d i l u t i o n ;  wh en  e q u a l  v o l u m e s  ( 2 5 0  p i )  o f  s e r u m  a n d  SEA w e r e  m i x e d ,  o x
c o mp l e m e nt  c au s ed  l y s i s  w i t h  t h e  same k i n e t i c s  as h a m s t e r  and human c o m p l e m e n t
a t  t h e  l o w e r  c o n c e n t r a t i o n ,  w h i l e  c h i c k e n  c ompl e me nt  g a v e  s i m i l a r  r e s u l t s  t o  
g u i n e a - p i g  c o m p l e m e nt  a t  t h e  l o w e r  c o n c e n t r a t i o n .  House  c om p l e m e n t  d i d  n o t  
i n d u c e  l y s i s  a t  e i t h e r  c o n c e n t r a t i o n .  E v e n  when SE we r e  s e n s i t i z e d  w i t h  mouse  
a n t i b o d y  and e xposed  t o  mouse c om p l e m e n t  a t  a d i l u t i o n  o f  1 : 2 ,  l y s i s  d i d  n o t  
o c c u r ,  a l t h o u g h  t h e s e  c e l l s  c o u l d  be l y s e d  by g u i n e a - p i g  c o m p l e m e n t .
TAPA
C r o s s  a c t i v a t i o n  a n d  t i t r a t i o n s . The  p a t t e r n  o f  a c t i v a t i o n  o f  AP i n  n o r m a l  
s e r a  by E f rom e ac h  s p e c i e s  i s  shown i n  T a b l e  I V .  T a b l e  V shows t h e  t i t r e  o f  
AP i n  e a c h  s p e c i e s '  s e r u m  a g a i n s t  RE a n d  SE a n d  T a b l e  V I  t h e  a c t i v i t y  i n
a g a r o s e  g e l s .  F o w l ,  b a d g e r ,  f e r r e t  and ox AP we r e  a c t i v a t e d  by a w i d e  r a n g e
o f  E. Human ,  r a b b i t ,  m o u s e ,  g u i n e a - p i g  a n d  h e d g e h o g  AP w e r e  m or e  s e l e c t i v e ;
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TABLE I I I
T i m e d - l y s i s  a ss a y s  o f  t o t a l  h a e m o l y t i c  c ompl e me nt  a c t i v i t y  (THCA) u s i n g  s heep  
e r y t h r o c y t e s  s e n s i t i z e d  w i t h  r a b b i t  a n t i b o d y
Complement
R e a c t i o n  vo lume ( M l ) Ti me ( m i n )  o f
s o u r c e Serum:SEA LP t 50 4 0 0
Human 2 5 : 1 0 0 0 1 . 9 3 . 5 6 . 7
Ox
Mouse
2 5 : 1 0 0 0  
5 0 0 : 5 0 0
2 5 : 1 0 0 0
5 0 0 : 5 0 0
2 . 2
no a c t i v i t y  - 
6 . 3
-  no a c t i v i t y  -
1 4 . 0
H am s t e r 2 5 : 1 0 0 0 1 . 8 5 . 3 1 0 . 9
G u i n e a - p i g 2 5 : 1 0 0 0  
2 5 0 : 2 5 0
1 . 1
1 . 7
1 . 7
5 . 4
3 . 1
1 0 . 5
F e r r e t 2 5 : 1 0 0 0 1 . 0 1 . 5 2 . 3
Bad ge r 2 5 : 1 0 0 0 0 . 5 1 . 1 2 . 1
Hedgehog 2 5 : 1 0 0 0 0 . 9 1 . 7 3 . 2
Fowl 2 5 : 1 0 0 0
5 0 0 : 5 0 0 1 . 2
— no a c t i v i t y —  
2 . 5 3 . 9
SEA: s e n s i t i z e d  e r y t h r o c y t e s ;  LP:  
t 1 0 0 : c* me t o  1 00 2  l y s i s .
l a g  ph as e ; t ^Q:  t i m e t o  50% l y s i s ;
a c t i v a t i o n  o c c u r r e d  m o s t  o f t e n  w i t h  r a b b i t ,  m o u s e ,  h a m s t e r  and g u i n e a - p i g  E 
( t h o u g h  n o t ,  o f  c o u r s e ,  w i t h i n  t h e  ho mo l og ous  s ys t e m)  and t o  some e x t e n t  w i t h  
b a d g e r  E. H a m s t e r  AP was a c t i v a t e d  o n l y  by  r a b b i t  a n d  g u i n e a - p i g  E.  Ox a n d  
f o w l  E ( t h r e e  i n  e a c h  c a s e )  a n d . b a d g e r ,  h e d g e h o g  a n d  f e r r e t  E ( f o u r  i n  e a c h  
c a s e )  a c t i v a t e d  t he  s m a l l e s t  number  o f  s e r a ,  w h i l e  r a b b i t ,  mouse,  h a m s t e r  and  
g u i n e a - p i g  E a c t i v a t e d  AP o f  a l l  o r  most  s e r a .
T i m e d - l y s i s  a s s a y s  ( T a b l e  V I I ) .  The r e l a t i o n s h i p  be t we en  t h e  s q u a r e  r o o t  o f  
LP,  o r  t^QQ was l i n e a r  t o  a c h a r a c t e r i s t i c  p o i n t  i n  e ac h  c a s e ,  e . g .  6 00  p i
f o r  c h i c k e n ,  150 p i  f o r  f e r r e t .  W i t h  l o w e r  c o n c e n t r a t i o n s  o f  serum t h e r e  was 
a mar k e d  i n c r e a s e  i n  t i m e  r e q u i r e m e n t ,  s u g g e s t i n g  t h e  c o n c e n t r a t i o n  o f  one o r  
more component s  was b e l o w  a c r i t i c a l  c o n c e n t r a t i o n .  LP and t ^ Q - L P  ( o r  t ^ Q Q -  
LP) w e r e  n o t  n e c e s s a r i l y  e q u a l l y  e f f i c i e n t ;  e . g .  w i t h  150 p i  f e r r e t  se r um and  
6 0 0  p i  ox  s e r u m  LP was  2 . 1  m i n ,  b u t  t  5Q- LP was 4 . 4  m i n  f o r  f e r r e t  a n d  o n l y  1 . 0  
min f o r  ox .  LP was s h o r t e s t  w i t h  f e r r e t ,  hedgehog and b a d g e r  s e r a ,  b u t  t ^ Q - L P  
was s h o r t e s t  w i t h  ox ,  f o w l  and human s e r a .
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TABLE V
The t i t r e  o f  t o t a l  a l t e r n a t i v e  p a t hw ay  a c t i v i t y  (TAPA)  i n  s e r a  f ro m  v a r i o u s  
s p e c i e s
TAPA ( c o m p l e t e  l y s i s  ( p a r t i a l l y s i s ) )  a g a i n s t :
Serum RE SE
Human 0 ( 4 ) 0 ( 4 )
Ox 2 ( 1 6 ) 0 ( 8 )
R a b b i t 0 ( 0 ) 0 ( 0 )
Mouse 0 ( 2 ) 0 ( 2 )
H a m s te r 4 ( 8 ) 0 ( 2 )
G u i n e a - p i g 0 ( 8 ) 0 ( 4 )
F e r r e t 6 4 ( 0 ) 8 ( 6 4 )
Bad ge r 8 ( 1 2 8 ) 8 ( 6 4 )
Hedgehog 8 ( 1 6 ) 0 ( 8 )
Fowl 4 ( 3 2 ) 2 ( 1 6 )
RE: r a b b i t  e r y t h r o c y t e s ; SE: sheep e r y t h r o c y t e s .
DISCUSSION
The v a r i a b l e s  i n  c o mp l e m e nt  f i x a t i o n  s y s te ms  a r e  many.  Opt imum a c t i v a t i o n  
o f  CP i n  ser um o f  a g i v e n  s p e c i e s  depends  upon t h e  s o u r c e  and number  o f  E,  t h e  
s o u r c e  o f  a n t i b o d y ,  t h e  c o n c e n t r a t i o n  o f  e s s e n t i a l  m i n e r a l s  i n  t h e  
e n v i r o n m e n t ,  a n d  t h e  t e m p e r a t u r e ,  t i m e  a n d  v o l u m e  o f  r e a c t i o n  ( B a r t a  a n d  
B a r t a ,  1 9 7 5 ;  B e r d e n  e t  a 1 . ,  1 9 7 8 ) .  D i f f e r e n c e s  e x i s t  e v e n  b e t w e e n
p h y l o g e n e t i c a l l y  c l o s e  s p e c i e s  ( B a r t a  and K l e i ,  1 9 7 8 ) .  I t  c a n n o t  be c o n c l u d e d  
t h e r e f o r e  t h a t  t h e  THCA r e s u l t s  o b t a i n e d  i n  t h i s  s t u d y  e m p l o y i n g  a s i n g l e  s e t  
o f  p h y s i c a l  c o n d i t i o n s  w e r e  o p t i m u m ,  b u t  some c o n c l u s i o n s  c a n  be  d r a w n  
r e g a r d i n g  t he  i n t e r a c t i o n  o f  v a r i o u s  c o m b i n a t i o n s  o f  a n t i b o d y  and c o m p l e m e n t .  
T h e  l o w  h a e m o l y t i c  a c t i v i t y  o f  o x ,  mous e  a nd  f o w l  c o m p l e m e n t  c o n f i r m e d  
p r e v i o u s  r e p o r t s  ( R i c e ,  1 9 5 0 ;  Or  I a n s  e_t  ^_al . . ,  1 9 6 2 ;  B e r d e n  a l . ,  1 9 7 8 ) .  T h e  
l o w  t i t r e s  o f  r a b b i t  c o m p l e m e n t  w e r e  u n e x p e c t e d .  T h e  r a b b i t  i s  a common  
s o u r c e  o f  c o m p l e m e n t  i n  c l i n i c a l  i m m u n o l o g y  and  t i s s u e  t y p i n g ,  t h o u g h  
a d m i t t e d l y  a g a i n s t  human a n t i b o d i e s ,  w h i c h  we d i d  n o t  e m p l o y ,  and w i t h  w e l l -  
r e c o g n i z e d  i n d i v i d u a l  v a r i a t i o n .  Human c om p l e m e nt  was s u r p r i s i n g l y  s e l e c t i v e .
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TABLE VI
Lysis of unsensitized erytlirocytes in agarose gels
Serum D i a m e t e r  o f l y s i s  (mm)
S p e c i e s  Vo l ume ( p i )
Sheep e r y t h r o c y t e s  i n  
CFTD APD
R a b b i t  e r y t h r o c y t e s  i n  
CFTD APD
2 7 . 8 to. 4 6 . 9 6 . 2
B ad g e r 5 8 . 3 6 . 9 8 . 8 7 . 9
10 1 0 . 0 7 . 6 9 . 2 8 . 5
2 7 . 4 7 . 5 7 . 2 7 . 4
F e r r e t 5 8 . 3 7 . 7 8 . 9 8 . 5
10 9 . 1 8 . 5 1 0 . 6 1 1 . 1
2 6 . 6 +  1 - -
R a b b i t 5 8 . 6 + - -
10 8 . 7 + - -
2 5 . 8 - 5 . 8 -
G u i n e a - p i g 5 6 . 0 - 6 . 0 -
10 9 . 0
"
9 . 0
CFTD:  c o m p l e m e n t  f i x a t i o n  t e s t  d i l u e n t ;  APD: a l t e r n a t i v e  p a t hw ay  d i l u e n t .
^Weak  p o s i t i v e  r e s u l t s ;  a l s o  s e e n  f o r  human a nd  h e d g e h o g  a g a i n s t  SE i n  b o t h  
d i l u e n t s .  N e g a t i v e  r e s u l t s  a g a i n s t  SE w i t h  o x ,  f o w l ,  h a m s t e r  a n d  m o u s e .  
A g a i n s t  r a b b i t  e r y t h r o c y t e s  weak p o s i t i v e  r e s u l t s  we re  o b t a i n e d  w i t h  human 
s e r u m  ( i n  b o t h  d i l u e n t s )  a n d  h e d g e h o g  s e r u m  ( i n  CFTD o n l y ) .  N e g a t i v e  
r e s u l t s  w i t h  o x ,  f o w l ,  h a m s t e r  and mouse.
The b a s i s  o f  s p e c i e s  s e l e c t i v i t y  i n  CP a c t i v a t i o n  i s  p o o r l y  u n d e r s t o o d .  The  
s e r a  o f  s e v e r a l  s p e c i e s  d i s p l a y i n g  p o or  h a e m o l y t i c  a c t i v i t y  h a v e  been e xa mi n e d  
f o r  t h e  p r e s e n c e  o f  c o m p l e m e n t  c ompon en t s;  t h e  most  common d e f i c i e n c y  i n  t h e s e  
s p e c i e s  was o f  C4 ( R i c e  and Cro wson,  1950;  B a r t a  e_£ a l . ,  1 97 6 ) .  T h i s  does  n o t  
d i s p r o v e  t h e  c o n c e p t  o f  i n c o m p a t i b i l i t i e s  be twe en  c e r t a i n  c o m b i n a t i o n s  o f  C lq  
and i m m u n o g l o b u l i n .  C l q  o f  v a r i o u s  s p e c i e s  a r e  c h e m i c a l l y  and s t r u c t u r a l l y  
q u i t e  s i m i l a r  ( H o f f k e n  e_t a_ l . ,  1 9 7 8 ) .  H o w e v e r ,  c h a r g e  and a c c e s s i b i l i t y  o f  
t h e  C2 do ma i n  o f  IgG a f f e c t  t h e  i n t e r a c t i o n  w i t h  C l q  ( B u r t o n  ejt a l . ,  1 9 8 0 )  and  
t h e s e  p r o p e r t i e s  p r o b a b l y  v a r y  f r o m  s p e c i e s  t o  s p e c i e s .  I t  r e m a i n s  t o  be 
e x p l a i n e d  wh y  g u i n e a - p i g  c o m p l e m e n t  was  u n i v e r s a l l y  a c c e p t a b l e  t o  o t h e r  
s p e c i e s '  a n t i b o d i e s .  The i n t e n s i v e  i m m u n i z a t i o n  s c h e d u l e  a d o p t e d  was t y p i c a l  
o f  t h a t  us e d  p r e v i o u s l y  by many w o r k e r s  t o  s t i m u l a t e  r a b b i t  a n t i b o d i e s  t o  SE.  
H o w e v e r ,  i t  i s  p r o b a b l e  t h a t  o t h e r  s p e c i e s  w o u l d  r e s po nd  w i t h  a n t i b o d i e s  o f  
d i f f e r e n t  i s o t y p e s  and s u b c l a s s e s ,  w h i c h  w o u l d  a f f e c t  CP a c t i v a t i o n  ( F e i n s t e i n  
a n d  H o b a r t ,  1 9 6 9 ;  K l a u s  £ £  £_i *> 19 7 9 ) ,  a n d  o f  d i f f e r e n t  a f f i n i t i e s  a n d
a v i d i t i e s .  G e n e t i c  as  w e l l  as  s p e c i e s  d i f f e r e n c e s  s h o u l d  be c o n s i d e r e d .
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TABLE VII
T i m e d - l y s i s  a s s a y s  o f  a l t e r n a t i v e  p a t h w a y  a c t i v a t i o n  by r a b b i t  
e r y t h r o c y t e s
Serum
Pv po j rn°n t
T i me  ( m i n ) o f
S p e c i e s Vol ume ( p l ) ^ LP c 50 t 100
1 Human f e m a l e 750 1 . 7 3 . 0 3 . 6
6 00 2 . 5 3 . 8 5 . 9
300 8 . 0 - -
Human mal e 750 2 . 7 7 . 0 9 . 2
600 3 . 5 9 . 2 1 2 . 4
Fowl . 750 1 . 2 1 . 8 3 . 5
6 00 2 . 2 3 . 0 4 . 4
300 6 . 0 1 0 . 1 1 3 . 2
F e r r e t 1000 0 2 . 3 4 . 0
750 0 3 . 2 5 . 7
6 00 0 . 9 3 . 6 6 . 2
300 1 . 7 5 . 4 8 . 5
150 2 . 1 6 . 5 1 0 . 0
75 3 . 2 1 5 . 0 -
G u i n e a - p i g 1 00 0 1 . 6 3 . 4 8 . 7
7 50 1 . 8 - -
6 00 2 . 3 - -
Mouse 5 0 0 1 3 . 0 1 0 . 5 -
2 Human f e m a l e 1 00 0 1 . 0 2 . 7 4 . 0
750 2 . 7 4 . 9 6 . 7
6 00 3 . 7 6 . 0 8 . 0
Human m a l e 1 0 0 0 2 . 2 4 . 4 5 . 4
750 3 . 0 6 . 6 9 . 0
6 00 4 . 0 7 . 2 1 0 . 0
Bad g e r 1 000 1 . 0 3 . 0 4 . 0
7 50 1 . 2 3 . 2 5 . 0
6 00 1 . 4 3 . 8 5 . 5
300 1 . 6 6 . 4 -
Hedgehog 6 00 0 . 7 1 . 9 3 . 0
3 00 1 . 7 3 . 9 7 . 0
H ams t er 1000 1 . 7 5 . 6 -
600 2 . 9 - -
Ox 6 00 2 . 1 3 . 1 5 . 0
3 00 4 . 7 1 0 . 3 1 3 . 0
LP:  l a g  phase ;  t 5Q: ci me Co 50% l y s i s ;  t 100- t i m e  t o  100% l y s i s .
V o l u m e  o f  serum added t o  3 ml  r a b b i t  E s u s p e n s i o n ;  e x c e p t  f o r  mouse  
wh er e  5 00  p i  serum was mi xed  w i t h  500  p i  r a b b i t  E s u s p e n s i o n .
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I t  s e e m s  u n l i k e l y  t h a t  a b i o l o g i c a l  p a t t e r n  e x i s t s  b e t w e e n  t h e s e  
x e n o g e n e i c  c o m b i n a t i o n s .  Why s h o u l d  a n t i b o d i e s  o f  on e  s p e c i e s  n e e d  t o  
i n t e r a c t  w i t h  c o m p l e m e n t  o f  a n o t h e r  s p e c i e s  i n  n a t u r e ?  E q u a l l y ,  h o w e v e r ,  t h e  
r e l a t i v e l y  p o o r  r e a c t i o n s  o f t e n  e l i c i t e d  b y  t h e  s y n g e n e i c  o r  a l l o g e n e i c  
s y s t e m s  a r e  p e r h a p s  s u r p r i s i n g .  We a g r e e  w i t h  H i l d e r a a n n  ( 1 9 7 8 )  c o n c e r n i n g  
" . . . . t h e  a r t i f i c i a l i t y  o f  m o s t  i j i  v i t r o  t e s t s  o f  c o m p l e m e n t - d e p e n d e n t  
c y t o t o x i c i t y . . . ” a n d  t h a t  we s h o u l d  " . . . u s e  o n l y  s y n g e n e i c  a n t i b o d i e s  a n d  
c om p l e m e n t  t o  me a sur e  t h e  f u n c t i o n a l  a c t i v i t i e s  o f  e i t h e r ,  i f  t h e  r e s u l t s  a r e  
i n t e n d e d  t o  r e v e a l  p r o b a b l e  i n t e r a c t i o n s  i n  t h e  l i v i n g  o r g a n i s m s . . . "  f o r  
" . . . i n . . .  1 i f e . . .  e v e r y  v e r t e b r a t e . . .  m u s t  d e p e n d  o n  i t s  own s e r u m  c o m p l e m e n t  
c omponent s  t o  a c t  i n  c o n c e r t  w i t h  i t s  own a n t i b o d i e s . "  But  does  t h e  a p p a r e n t  
w e ak ne s s  o f  t h e  s y n g e n e i c  o r  a l l o g e n e i c  r e a c t i o n  i n d i c a t e  t h a t  t h e  i n  v i t r o  
c y t o t o x i c  e f f e c t s  o f  c om p l e m e n t  a c t i v a t i o n  a r e  w e a k e r  t h a n  we h a v e  p r e v i o u s l y  
i n f e r r e d  f r o m  x e n o g e n e i c  c o m b i n a t i o n s ?
I t  i s  g e n e r a l l y  b e l i e v e d  t h a t  AP i s  a mechan i sm o f  i n  v i v o  d e s t r u c t i o n  o f  
c e l l s  b e a r i n g  " f o r e i g n "  a n t i g e n s  and some p a t h o g e n s  ( M c C o n n e l l  e t  a l . ,  1 9 8 1 ) .  
T h e  r a n g e  o f  AP r e c o g n i t i o n  a n d  f u n c t i o n s  r e m a i n s  t o  be d e f i n e d ,  a n d  i t s  
a c t i v a t i o n  by  x e n o g e n e i c  E m u s t  be  a c k n o w l e d g e d  a s  a t o o l  w i t h  n u m e r o u s  
l i m i t a t i o n s .  N e v e r t h e l e s s ,  o p t i m u m  c o m b i n a t i o n s  s h o u l d  be e s t a b l i s h e d  f o r  
t h i s  a s s a y  a l s o ,  a nd  a n  o v e r v i e w  o f  t h e  p h y l o g e n e t i c  d i s t a n c e  r e q u i r e d  f o r  
a c t i v a t i o n  m i g h t  h e l p  us  u n d e r s t a n d  t h e  s p e c i f i c i t y  a nd  e v o l u t i o n  o f  t h i s  
s y s t e m .  O u r  r e s u l t s  i n d i c a t e  a c o n s i d e r a b l e  s p e c i e s  v a r i a t i o n  i n  t h e  
a c t i v a t i o n  o f  AP b y  x e n o g e n e i c  E. To a l a r g e  e x t e n t  t h i s  w a s  a p r o p e r t y  o f  
t h e  E ,  some a c t i v a t i n g  w i d e l y ,  some r a r e l y .  I n  g e n e r a l ,  s p e c i e s  w h o s e  E 
s t i m u l a t e d  many o t h e r  s p e c i e s '  AP p o ss es se d  AP o f  o n l y  l i m i t e d  r e s p o n s i v e n e s s .  
T h i s  m i g h t  be  a n  i m p o r t a n t  c a u s e  a n d  e f f e c t  r e l a t i o n s h i p ,  s u g g e s t i n g  t h a t  E 
w h i c h  a c t i v a t e  AP e f f i c i e n t l y  a r e  u n d e s i r a b l e ,  o r  e v e n  s e l f - e l i m i n a t e d ,  i n  a 
h o s t  w i t h  a v i d  AP.  Van D i j k  ^ t  a l . ( 1 9 8 3 )  e xa m i n ed  t h e  c r o s s  a c t i v a t i o n  o f  AP 
b y  E i n  a l l  c o m b i n a t i o n s  o f  13 s p e c i e s ,  7 o f  w h i c h  w e r e  a l s o  e x a m i n e d  b y  u s .  
T h e y  t o o  n o t e d  a n  i n v e r s e  r e l a t i o n s h i p  b e t w e e n  AP r e s p o n s e s  a n d  t h e  
s t i m u l a t i o n  c a p a b i l i t i e s  o f  E.  H o w e v e r ,  i n  t h e i r  h a n d s  r a b b i t  AP w a s  n o t  
a c t i v a t e d  by  a n y  E ;  i n  o u r  s t u d y  mous e  a n d  g u i n e a - p i g  E a c t i v a t e d  r a b b i t  A P .  
I t  i s  i n t e r e s t i n g  t h a t  t h e  s e r a  w i t h  b r o a d e s t  AP r e s p o n s e  w e r e  among t h e  most  
p r i m i t i v e  o f  t he  s p e c i e s  e x a m i n e d ,  i . e .  b a d g e r ,  f e r r e t  and f o w l ;  t h e  e x c e p t i o n  
was t h e  he d g eh og ,  a s p e c i e s  p e r h a p s  r e q u i r i n g  u n i q u e  c o n d i t i o n s  f o r  op t imu m  
a c t i v a t i o n .  C o n v e r s e l y ,  t h e  m o s t  e f f i c i e n t  a c t i v a t o r s  o f  AP w e r e  E f r o m  
r a b b i t s  a n d  l a b o r a t o r y  r o d e n t s .  T h u s ,  t h i s  i n i t i a l  s t u d y  s u g g e s t s
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p h y l o g e n e t i c  g r o u p i n g s  w o r t h y  o f  f u r t h e r  i n v e s t i g a t i o n .  An u n r e s o l v e d  
p o s s i b i l i t y  i s  t h e  i n v o l v e m e n t  o f  n o n - s p e c i f i c  a n t i b o d i e s  t o  E i n  t h e  
a c t i v a t i o n  o f  AP.  Some a n t i b o d i e s  enha nc e  AP ( N e l s o n  and Ruddy,  1 979 ;  Moo r e  
e j ^ a _ l . ,  1 9 8 1 ) ,  a n d  s p e c i e s  d i f f e r e n c e s  i n  t h e  i m m u n o g l o b u l i n  c l a s s e s  a nd  
s u b c l a s s e s  o f  h e t e r o p h i l e  a n t i b o d i e s  c o u l d  c o n t r i b u t e  t o  d i f f e r e n c e s  i n  AP 
a c t i v a t i o n .  T h i s  i s  a d i f f i c u l t  p r o b l e m  t o  ov e r c o m e ,  f o r  a b s o r p t i o n  o f  s e r um  
i n  t h e  c o l d  h a s  some e f f e c t s  on c o m p l e m e n t  l e v e l s  and  r a r e l y  c o m p l e t e l y  
r em o v es  a n t i b o d i e s .
W h i l e  g r o u p s  o f  r e l a t e d  s p e c i e s  s ho w  g r e a t e r  o r  l e s s e r  c o m p l e m e n t  
e f f i c i e n c i e s ,  an o v e r a l l  d e v e l o p m e n t a l  p h y l o g e n e t i c  p a t t e r n  r e m a i n s  t o  be s ee n  
( G i g l i  a n d  A u s t e n ,  1 9 7 1 ;  B a l l o w ,  1 9 7 7 ) .  A m or e  d i v e r s e  a p p r o a c h  t h a n  
a c t i v a t i o n  o f  CP by  a s i n g l e  x e n o g e n e i c  s o u r c e  o f  a n t i b o d y ,  o r  o f  AP b y  a 
s i n g l e  x e n o g e n e i c  s o u r c e  o f  E ,  w i l l  a s s i s t  i n  t h e  e v a l u a t i o n  o f  t h i s  
p h y l o g e n y ,  a n d  o u r  s t u d y  i s  o f f e r e d  a s  a s t e p  i n  s u c h  d i r e c t i o n .  O u r  c h o i c e  
o f  s p e c i e s  was  i n f l u e n c e d  b y  o u r  i n t e r e s t  i n  t h e  n a t u r a l  o c c u r r e n c e  o f  some  
d i s e a s e s .  W h e t h e r  t h e r e  i s  a r e l a t i o n s h i p ,  d i r e c t  o r  i n d i r e c t ,  b e t w e e n  t h e  
a v i d i t y  o f  CP o r  AP a n d  s u s c e p t i b i l i t y  o r  r e s i s t a n c e  t o  c e r t a i n  i n f e c t i o u s  
d i s e a s e s  r e m a i n s  t o  be s e e n .  N e v e r t h e l e s s ,  i t  i s  p a r t i c u l a r l y  i n t e r e s t i n g  
t h a t  b a d g e r ,  f e r r e t  a n d  h e d g e h o g ,  a n i m a l s  w i t h  h i g h  s u s c e p t i b i l i t y  t o  
m y c o b a c t e r i a ,  had h i g h  l e v e l s  o f  AP.  T h i s  s u g g e s t s  t h a t  AP a c t i v a t i o n ,  w h i c h  
a l m o s t  c e r t a i n l y  i s  i n d u c e d  v i v o  by  m y c o b a c t e r i a ,  p l a y s  l i t t l e  o r  no p a r t  
i n  p r o t e c t i o n .  I n d e e d ,  i t  m i g h t  be  s p e c u l a t e d  t h a t  AP a c t i v a t i o n ,  w i t h  
c o n s e q u e n t  g e n e r a t i o n  o f  o p s o n i n s ,  i s  t o  t h e  b i o l o g i c a l  a d v a n t a g e  o f  a 
f a c u l t a t i v e  i n t r a c e l l u l a r  p a r a s i t e ;  p h a g o c y t o s i s  and hence  t h e  a t t a i n m e n t  o f  
t h e  d e s i r a b l e  i n t r a c e l l u l a r  e n v i r o n m e n t  m i g h t  be more e f f i c i e n t  o f  o r g a n i s m s  
p o s s e s s i n g  a p p r o p r i a t e  a c t i v a t o r s  o f  AP a nd  i n  h o s t  s p e c i e s  w i t h  a v i d  AP.
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